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Hypothermic machine perfusion (HMP) is well established in the practice of renal 
transplantation and is associated with improved short and long-term outcomes for 
selected organs. Despite the advantages of this therapy during the period prior to 
transplantation, the mechanisms by which these benefits occur are not entirely clear 
and are likely to include factors additional to improved flow dynamics. 
In the first part of this thesis, using both a local and national transplant dataset, I 
aim to establish the benefits (if any) and rationale for HMP relevant to current UK 
practice for both deceased and live donor kidneys. 
In the second part of this thesis the mechanisms by which HMP exert benefit are 
further interrogated, with a particular focus on metabolism. Nuclear magnetic 
resonance (NMR) spectroscopy is the principal modality through which this is 
investigated and in addition to established 1D 1H NMR protocols, glucose tracer 
studies using 2D 13C NMR are described. Whole organ ex vivo perfusion is studied in 
this work using human kidneys (both transplanted and non-transplanted) and 
porcine organs, with the porcine model validated for metabolic studies.  
In the final section, methods to modify metabolism during HMP are attempted, with 
the effects of supplemental oxygenation described.  
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Benefits of transplantation 
The evolution of renal transplantation over the past sixty years is a triumph of 
modern medicine, with one-year graft survival rates in the contemporary era of over  
90%(8). Transplantation has become irrefutably the treatment of choice for patients 
with end stage renal failure (ESRF), improving both quality and quantity of life (9). 
Such are the benefits of transplantation that even in high-risk patients with complex 
medical problems there is a distinct survival advantage compared with the 
alternative of dialysis (10, 11). 
In addition, from a health economics perspective, kidney transplantation is 
advantageous with a cost saving of £250,000 per kidney compared with 
haemodialysis (based upon a median graft survival of ten years) (12). 
Types of donor organs for transplantation 
Donor organs can be broadly classified by donor type, either deceased or living 
donor. Whilst the numbers of living donor kidneys transplanted annually are 
increasing, and such organs have the best outcomes, deceased donor organs still 
account for the majority of organs transplanted in the UK (8). Deceased donor 
organs can be further categorised according to the physiology of the donor; 
donation after brain death (DBD) and donation after cardiac death (DCD). By 
definition, donors with brain stem death have an irreversible neurological injury that, 
amongst other things, annihilates the respiratory centres and neurological impetus 
to breathe. However, such patients do have a cardiac output, provided that they are 
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sufficiently oxygenated via a ventilator. DBD donors are considered both medically 
and legally dead in the UK and resultantly the organ donation procedure for these 
patients can occur in a controlled fashion whilst the donor organs are being 
perfused. In contrast DCD donors also have a grave neurological injury but do not 
fulfil brain stem death criteria. As such patients are neither medically nor legally 
dead, organ retrieval can not commence until the cessation of cardiorespiratory 
output has occurred (plus five minutes in the UK). This cardiorespiratory arrest is 
typically precipitated by the cessation of all supportive therapy (e.g. inotropes, 
ventilation). Needless to say, for DCD donors, there is a period between the cardiac 
arrest and cold perfusion of organs whereby the organs are both warm and 
ischaemic, termed warm ischaemia time (WIT). This warm ischaemia is known to be 
more detrimental than equivalent periods of cold ischaemia. Historically DBD and 
DCD donors were called heart beating and non heart beating donors, but such terms 
were deemed over-simplistic. 
 
Increased usage of extended criteria kidneys 
Despite the ever-growing demand, transplantation is limited by the paucity of 
available organs and considerable efforts have been made to expand the donor pool, 
reflected by increased transplant numbers both in the UK and worldwide (8). 
Patients not fortunate enough to have a suitable live donor must rely on a deceased 
donor organ. Such are the benefits of transplantation and the discrepancy between 
supply and demand that organs previously deemed as unsuitable for transplantation 
are now being utilised, including extended criteria donor (ECD) organs. A definition 
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of an extended criteria donor is given in Table 1. 
o Donors aged ≥ 60 years 
o Donors aged 50-59 plus at least two of the following 
! Hypertension 
! Intra-cerebral cause of death 
! Pre-terminal creatinine > 132 µmol/L 
Table 1 Definition of extended criteria donor (ECD) 
 
Techniques for organ preservation 
Organs have been traditionally cold stored in the interval between organ retrieval 
and implantation. This period of cold ischaemia or cold ischaemia time (CIT) is 
known to cause significant detriment to graft survival if excessive and is therefore 
kept to a minimum (13-15). Whilst there is some evidence that a controlled period of 
normothermic or sub-normothermic perfusion may have a beneficial effect in 
selected kidneys prior to transplantation (16-18), this has not been validated in high 
volume studies and is not used outside of specialist academic centres. Thus cold 
storage to minimise any metabolic function and rapid implantation to minimise CIT 
continue to drive the practice of kidney transplantation to date. The two methods for 
cold preservation of kidneys, static cold storage (SCS) and hypothermic machine 
perfusion (HMP), are discussed below. 
Static cold storage (SCS) 
Static cold storage (SCS) is the traditional modality of organ preservation and 
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remains the most commonly used method worldwide (19). The governing principles 
are simple and have undergone little change since the inception of renal 
transplantation some sixty years ago, namely the deceleration of metabolism that 
occurs as the temperature of the kidney is reduced. At storage temperatures below 
4°C, the metabolic function within the kidney is reportedly only 5-8%, compared 
with en vivo conditions (20). During periods of SCS, the kidney is essentially stored 
in hypertonic solution surrounded by ice within a polystyrene storage container. 
History of static cold storage 
Whilst Belzer and colleagues developed the machinery and perfusates for mechanical 
perfusion in the 1960's, Dr. Collins and his team were championing a much simpler 
kidney storage technique; namely SCS. Following the initial cold flush to remove any 
remaining blood, organs were preserved in the eponymous Collins solution in which 
the high concentration of potassium and low concentration of sodium resembled the 
intracellular environment. A high concentration (140 mM) of glucose also ensured 
that the solution was slightly hypertonic (350 mOsm/L). Despite the lack of 
impermients in Collins solution, such as lactobionate, hydroxyethyl starch (HES), or 
mannitol, the solution proved effective at storing canine kidneys for up to 30 hours 
(21). Although unacceptable by today's standards, human trials later proved cold 
storage with Collins solution to be superior to the Belzer perfusion technique for 
kidneys with prolonged preservation times, with one year graft survival of 53% vs. 
40% (P<0.001) (22). This results were equivalent for machine perfused kidneys in 
other studies from same era (23, 24). Given the lack of clinical benefit for HMP, 
combined with the easily reproducible, transportable, low-cost advantages of SCS, 
this quickly gained favour as the organ preservation modality of choice. Indeed only 
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2% of all kidneys transplanted between 2000 and 2007 were preserved using 
machine perfusion (25).  
Although the fluid used for SCS preservation of kidneys changed over the 
subsequent decades, from Collins solution to EuroCollins to University of Wisconsin 
(UW) solution, the principle did not. Clinical outcomes for renal transplantation 
improved dramatically over the subsequent decades, owing largely to improved 
immunological therapy including the widespread usage of calcineurin inhibitors as 
part of the immunosuppressant regimen. The relative benefit, if any, of machine 
perfusion seemed to be small compared to the huge improvements achieved 
through improved perioperative medical care.  
Clinically used preservation fluids for SCS 
It was quickly established that fluids commonly used for intravenous replacement 
(e.g. 0.9% NaCl, Ringers lactate, etc.) were unsuitable for organ preservation and 
resultantly, a multitude of fluids were designed for this purpose. Clinically utilised 
preservation fluids with their constituent ingredients are listed in Table 2Error! 
Reference source not found.. The University of Wisconsin solution (UW) was first 
designed over thirty years ago but is still considered the gold standard in most of the 
world for the initial cold flushing of organs during procurement as well as for static 
organ preservation. UW contains lactobionate and hydroxyethyl starch (HES) as 
impermeants. Similar to Collins solution, the Na+/K+ ratio of UW resembles 
intracellular concentrations to minimise the ATP requirement necessary in 
maintaining transcellular concentration gradients via Na+/K+ ATPase pumps. The 
amount of HES present in UW is 50 g/L making a 5% solution (molecular weight 
range 100-1000 kDa, mean 250 kDa) (26).  Other constituents include raffinose, 
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glutathione to limit the harmful effects of reactive oxygen species, and adenosine to 
enhance ATP synthesis. A systematic review and meta-analysis of preservation 
solutions used for SCS of kidneys concluded that there were higher rates of delayed 
transplant function for EC (Eurocollins) preserved kidneys than those stored in either 
UW or histidine-tryptophan-ketoglutarate solution (HTK). There was no difference 
found between UW, Celsior and HTK preserved kidneys (27).  
 




Hypothermic machine perfusion (HMP) 
Hypothermic machine perfusion (HMP) involves the recirculation of chilled 
preservation fluid through the renal vasculature in the period prior to 
transplantation. The device used in clinical practice in the UK (LifePort© kidney 
transporter) delivers pulsatile flow through the renal artery of specialized perfusion 
fluid (KPS-1®) at a fixed maximal pressure (commonly 30 mmHg).  
History of machine perfusion 
Ex vivo organ perfusion is not a new concept but has recently been propelled back 
into the domain of clinical interest for two reasons. Firstly there is a recognition that 
the quality of deceased donor organs is inferior to previous generations, and 
therefore the optimisation of organs during the preservation window is paramount 
for ensuring the best outcome for these marginal kidneys. Secondly, the clinical 
benefits of HMP have been validated by a high quality multinational randomised 
controlled trial (28, 29). 
The basic technique that facilitated renal transplantation was the vascular 
anastomosis as described by the French surgeon Alexis Carrell at the beginning of 
the 20th Century, for which he was later awarded a Nobel prize. Carrell himself, 
along with the aviator Charles Lindbergh performed multiple large animal transplant 
experiments, which were largely doomed due to immunological barriers such as HLA 
incompatibility that would only be described decades later. However, Carrell and 
Lindbergh were advocates of machine perfusion and felt it was the most 
physiological way to preserve organs ex vivo. The organ preservation system that 
they described consisted of an organ chamber and mechanical pump that remains 
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the basis of machine perfusion devices to this day (30, 31). 
Further animal studies demonstrated the feasibility of hypothermic machine 
perfusion of kidneys, with refinements of both machinery and greater understanding 
of preservation fluids. Groups including the one lead by Arthur Humphries were able 
to achieve good functional outcomes in a canine model following prolonged 
perfusion times (32-34). An early machine device is shown in Figure 1.  
Much credit for the translation of machine perfusion from the laboratory to clinical 
practice is owed to teams lead by Folkert Belzer in the 1960's. Belzer found that he 
was able to achieve excellent graft and animal survival in a canine autotransplant 
model following 72 hours of machine perfusion (35). This was performed at 6-8°C 
using an oxygenated autologous plasma based perfusate solution. The problem of 
hypothermic aggregation was circumvented by ultrafiltration to remove lipoproteins 
and similar molecules (36). As the perfusion fluids became more sophisticated, 
plasma was exchanged in favour of albumin as a colloid. Much of this work was 
performed by Dr Claes in Gothenburg, whose albumin-based solution was far easier 
to prepare than the plasma ultrafiltrate. Further modifications to their Gambro 
perfusion machine included surface oxygenation in favour of membrane oxygenation 
(37). This perfusion technique was utilised with moderate success in the early 1970's 
(38). Despite recognising the advantages of a synthetic perfusion fluid, including a 
reduction in disease transmission, early perfusates largely contained human 
products. Indeed, it was not until the early 1980's that a fully synthetic perfusate 
solution was developed by Belzer containing hydroxyethyl starch (HES) as the colloid 
component in place of albumin (39). This was successful in preserving canine 
kidneys for up to seven days (40, 41). 
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However, as mentioned earlier, despite some encouraging results, SCS continued to 
be the organ preservation modality of choice as dramatic improvements in 
immunosuppressive therapy lead to significant improvements in outcome. Any gains, 
if any, from the cumbersome, labour intensive, expensive process of machine 






Figure 1 Early example of an oxygenated HMP device 
Reproduced from Humphries et al. (32) with permission from Wiley & Sons Inc. 
Clinical evidence to support HMP 
Although the benefits of HMP are now widely accepted, for several decades there 
was insufficient evidence to support its use. Whilst there were some reports to the 
contrary, multiple studies reported no significant difference in the rates of delayed 
graft function (DGF) between HMP and SCS kidneys (42-45). Similarly, no advantage 
for one-year graft survival was demonstrated (44, 46) or reduction in primary graft 
non-function (43, 44, 47). 
To provide robust scientific evidence as to the benefits, if any, of HMP in the modern 
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era of transplantation, a randomised controlled trial (the machine preservation trial) 
was commissioned and in 2009 the results from this well-designed prospective 
paired analysis randomised control trial were published. The machine preservation 
trial group reported reduced rates of DGF (20.8% vs. 26.5%, p=0.05) and improved 
1-year graft survival (94% vs. 90% p=0.04) for consecutive kidneys preserved with 
HMP compared to the contralateral organ preserved with SCS (28). In a thorough 
meta-analysis published in 2012, which included the machine preservation trial 
results, the use of HMP was supported for reducing the incidence of DGF post 
transplantation (48) but was unable to identify superior graft survival from the 
studies analysed. However, follow on findings reported after three years found that 
overall, 3-year graft survival was better for machine-perfused kidneys (91% vs. 
87%; adjusted hazard ratio for graft failure, 0.60; P=0.04) (29). This study provided 
the most robust evidence to date to support the usage of HMP in kidney 
transplantation. However, whilst clearly demonstrating that HMP can be utilized in 
kidney transplantation with beneficial effect, there are several important points 
regarding the study that warrant further elaboration. Firstly, the kidneys in this study 
were randomized to either the SCS or HMP group, and if allocated to the HMP group, 
this was commenced at the retrieval centre itself. This differs drastically to 
transplant practice in the UK whereby all kidneys are placed in SCS conditions at the 
retrieval centre and then transferred to the recipient centre. Thus HMP occurs after 
a period of SCS organ preservation, which can be protracted depending on the 
distance travelled. Therefore the superiority of HMP following SCS over an equivalent 
period of SCS was not determined in the machine perfusion study and this warrants 
further investigation (see discussion and future work Chapter 10). Secondly, the SCS 
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and HMP kidney groups in the machine perfusion study had equivalent durations of 
CIT prior to transplantation (median 15.0 hours). Therefore, the study does not help 
the clinician faced with the decision of whether to commence HMP when a kidney 
arrives at the recipient centre. Whether it is better to implant the kidney as soon as 
it arrives and therefore keep CIT to a minimum or whether it is advantageous to 
commence HMP at this point and effectively prolong the CIT is unanswered by the 
machine perfusion study. Furthermore, if a period of HMP is advantageous, the 
optimal time for which organs should be perfused is also not established. This poses 
an interesting question from a mechanistic perspective regarding HMP, namely 
whether HMP results in actual improvement in organ function in the pre-transplant 
period or whether it merely decelerates the destructive processes that occur once 
the organ has been removed from the donor. 
Interestingly, the results for DCD kidneys undergoing HMP are less clear than for 
DBD organs. Indeed subgroup analysis based on the machine preservation trial 
failed to demonstrate a graft survival advantage for DCD kidneys undergoing HMP 
(29). This finding was further verified by a UK-based randomised multicentre paired 
trial which found no advantage for HMP in DCD kidneys compared with cold storage 
(49). The reasons for this are unclear and warrant further investigation.  
 
Mechanisms of HMP 
Whilst the clinical benefits of HMP are now supported by high quality evidence, the 
mechanism behind these benefits are less clear and is likely to be multifactorial. In a 
review article by Taylor in 2010, he listed three probable major physiological benefits 
of HMP over static cold storage as well as a further seven potential, financial or 
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logistical benefits (50) (Table 3). 
 
"Maintains the patency of the vascular bed 
Provides nutrients, and low demand O2 to support reduced energy demands 
Removes metabolic by-products and toxins 
Provides access for administration of cytoprotective agents and/or immunomodulatory drugs 
Increases available assays for organ viability checks 
Can facilitate change from emergency to elective surgery with reduced costs and improved outcomes 
Improves outcomes as demonstrated by reduced Primary Non-Function and Delayed Graft Function 
Permits use of expanded criteria kidneys, or organs from non-heart-beating donors to increase donor pool 
Economic benefit for transplant centers & reduces health care costs 
Provides technology for ex vivo use of non-transplanted organs for pharmaceutical research." 
Table 3 Beneficial effects of HMP (Taylor 2010) 
 
Commercially available HMP machines 
There are several commercially available HMP machines; the LifePort© Kidney 
Transporter (Organ Recovery Systems) (Figure 2), RM3 (Waters Medical Inc.) 
(Figure 3), and the Organ Assist devices. The LifePort© is the device utilised in 
clinical practice in the UK and is approved by the UK body the National Institute for 
Health and Care Excellence (NICE) (25). The key mechanical difference between the 
LifePort© (and Organ Assist) and the RM3 is that the latter is a flow-driven device 
(i.e. flow rates can be set), in comparison to a pressure-driven device. Flow through 
the kidney is directly proportional to the driving pressure and inversely proportional 
to the resistance (flow = pressure / resistance). Therefore when perfusing a high 
resistance kidney, the flow-driven RM3 device would deliver fluid at a high pressure 
 
 15 
in order to meet the flow demands. Although perfusion pressures during HMP are 
largely subphysiological, there is some evidence that high pressure can have 
deleterious consequences. Maathuis et al. performed a porcine autotransplant 
experiment comparing the effect of two different pulsatile perfusion pressures 
(60/40 mmHg and 30/20 mmHg) versus cold storage in a hypothermic, oxygen 
supplemented model (51).  Levels of von Willebrand factor (vWF) and monocyte 
chemotactic peptide-1 were higher in the 60/40 mmHg perfused kidneys compared 
to 30/20 mmHg group. The authors postulated that increased shear stress at these 
pressures induces endothelial injury release of vWF and could lead to graft 
thrombosis (51). 
Conversely, LifePort© delivers perfusion at a constant pressure (adjustable between 
30-60 mmHg). Whilst this would avoid potential endothelial injury from a high 
perfusion pressure within a high resistance organ, the flow would be limited, and 
thus the beneficial effects of perfusion would likely be diminished. 
In a small prospective randomised trial comparing the RM3 flow-driven device and 
LifePort© pressure-driven device the authors concluded that the pressure-driven 
system gave superior results. However, there was no significant difference in rate of 





Figure 2 LifePort© Kidney Transporter 1.0 (Organ Recovery Systems)  
 
Figure 3 Walters RM3 Renal Preservation System 
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Clinically used fluids for HMP 
The fluid licensed for use with the LifePort© hypothermic machine perfusion device is 
Kidney Perfusion Solution-1 (KPS-1®). In many ways, this resembles UW solution, 
and is also known as UW machine perfusion solution (UW-MPS). However, there are 
several key differences between conventional UW and the solution used for HMP. 
Firstly, KPS-1® has an extracellular-like Na+/K+ balance in contrast to the 
intracellular concentrations in UW and Eurocollins. Secondly, raffinose and 
lactobionate which are present in UW as impermeants have been substituted with 
gluconate and mannitol. Glucose is also included in the KPS-1® solution at a 
concentration of 10 mM (Table 4). The role of impermeants in preservation fluids is 
discussed further below. 
 
Constituents Amount/1000 mL Concentration, mM 
Calcium chloride 
(dehydrate) 0.068 g 0.5 
Sodium hydroxide 
0.70 g  
HEPES (free acid) 
2.38 g 10 
Potassium phosphate 
(monobasic) 3.4 g 25 
Mannitol (USP) 
5.4 g 30 
 
 18 
Glucose, beta D (+) 1.80 g 10 
Sodium gluconate 17.45 g 80 
Magnesium gluconate D (–
) gluconic acid,  
hemimagnesium salt 
1.13 g 5 
Ribose, D (–) 0.75 g 5 
Hydroxyethyl starch (HES) 50.0 g n/a 
Glutathione (reduced) 0.92 g 3 
Adenine (free base) 0.68 g 5 
Sterile water for injection To 1000 mL volume n/a 
 
Table 4 Concentrations and constituents of KPS-1® perfusion fluid. 
Source: http://www.organ-recovery.com/kps-1 
Histological changes following HMP 
Maathuis et al. were unable to determine any histological differences between 
machine-perfused and cold stored porcine kidneys using light microscopy (20x 
magnification) following haematoxylin and eosin and periodic acid-Schiff staining 
(51). Renal cortical biopsies were compared with control pigs using an ischaemia 
reperfusion injury scale (IRI) (53). Markers of injury include mesangial matrix 
expansion, brush border loss in proximal tubule, oedema, tubular dilatation, tubular 
cell vacuolisation, necrosis, endothelial cell oedema and interstitial fibrosis. Although 
the time points used for analysis are not well defined in the manuscript, the authors 
report that the IRI scores were low across both study groups and that there were no 
significant differences between the HMP and cold stored kidneys (51). Similarly, 
there was no difference seen on light microscopy of porcine kidneys after either 4 or 
28 hours in a paired SCS HMP models as reported by my predecessor Ms Guy (54).   
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Metabolic support during organ preservation 
The concept that organ preservation is harmful is ingrained into the practice of 
organ transplantation. Damage limitation of these destructive processes is achieved 
through hypothermia (thus restricting any cellular metabolism) and minimising the 
duration of preservation (i.e. the cold ischaemia time). Even with the advent of HMP, 
cold ischaemia times are still kept to a minimum though the optimal duration of 
machine perfusion has not been established.  
The metabolism within the kidney is thought to be halved for every 10°C decrease in 
temperature with only 5-8% of normal metabolic function occurring at 4°C (20), 
with a similar decrease in oxygen requirement (36). This deceleration of cellular 
metabolism during hypothermia is though to preserve organ ATP reserves and limit 
the accumulation of harmful by-products such as lactic acid. 
However, hypothermia does not cause a uniform deceleration of all metabolic 
pathways (50) and furthermore, the effect on cellular metabolism of hypothermia 
within different organs is not uniform (55). If indeed certain enzymes are particularly 
thermo-sensitive, then manipulation of such pathways may offer a mechanism for 
protective metabolic support. 
There are surprisingly few recent reports detailing renal metabolism during either 
SCS or HMP conditions and, as discussed, is likely to reflect the belief that such 
metabolic activity during organ preservation is deleterious. Indeed the beneficial 
effects of HMP were largely thought to be mechanical, with the potential benefits of 
metabolic support during HMP only reported relatively recently (50, 56). 
The concept that preservation is an intrinsically harmful process is in contrast to the 
scientific approach to other biological systems whereby cells can be supported in a 
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hypoxic media environment for extensive time periods. The metabolic simplicity of 
currently used perfusion fluids, which have been designed principally to prevent 
cellular lysis (through osmotic and pH stability) and maintain transmembrane 
electrolyte balance, is in stark contrast to cell culture fluids which are designed with 
the intention of supporting all of the metabolic needs of the cell in question. A 
typical composition of cell culture fluid is listed in Table 5. In addition to the salt 
solution and buffers present in perfusion fluids, cell culture media typically consist of 
essential and non-essential amino acids, growth factors and hormones (e.g. insulin). 
These media can be serum-free or serum-based, and there are advantages of each 
(57). 
Several groups have aimed to preserve kidneys with perfusion fluid more akin to 
culture media in order to provide necessary nutrients and facilitate metabolism. In a 
canine autotransplant model, Brasile et al. used ischaemically damaged kidneys and 
either re-implanted them immediately or subjected them to sub-normothermic 
(32°C) oxygenated machine perfusion with their culture media-like fluid before 
autotransplantation. The dogs in the perfusion group all survived in comparison to 
the non-perfused group in whom a rapid postoperative rise in creatinine was 
observed (58). This study demonstrated the principle that, provided adequate 
nutritional support is present, organ preservation can improve the function of 
damaged organs and is not merely a damage limitation exercise. Subsequent studies 
have suggested that prolonged preservation times (up to 48 hrs) can be achieved 
and that growth factors such as fibroblast growth factor (FGF-1 and FGF-2) also 
improved the outcomes in this canine model (58, 59). 
In a non-oxygenated porcine HMP model, Baicu et al. measured concentrations of 
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isolated metabolites in the perfusion fluid over 72 hours (60). Although the perfusate 
used was replaced every 24 hours, they demonstrated an increase in perfusate 
glutamate concentrations during perfusion with both UW-MPS (KPS-1®) and their 
own solution (Unisol-UHK). A similar rise in the perfusate ammonium (NH4+) levels 
was noted although less pronounced in the UW-MPS (KPS-1®) group. The suggested 
mechanism for the increase in glutamate was the reduction (and deamination) of 
glutamine to glutamate by glutaminase (releasing ammonium as a by-product). The 
source of glutamine in both fluids was thought to be glutathione (reduced) which 
had been largely oxidised in the UW-MPS group by the time of fluid usage and 
resulted in lower levels of glutamate in this group (60-62). The authors also 
conclude that the deamination of glutamate occurs (releasing ammonium) to form 
alpha-ketoglutarate, an important TCA cycle intermediate (60).  
In contrast to the renal setting, there have been extensive attempts to describe  
hepatic metabolism during machine perfusion (63). Whilst such studies are useful, 
caution should be exercised when comparing these two systems (liver and kidney) 
during isolated ex vivo single organ perfusion, not least as both have independent 
metabolic and excretory properties. Further comparisons are weakened as liver 
perfusion systems are largely oxygen enriched, which is not the case with HMP used 
in clinical practice (64-67). However, in both human and animal models, 
hypothermic liver perfusion has been shown to increase ATP levels (64-68) and aid 
glutathione recovery (65, 67). 
Considerations for HMP metabolic studies 
Evaluation of kidney metabolism during preservation using perfusate appears 
attractive. The HMP device widely used in clinical practice (LifePort© Kidney 
 
 22 
Transporter 1.0 (Organ Recovery Systems, Chicago, IL)) has a designated sampling 
port to remove samples of perfusion fluid or perfusate in an easy and sterile fashion. 
Furthermore, the volume of fluid required for most metabolic analysis is small 
(several ml) in comparison to the volume of circulating fluid (1 L). However, a major 
limitation of using perfusate as a tool for organ metabolism assessment is that it 
determines the concentration of metabolites in perfusion fluids circulating through 
the intravascular environment of the kidney. Metabolic conditions within the 
interstitial extracellular fluid and more importantly the intracellular compartment may 
be quite different. The inference of the intracellular environment from perfusate 
concentrations is therefore limited, and would depend on the cellular permeability 
for that specific metabolite amongst other factors. For organs preserved via a SCS 
method, analysis of the fluid bathing the kidney is even less useful as it is very 
unlikely to represent the intrarenal environment. Alternatives to perfusate have been 
suggested including analysing the metabolites in fluid obtained via a microdialysis 
catheter inserted into the extracellular interstitial space (69) (Figure 4). However, 
there are also limitations of this approach as the metabolic microenvironment 
surrounding the catheter is altered as a consequence of the dialysis process itself. 
Determination of intracellular metabolism would seem to be imperative in 
understanding the complex process occurring during organ preservation. Cell 
extraction of tissue samples is the best described way of doing this and various cell 
extraction techniques have been proposed for this purpose. Largely these involve 
the cessation of metabolism via rapid freezing of tissue (-80°C) and mechanical 
homogenisation in the presence of methanol. However thorough metabolic analysis 
often requires a reasonable mass of tissue (e.g. 1 g) in order to perform the multiple 
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analyses to establish metabolite type, concentration, and flux. Whilst 'metabolomic' 
modalities such as nuclear magnetic resonance (NMR) spectroscopy analysis have 
enhanced this process, some metabolites are technically difficult to distinguish on 
conventional 1H-NMR  (e.g. pyruvate). In addition, tissue biopsy during HMP is 
problematic as removal of tissue from this pressurised system results in perfusate 
leak through the biopsy site and decrease in the intrarenal resistance. In effect, only 
one large volume tissue sample is achievable during HMP without jeopardising the 
metabolic integrity of the system. This is one of the limitations of whole organ 
metabolic HMP studies and is one of the reasons that we propose a HMP cell line 
model to complement experimental work (Chapter 10). The problems of fluid 
leakage are not encountered in the clinical setting if tissue biopsy occurs at the end 
of HMP, as once the kidney is reperfused with blood following transplantation, 
activation of the clotting cascade rapidly 'plugs' any tissue discontinuity. Repeated 
biopsy on the same kidney during SCS would appear less problematic, although 
following biopsy and breach of the capsule, an inflow and efflux of metabolites into 




Figure 4 Placement of microdialysis catheter during HMP.  
























Although great advances have been made in the field of transplantation, to date, 
there remains no single reliable pre-transplant predictor of post-transplant graft 
function. This is of increasing importance in the current era whereby marginal donor 
kidneys are being increasingly utilised in an attempt to address the problems of 
organ shortage (70-73). As such, there is a clinical need for a reliable test to 
determine the 'usability' of such marginal organs. Although scoring systems have 
been proposed for this purpose, often using histological parameters from a kidney 
biopsy (74), they are not used widely. In practice, donor information such as patient 
age, comorbidity and pre-mortal creatinine is used to judge the 'transplantability' of 
a kidney, often in conjunction with any histological information. However even this 
combined approach has a limited capacity for accurate prediction of graft outcomes 
(75, 76). Furthermore, clinically used measurements for the monitoring of post-
transplant graft function also have limitations as rejection can occur in the presence 
of normal creatinine values and structural changes on renal biopsy only present after 
significant injury has occurred (77).  
The identification of a biomarker during the pre-transplant period would be 
attractive and useful but to date has proved elusive. HMP seems well suited for 
biomarker analysis as perfusate samples are readily available, non-invasive and 
should offer insight into the cellular components within the organ. Furthermore, 
machine perfusion also provides the opportunity for repeated measurements, which 
may predict graft function with greater accuracy. Low intrarenal resistance during 
perfusion has been shown to correlate with improved post transplant function, but 
several studies have demonstrated that organs should not be rejected solely on flow 
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dynamic information, which strengthens the need for a perfusate biomarker (78-81).   
In a systematic review by Bhangoo et al. (82), there was found to be a paucity of 
high quality HMP biomarker studies. Elevated levels of glutathione-S-transferase 
(GST), lactate dehydrogenase (LDH) and aspartate transaminase (AST) were 
significantly associated with delayed graft function in the majority of studies. AST is 
expressed from injured renal parenchymal cells. GST is a marker of renal tubular 
injury. LDH is a non-specific marker of cellular injury (82). However, there was 
insufficient evidence to recommend any single parameter as a sensitive pre-
transplant biomarker. Given the complex nature of whole organ metabolism during 
ex vivo perfusion a combination of biomarkers, or biomarker panel may be more 






 The purpose of ex vivo oxygenation during organ perfusion is to deliver an 
adequate amount of oxygen at a cellular level to support aerobic metabolism and 
prevent ischaemic injury. Oxygenation of organs during the preservation period 
would seemingly provide a more physiological storage environment. However, the 
benefit, if any, of oxygenation during HMP is not clear with evidence to date largely 
inferred from small scale animal experiments (83).  
Aside from the technical challenge of oxygen delivery, there are concerns that 
unregulated oxygenation may pose risks to the perfused kidney (56). High levels of 
oxygenation have been shown to result in the formation of free radicals leading to 
tissue injury (84). Furthermore, specific protective mechanisms such as the hypoxia 
inducible factor (HIF) pathway are active in ischaemic conditions with concerns that 
supplemental oxygenation may ameliorate such beneficial processes. 
The role of oxygenation during HMP for transplant kidneys is further explored in 
Chapter 9.  
Oxygenators 
The technology involved in ex vivo oxygenation has been largely driven by the 
development of cardiothoracic surgery and the need for cardiopulmonary bypass. 
The ambition to replicate the physiological process by which carbon dioxide is 
removed from blood and oxygen is delivered through diffusion at the alveolar 
membrane led to the evolution of modern day oxygenators as it was quickly 
established that direct oxygenation of blood ex vivo resulted in blood trauma and the 
potential for gas emboli (85).  The early bypass circuits used bubble oxygenators, 
but these have been superseded by modern membrane oxygenators through which 
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gaseous diffusion occurs across membrane micropores (85). Indeed modern day 
perfusion experiments largely use membrane oxygenators to achieve the required 
oxygen tensions within the perfusate. The oxygenator incorporated into the 
OrganAssist device as well as the oxygenators used in this thesis are membrane 
oxygenators.  
Oxygen carriers 
Whilst red blood cells containing haemoglobin are the natural, and probably most 
efficacious oxygen carrier, there are a variety of interesting synthetic oxygen carriers 
available, which could potentially be useful during organ perfusion. Perfluorocarbons 
(PFCs) are stable synthetic compounds containing fluorine. They have a high affinity 
for gases such as oxygen, but themselves are insoluble in water and need to be 
emulsified in a surfactant (86). PFCs have been used in animal machine perfusion 
experiments as an oxygen substitute (87). Pyridoxylated haemoglobin 
polyoxyethylene (PHP) is a form of haemoglobin that has been pyridoxylated, 
stabilising it for use in the absence of red cells and has also been used in perfusion 
models (59, 88). Several other oxygen carrier molecules have been used for 
perfusion studies including Hemarina-M101, which is an extracellular form of 
haemoglobin derived from a marine invertebrate. This product has proven to be 
efficacious at oxygen delivery over a range of temperatures and has been used in a 
pig autotransplant model during HMP with positive results (89). The advantages, if 
any, of oxygen carriers over active oxygenation of perfusion fluid without such 
carriers has not been established. 
Free radical formation 
Free radicals are atoms or groups of atoms with unpaired electrons. These can have 
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a positive, neutral or negative charge. When such free radicals are derived from 
oxygen, they are termed reactive oxygen species (ROS) and includes the superoxide 
(O2•-), peroxide (O2•2-), and hydroxyl radical (•HO).  
The formation of ROS is a normal physiological phenomenon and occurs as a 
consequence of the electron transport chain within cell mitochondria. A common 
property of free radicals is that they are highly reactive. Whilst some of these 
reactions can be protective, there are also many deleterious effects of unregulated 
ROS. The toxic effects of ROS are well described in damaging the phospholipid layer 
of the cell membrane, a process known as lipid peroxidation (90). To counter the 
harmful effects of ROS, a parallel system of antioxidants has evolved to protect cells 
from oxidative stress including enzymatic and non-enzymatic processes. 
Enzymatic antioxidants include superoxide dismutases (SOD), which catalyse the 
conversion of superoxides into the more stable compounds of hydrogen peroxide 
and oxygen. This reaction is depicted in Figure 5. Upregulation of SOD occurs in the 
presence of high oxygen concentrations, and its potential beneficial antioxidant 
effects have been exploited in human studies. In a prospective randomised kidney 
transplant trial, 200 mg of SOD given intraoperatively was found to significantly 
reduce the incidence of postoperative acute rejection (91). However, these beneficial 
effects were not observed when a similar study using SOD was performed on a 
different cohort (92). 
Another important antioxidant is the tripeptide glutathione, composed of glutamic 
acid, glycine, and cysteine (Figure 6). This contains an exposed sulphydryl group 
that is highly reactive and therefore a target for free radical interaction, resulting in 
oxidation (Figure 7).  Reduced glutathione is a central component of the 
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preservation solution UW-MPS/KPS-1®, and studies have demonstrated inferior graft 
function following preservation of kidneys in the absence of glutathione (93). 
Activation of antigen presenting cells via a ROS mediated process during kidney 
ischaemia and reperfusion is thought to be central to the development of acute 
rejection (94, 95). The accumulation of ROS precursors occurs as a result of 
ischaemia. Based on a tourniquet limb model of ischaemia reperfusion, Freidl et al. 
postulated that the mechanism for this is largely through the utilisation of 
intracellular ATP, resulting in the increase in ADP levels which are then catabolised 
into hypoxanthine (and inosine and adenosine) (96). Levels of xanthine oxidase 
were found to increase through conversion from xanthine dehydrogenase via 
calcium-dependent proteases that are activated in the hypercalcaemic environment 
resultant from ischaemia (96). The oxidation of hypoxanthine and xanthine during 
reperfusion is thought to be the principal pathway during this ischaemic process 
(90). 
 





Figure 6 Chemical composition of reduced glutathione molecule 
By Jjexpat - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=49205211 
 
 
Figure 7 Chemical composition of oxidised glutathione 
 
Hypoxia inducible factor (HIF) 
Hypoxia inducible factors (HIF) are a family of oxygen sensitive heterodimeric 
transcription factors that play a major role in the cellular response to periods of 
hypoxia (97). Given the significant periods of both hypoxia and ischaemia during the 
organ donation and preservation period as well as the subsequent ischaemia-
reperfusion injury, the HIF pathway may provide a target for organ optimisation. 
The hypoxia inducible factor (HIF) pathway is activated as part of the cellular 
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response to hypoxia and exerts its beneficial effects via multiple mechanisms. 
Upregulation of the HIF pathway has been shown in an animal model to reduce 
ischaemia reperfusion injury (IRI) (98-100) which is known to be deleterious during 
renal transplantation and is associated with an increased risk of delayed graft 
function (DGF) and reduced graft survival (101). Furthermore, in hypoxic conditions, 
activation of the HIF pathway is associated with upregulation of mechanisms that 
facilitate glycolysis such as facultative glucose transporter-1, aldolase A, 
phosphoglycerate kinase 1 and pyruvate kinase M (102).  
The increased delivery of glucose to the intracellular environment and subsequent 
glycolysis to produce ATP (103, 104) would be seemingly beneficial during HMP 
given the glucose rich environment of clinically used perfusion fluids (KPS-1® /UW-
MPS) in the absence of oxygen carriers or exogenous oxygen. 
Findings from animal studies indicate that HIF pathway activation is not exhausted 
even after total mechanical ischaemia (such as during DCD retrieval conditions) (98). 
Given that there are potential benefits to further HIF stimulation following organ 
retrieval and HMP can deliver pharmaceutical agents to the cells within an organ, it 
is perhaps surprising that there are no previous reports detailing the role of 
pharmacological HIF pathway stimulators during HMP. 
HMP provides a novel opportunity to pre-condition organs prior to transplantation. 
Given these two potentially protective mechanisms of HIF activation during organ 
preservation, namely amelioration of the IRI phenomenon and promotion of 
glycolytic activity, the HIF pathway appears to be a target for metabolic optimization 
during the organ preservation period.  
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Metabolomics and NMR spectroscopy 
Metabolomics is the identification and quantification of the complete set of 
metabolites, or metabolome, within a biological system (105). The complete number 
of human metabolites present (or human metabolome) is not known, but there have 
been over 40,000 identified to date (106). Metabolites are small molecules (<1500 
Daltons) which participate in general metabolic reactions that are required for the 
maintenance, growth and function of a cell (107). The metabolites within a system 
reflect intrinsic biochemical activity, which is known to be highly sensitive to 
environmental factors. Metabolomics, like other 'omics' studies such as genomics 
and proteomics, have been the subject of great scientific interest in recent years. 
NMR spectroscopy is a valid method for identification of constituent metabolites 
within a biological sample, with proponents highlighting the highly sensitive, 
reproducible nature of this technique (7). Metabolic pathways are reflective of the 
genome and proteome with up to 10,000-fold increase in metabolite concentration 
resulting from a single amino acid change in a protein or base change in a gene 
(108). Furthermore, metabolic changes are apparent within minutes of a biological 
event and therefore provides an almost 'real-time' feedback (105). Whilst NMR 
metabolomics experiments have been described since the early 1980s (109), the 
development of high throughput NMR spectrometers with the necessary software for 
analysis has been relatively recent and has greatly improved its scientific utility 
(105). Indeed, the development of modern NMR spectrometers combined with the 
set-up of standardized sample preparation and acquisition protocols (110) have 
enabled the analysis of thousands of molecules with high sensitivity and 
reproducibility within a few minutes (111). 
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Whilst conventional metabolomic analysis provides an excellent snapshot of the 
biochemical milieu at a given time point, interpretation of pathway activity is 
difficult, given that most metabolites can be the product of multiple precursors. 
Metabolic flux analyses have been used successfully to determine pathway activity 
within isolated cell lines. However, the applicability to complex whole organ systems 
with structural and biochemical heterogeneity is limited and introduces large errors 
into the metabolic modelling software programmes. Isotopic tracer studies have 
been developed in order to gain mechanistic information of biological progression 
within a system, which is much more applicable to whole-organ analysis. Such 
isotopic metabolomic studies have been undertaken in the human clinical setting and 
are discussed in further detail below. 
There are two commonly employed techniques for performing metabolomic analysis, 
namely nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS). A comprehensive review of the physico-chemical principles of each modality 
and their relative merits is outside the scope of this thesis, but a summary of the 
modality (NMR) used throughout this thesis is given below. Needless to say, there 
are limits to both techniques but when used in conjunction they can provide a 
reliable, highly sensitive picture of the type, concentration and biochemical structure 
of a given compound. 
NMR spectroscopy is a technique dependent on the magnetic properties of specific 
atomic nuclei. The nuclei that are most commonly exploited for NMR analysis (e.g. 
1H, 13C, 15N, 31P) have an imbalance of protons and neutrons and therefore impose a 
small magnetic field from their spinning nuclei. NMR metabolomic techniques have 
been used to gain clinical insight into a multitude of pathological conditions, ranging 
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from cancer (112) to neurodegeneration (113) and a full range of the clinical 
applications of NMR is outside the remit of this chapter.  
Mechanical and quantum principles of NMR spectroscopy 
 In the absence of an external magnetic field, the nuclei of 'NMR detectable' atoms 
are not aligned in any preferential direction and therefore have no net 'lie' or 
magnetisation vector (Figure 8). However, when in the presence of an orientated 
homogeneous external magnetic field, the nuclei align themselves either parallel or 
antiparallel to the direction of the field lines, with a slight preference for nuclei 
aligned in the lower energy parallel direction (Figure 9). 
 





Figure 9 Magnetisation vectors of 1H nuclei in an external magnetic field 
 
As nuclei carry charge, a spinning nucleus possesses a magnetic moment (!) which 
is a product of the magnetogyric ratio (γ) and the angular momentum (P) such that: 
! = γP 
Although the net magnetisation of any single nucleus over time is parallel or 
antiparallel to the field lines, the individual nuclei actually precess around this 
magnetic axis, much like a spinning top in the earth’s gravitational field. This circular 
motion or precession rate is dependent on the magnetogyric ratio (γ) which is 
constant for any given nucleus and is a measure of how 'strongly magnetic' it is 
(114). Precession rate is also proportional to the external magnetic field strength 




In quantum mechanical terms, all nuclei possess a spin quantum number I, which 
may be zero (e.g. 12C), half (e.g. 1H) or one (e.g. 2H) or more. Where I=0, the 
nucleus has no net spin and is therefore not detectable by NMR spectroscopy. For 
protons, the most widely exploited nucleus in NMR spectroscopy, the spin quantum 
number I = 1/2 which means that any nucleus can exist in the +1/2 (up or α state) 
or -1/2 (down or β-state). As discussed, when an external magnetic field is applied 
the spins align in the direction of the magnetic field (either parallel α or antiparallel 
β), with slightly more nuclei in the α state compared to the β state. The difference in 
energy between the α and β states is proportional to the strength of the external 
magnetic field applied (B0). Nuclei in the lower energy α state can absorb a discrete 
photon of energy and transform into the higher energy β state. As the energy 
required is discrete, this corresponds to a specific frequency of electromagnetic 
radiation. This energy of the photon (∆E) is a product of the precession frequency 
(ν0) and Planck's Constant (h) such that: 
∆E = hν0= hγB0/2π 
Indeed, the early NMR spectrometers relied on a radio-frequency electromagnetic 
radiation that was gradually changed in the vicinity of the specimen. When the 
frequency of radiation correlated to the resonance frequency of a nucleus in the 
specimen, energy was absorbed (∆E) and this was recorded as a peak. 
Chemical shift 
The resonance frequency of a particular nucleus within a sample depends largely on 
the composition of the nucleus itself. However, due to the surrounding electron 
bonds, this frequency is also influenced by the chemical environment around it. The 
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alteration in resonance frequency from the fundamental frequency of the nucleus 
due to the surrounding electron environment is in the order of parts per million 
(ppm), and this concept of chemical shift is essential to the identification of 
compounds in NMR spectroscopy. Thus in 1H NMR spectroscopy, a proton within a 
methyl group attached to a methylene group has a much smaller chemical shift than 
a proton within a methyl group attached to an electronegative oxygen containing 
group.  
An NMR spectrum is a graphical demonstration of the shift in resonance frequencies 
from the fundamental resonance frequency for the nucleus of interest. Each peak 
within the spectrum is resultant from a proton with resonance frequency different to 
the fundamental proton resonance frequency and therefore represents a unique 
chemical environment. Each molecule, therefore, may have multiple distinct peaks in 
the spectrum; a simplified spectrum for methanol is demonstrated in Figure 11.  
Splitting 
Close examination of NMR spectra will reveal that many 'peaks' are actually two or 
more peaks closely spaced. This phenomenon of splitting can be explained by 
considering two protons (proton 1 and 2) attached to adjacent carbon atoms within 
an organic compound. The protons attached to the adjacent carbons are close 
enough to exert a magnetic influence on each other. As all nuclei within a substance 
exist in either the up (α) or down (β) state, then the magnetic field strength 
experienced by proton 1 will be either slightly more (external field + α ) or slightly 
less (external field + β) than the external field alone, depending on the magnetic 
orientation of proton 2, with almost half of the molecules of the substance in each 
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state. As the resonance frequency (ν0) of a nucleus is proportional to the magnetic 
field strength experienced by that nucleus, there will be two distinct resonance 
frequencies for the protons in this example resulting in spectral splitting. In an 
identical fashion, proton 1 will split the peak of proton two into two distinct peaks. 
The small frequency difference between the doublet of peaks in this example is 
known as the coupling constant (J), which is measured in Hz.  
For a methyl group (CH3) the three protons can all be in either the up (α) or down 
(β) state, resulting in four different perturbations of magnetic influence (all α, all β, 
two α one β, two β one α). The scenario of two α or two β is the most likely by a 
factor of three. Therefore a proton on an adjacent carbon is split by the methyl 
group into a quartet in the ratio of 1:3:3:1 (Figure 12).  
Pulsed NMR 
During modern NMR analysis, a strong pulsed radio frequency is applied to the 
sample, perpendicular to the external magnetic field. This is exerted at a single 
frequency (approximately the midpoint of the required spectrum). The strength of 
the pulse is such that it exerts a bandwidth phenomenon affecting a range of nuclei. 
The effect of the strong pulsed wave is twofold. Firstly the nuclei are able to move 
freely between the α (low energy) and β (high energy) state as the specific energy 
required (photon) corresponds to the frequency of radiation. Secondly, the 
precession of the nuclei synchronise such that the net effect of all nuclei is a rotating 
magnetic dipole in the xy plane (Figure 13). NMR spectrometers contain a coil 
surrounding the sample probe, and much like a dynamo on a bicycle, the rotating 
magnetic dipole of the 'pulsed' nuclei induces a small electric current in the 
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surrounding coil. The frequency of the induced current (Hz) is dependent on the rate 
of precession of the nuclei. As the rate of precession for a nucleus is dependent on 
the chemical environment surrounding it, each group of protons within a sample 
with a unique surrounding chemical environment will induce an electric current with 
a slightly different frequency. The overall signal induced will be a summation of all of 
the individual signals.  
If the RF irradiation was continuous, a continuous alternating current would be 
induced with a sinusoidal waveform. However, the RF pulse applied to the sample is 
typically only 10 microseconds for a standard 1H spectrum. Upon cessation of the RF 
pulse, the precession of nuclei once again become desynchronised with restoration 
of the α / β discrepancy - a phenomenon known as R1 longitudinal nuclear 
relaxation. The net magnetisation vector of the nuclei realigns to the external 
magnetic field with 'petering out' of the induced current, a phenomenon known as 
the free induction decay (FID). 
Fourier transformation 
For a given sample, the waveform of the induced current is a summation of all the 
electrical current produced from all the nuclei with differing resonance frequencies 
within the sample (Figure 14). To convert this information into something 
interpretable, Fourier transformation (FT) is applied. This converts the summated 
waveforms with time and amplitude on the x and y axis to a waveform with 
frequency and amplitude on the x and y axis (Figure 15). The frequency is denoted 
in parts per million (ppm) and represents the chemical shift from the absolute 
resonance frequency of a standard reference compound. Each nucleus with a 
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different magnetic resonance is represented by a peak at a different frequency (or 
ppm). The number of peaks for a particular compound depends on the number of 
nuclei within that compound surrounded by a unique chemical environment. The 
height of each peak, or more precisely the area underneath it, is a function of the 
concentration of nuclei with that specific resonance and permits accurate 
quantification of compounds. 
The deconstruction of summated rapidly decaying waveforms into individual peaks 
within the 1D spectrum requires significant computation and can lead to artefact 
errors from random 'noise'. To minimise this, and improve the signal to noise ratio, 
this sequence of pulse excitation and FID recording is repeated multiple times for 
each sample and significantly enhances the sensitivity of this technique. 
Of the NMR ‘visible’ nuclei, 1H the considerably the most sensitive and resultantly 
accounts for the majority of NMR-based metabolomic studies. 13C studies, by 
comparison, are 5700 times less sensitive than 1H NMR due to the low natural 
abundance of 13C  (1.1%) and a much lower resonance frequency. The sensitivity is 
dependent on the natural abundance levels, the magnetogyric ratio of the nucleus in 
question at start of the pulse sequence times and the magnetogyric ratio of the 







Figure 10 Mechanical vector model demonstrating the magnetisation vector of a 
single nucleus, multiple nuclei and the bulk magnetisation 
 
Figure 11 1D 1H NMR spectrum of methanol (schematic) 
Sample at 30°C with chemical shift demonstrated (x-axis) The two unique 
environments of the 1H nucleus produce two peaks on the spectra, with a greater 




Figure 12 Chemical splitting effect of a methyl group 
Chemical splitting effect of the three protons of a methyl group on a proton attached 
to an adjacent carbon. A quartet pattern is observed with intensity ratio 1:3:3:1 
 
Figure 13 Schematic effects of RF pulse applied to a sample 
Equal numbers of nuclei exist in the alpha and beta state following irradiation with 
synchronisation of precession such that the net magnetic field follows a circular path 




Figure 14 FID waveform 
A schematic example of FID waveform (right) as a summation of multiple different 
ones (three in this example). 
 
Figure 15 Schematic representation of a Fourier transformation (FT) 
A waveform with amplitude (y) and time (x) is converted to amplitude (y) and 
frequency (x) in cycles/sec or Hz. In this example, a summation of two induced 
currents undergoes FT to produce two individual peaks on the spectrum. 
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The rationale for 2D NMR spectroscopy 
In one dimensional (1D) NMR spectroscopy there is only one time dimension utilised, 
corresponding to the FID, which undergoes Fourier transformation to produce a 
typical NMR spectrum. 
One of the great limitations of 1D NMR spectroscopy is that it can be difficult to 
distinguish between compounds if the nuclei within them have similar chemical 
shifts. This is particularly problematic for smaller compounds whereby there are few 
peaks on the spectrum to utilise and particularly when present in low concentrations 
and near to other compounds with a resonant frequency at high concentrations. 
Two dimensional (2D) NMR spectra can be extremely helpful in determining the 
structure of compounds which have spectra that overlap. In 2D NMR spectroscopy, 
two distinct time dimensions are involved. Essentially there is a variable wait time 
between initial RF pulse and a subsequent one. This wait time effects the FID signal 
generated and hence, variation of the wait time produces a range of FID signals. 
There are two different classes of 2D NMR spectroscopy experiments: correlation 
experiments and Overhauser effect experiments. Correlation experiments provide 
information regarding the connections or coupling within a molecule. Overhauser 
effect experiments provide information on spatial proximity within a molecule. 
Experiments contained within this thesis utilise one type of correlation spectroscopy: 
heteronuclear single quantum coherence (HSQC). However, needless to say, 
multiple types of 2D spectroscopy can be performed in the analysis of any sample 
and can give complementary information to determine the quantity and structure of 
a compound.  
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2D HSQC experiments (Figure 16) are used in this thesis to determine mechanistic 
metabolic information regarding metabolism during HMP. [U-13C] glucose (i.e. 13C 
nuclei in all six carbon positions of the glucose molecule) is used as a metabolic 
tracer.  
In 2D 1H,13C-HSQC NMR, the 1H chemical shift is presented on the x-axis and is 
correlated with the 13C chemical shift on the y-axis. Where there is a proton attached 
to a 13C carbon nucleus, a signal appears on the spectrum at the intersection of the 
two chemical shifts. Because both 1H and 13C chemical shifts are used, in comparison 
to 1D NMR, the likelihood of signal overlap is significantly reduced in HSQC spectra. 
This type of 2D NMR experiment exploits the spin properties of both 1H and 13C 
nuclei. The pulse sequence used involves heteronuclear (1H-13C) decoupling 
procedures, but 13C-13C couplings remain active. As a result, the peak on the 
spectrum resulting from a 13C nucleus is altered if an adjacent 13C nucleus is present 
such that the signal is split into two. Similarly, if there is a 13C nucleus positioned on 
each side of the 13C nucleus of interest, the signal is split into four components. The 
natural abundance level of 13C is well known and consistent (1.1%) and the 
probability of two neighboring carbon nuclei being 13C is very low (1.1%2 = 
0.0121%). 
Using quantum mechanical simulations, the amount of 13C-labelled substrates can be 
calculated relative to the amount of molecules in which a single nucleus will exist as 
the 13C isotope due to natural abundance levels (1.1%). Absolute concentrations of 
a given metabolite are easily determined using conventional 1D 1H NMR and 
therefore using a combination of 2D 1H,13C-HSQC and 1D 1H NMR, the absolute 
concentration of isotopic 13C-labelled substrates can be determined. The 2D HSQC 
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theory and protocols are discussed in further detail in Chapter 8 (p142). 
   
Figure 16 Example 2D 1H,13C-HSQC 
Region depicted from a heteronuclear single quantum coherence NMR spectrum 
(2D-HSQC) 
 
NMR in transplantation studies 
There has been great interest in the application of metabolomics to renal 
transplantation as a tool for identification of biomarkers applicable to 
transplantation, largely driven by the need for a clinically useful biomarker to predict 
post-transplant graft function.  
Proteomic studies have been performed extensively, and a multitude of potential 
biomarkers have been identified, many through non-targeted proteomic studies 
(115, 116). The most promising of these are neutrophil gelatinase-associated 
lipocalin (NGAL) (117, 118), kidney injury molecule-1 (KIM-1) (119-121), interleukin-
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18 (118), α- and π-glutathione S-transferase (GST) (122), liver fatty-acid-binding 
protein kidney (L-FABP) (123), and N-acetyl-β-d-glucosaminidase (NAG) (117, 124). 
However, whilst such studies are encouraging, it must be remembered that these 
biomarkers are yet to transcend into clinical practice. 
Hypothermic machine perfusion appears to be particularly well suited to 
metabolomic analysis as the circulating perfusate biofluid is plentiful, easily 
accessible, contains a range of metabolites and would be suited to repeat analysis. 
Indeed Bon and colleagues have suggested that 1D 1H NMR spectroscopy of 
perfusate could be used to provide real-time analysis to make organ viability 
decisions (125). However, despite the obvious attractions of metabolomic analysis of 
perfusate samples, there are no reports detailing the metabolomic profile of human 
perfused kidneys using 1H-NMR.  
Repeated studies have demonstrated a significant increase in the concentration of 
trimethylamine-N-oxide (TMAO) in urine and serum of dysfunctional grafts in both 
animal and human transplant models (126-129). TMAO is produced by the renal 
medulla with raised levels thought to be the consequence of ischaemic injury to 
medullary cells (105). However, the concentration of TMAO may also be related to 
transplant immunosuppression medication with higher blood levels (compared to 
controls) demonstrated in a rats treated with combination immunosuppression 
(130).  
Rush et al. demonstrated a correlation between the metabolomic profile of urine 
post-transplantation and histological rejection (131). They suggested that urinary 
metabolomics could be used a non-invasive way of determining major post-
transplant morbidity such as rejection. This concept has been echoed by other 
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similar studies (132), and characteristic urinary metabolic profiles have been shown 
to correlate with other histological abnormalities such as acute tubular necrosis 
(ATN) (133). 
Hene et al. (134) performed 31P NMR analysis on 42 human kidneys preserved using 
cold storage in HTK solution. Organs were subsequently transplanted and whole-
organ analysis performed. The group found there were differences in the 
phosphomonoesterase / inorganic phosphate ratios (PME / Pi) between kidneys, with 
the highest ratios observed in live donor kidneys and the lowest from donation after 
cardiac death (DCD) donors. They concluded that the PME/Pi ratio was a marker of 
the high energy phosphate status of the kidney. Interestingly the group did not 
compare ATP levels between the storage groups using NMR and reported that ATP 
was hard to detect using their NMR protocol (134). 
Despite the attraction of using a metabolomics approach for analysing various 
transplant models, some degree of caution must be adopted. The metabolomic 
spectra obtained from a sample of urine or plasma can contain hundreds of different 
data points with large numbers of discrete metabolites present. Metabolomic 
transplant studies are often small with patient numbers normally between ten and 
one hundred and often statistically underpowered to identify pertinent metabolic 
differences (77). Further methodological problems arise, particularly for non-
targeted metabolomic studies. Given the potential for large numbers of metabolites 
to be identified within a sample, there is a risk of detecting false positive 
significance, particularly at a significance level of 0.05 as is the case with most 
studies. Metabolomic studies only provide a metabolic 'snapshot' of the type and 
concentration of metabolites present at a particular time point. Conventional 1D 1H-
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NMR and MS merely identifies metabolites but does not provide mechanistic 
information regarding metabolic pathway activity. To determine pathway activity 
within entire transplant organs, isotopic tracer studies have been proposed and are 
further discussed below (p45, p51). 
Patients undergoing renal transplantation are an extremely heterogeneous group 
often with significant comorbidities (e.g. diabetes, hypertension). Furthermore, 
deceased donors are also a heterogeneous group with markedly different pre-mortal 
conditions (length of time in intensive care, nutritional status, cause of death, etc.), 
all of which invariably affect metabolism and therefore the exquisitely sensitive 
metabolome. In addition, from the moment of transplantation patients are 
commenced on a multitude of immunosuppression medications. Some of these 
drugs (such as the calcineurin inhibitor tacrolimus) need dose titration, and some 
(such as the steroid prednisolone) are fixed dose irrespective of body habitus. 
Immunosuppressive drugs have been shown to affect the metabolomic profile of 
urine (135-138) and blood (130), with detectable changes present after a single 
dose (137). 
Metabolomic analysis of urine poses further problems as often patients undergoing 
transplant do have some residual renal function and therefore native urine output. 
The volume of urine produced by the transplanted kidney is also variable both 
chronologically and between patients. The concentrating effect of the kidney is not 
uniform for all metabolites and for many this parameter is not known. Although 
many studies have tried to circumvent this issue by normalising the data to urinary 
creatinine levels, this metod is also likely to be inaccurate (139). Therefore drawing 
meaningful conclusions from the urinary metabolites identified in the mixture of 
 
 51 
native and transplant urine can be difficult. 
In summary, metabolomics studies in renal transplantation have identified potential 
biomarkers in both the plasma and urine that correlate with both post-transplant 
graft function and histological injury. However, none of these have been validated in 
a large patient series, or transcended into clinical practice. Interestingly, there are 
relatively few publications whereby a metabolomics-based approach has been used 
to try and determine the type and degree of metabolism during hypothermic 
machine perfusion. The most significant was a recent report by Bon et al. (125), 
whereby the perfusate of pig kidney was analysed using 1D 1H NMR. They found 
that the perfusate metabolites corresponded to post-transplant graft function in their 
auto-transplant pig model. The metabolomics-based approach to organ preservation 
is something that is explored in detail in this thesis in Chapters 5, 6 and 7 (p105, 
p116, p132). We hope that through a detailed understanding of metabolism during 
machine preservation the possibility of metabolic manipulation in order to improve 
post-transplant graft function could be explored. Furthermore, metabolic studies 
could reveal a clinically useful biomarker to denote organ viability. However, given 
the resources already invested to date, the hunt for an elusive biomarker of post-
transplant function may well be futile, and a metabolic profile rather than a single 
marker will prove to be the most robust indicator of organ viability. 
Isotopic NMR tracer studies 
Identification and quantification of metabolites provide an understanding as to the 
properties of a biological system. This may be sufficient to identify disease states 
and identify certain active metabolic pathways. However, many metabolites can be 
 
 52 
an intermediate in multiple different pathways with extensive interactions present. 
For example, the amino acid alanine is commonly produced from pyruvate through 
the enzyme alanine aminotransferase, which is known to be present in renal tubules 
(140, 141). However, alternative metabolic pathways can also lead to the 
accumulation of alanine, such as the catabolism of larger amino acids such as 
tryptophan (142). The metabolic 'snapshot' provided by conventional 1D 1H NMR / 
MS has limitations for the understanding of cellular metabolism in isolated ex vivo 
organ perfusion models. Identification and quantification of a metabolite is 
insufficient to determine mechanistic information. For a given metabolite in the 
perfusion fluid, metabolism of pre-existing intracellular substrate stores, metabolism 
of substrates derived from the perfusion fluid, and release of metabolites secondary 
to cellular lysis are all credible explanations for the substrate precursor.  Even with 
serial metabolite levels, such relationships are unclear. For this purpose, isotopic 
studies provide valuable additional information. 
Incorporation of stable isotopes such as 13C or 15N into common compounds enables 
metabolic tracer studies within a biological system. This is not a new concept with 
initial studies reported over 40 years ago (143). Glucose in which the carbons 1 and 
2 are in the 13C isotopic form ([1,2-13C] glucose) and in all six carbon positions ([U-
13C] glucose) are examples of compounds used for NMR tracer studies and are 
readily available and relatively inexpensive. The principle of tracer studies is simple, 
irrespective of the modality used for detection. For example, if [1,2-13C] glucose is 
added to the perfusion fluid of a kidney during HMP and [2,3-13C] lactate is detected 
then there is strong evidence of de novo glycolysis (Figure 17). Although 
theoretically possible, the relative population of naturally occurring [2,3-13C] lactate 
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is less than 1/8,000 (the natural abundance of 13C is 1.1%).  
In a study of the metabolism of human lung cancer tissue, patients underwent 
intravenous infusion of fluid containing universally labelled [U-13C] glucose before 
lung cancer resection (144). The metabolomic profiles of resected cancerous tissue 
was then compared to the surrounding non-involved lung tissue using both NMR and 
gas chromatography-mass spectrometry (GCMS). Increased levels of 13C-labelled 
lactate, alanine, succinate, glutamate, aspartate and citrate were noted in the 
tumour tissue. The authors concluded that this was representative of greater 
glycolytic and TCA cycle activity in the tumour tissue and further postulated that TCA 
intermediates were required for the synthesis of proteins and other substrates for 
the growing tumour (144). 
In a rat lung transplant model, rat lungs were flushed and then preserved with [U-
13C] glucose and/or [3-13C] pyruvate following inflation with oxygen (145). After 6 
hours of preservation, tissue extracts were analysed using 1D 13C NMR spectroscopy. 
There was evidence of acetyl-CoA in both groups, highlighting TCA cycle activity. 
However, the proportion of labelled acetyl-CoA was significantly higher in the 
pyruvate labelled group with evidence of gluconeogenesis and glycogen synthesis in 
the 13C pyruvate-only group and the authors conclude that the addition of pyruvate 
in lung preservation fluid would be more useful than glucose as both an anabolic 
and catabolic substrate (145). There are multiple reports using 13C and other NMR 
detectable isotope tracer studies on cell lines including those specific to the kidney. 
However, to our knowledge, there are no published reports of ex vivo kidney 
perfusion whereby isotopic 13C substrates are introduced into the perfusion fluids 





Figure 17 Conversion of 13C labelled glucose into lactate 
In this example, glucose labelled with the isotope 13C in the 1 and 2 carbon nucleus 
positions ([1,2-13C] glucose) are converted into two pyruvate and two lactate 
molecules with isotopic labelling in the 2 and 3 carbon positions [2,3-13C] pyruvate 
and [2,3-13C] lactate in one half of the molecules.  
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Hypothermia and hypoxia in biology overview 
Unlike certain mammals, humans have few natural mechanisms to cope with either 
severe hypoxia or hypothermia. Prolonged exposure to such conditions culminates in 
cell death and principally occurs when the cellular ATP reserves are insufficient to 
sustain the ATP-dependent processes necessary to maintain transmembrane ionic 
gradients (55). This can result in membrane depolarisation with a catastrophic influx 
of Ca2+, leading to membrane rupture and cellular necrosis (146). The brain and 
heart appear particularly sensitive to such extremities as evidenced by either brain 
dysfunction or cardiac arrhythmia as the predominant cause of death in such 
conditions. In contrast, human skeletal muscle is amongst the most refractory 
tissues to hypoxic conditions (55). 
Under normal physiological conditions, the kidneys are metabolically highly active. 
The renal blood flow per gram of tissue is amongst the highest in the body and the 
kidneys receive 20-30% of the cardiac output and consume 10% of the bodies 
oxygen. The functions of the kidney are multiple and many, such as the filtration 
and selective reabsorption of electrolytes, are highly ATP-dependent. As a result, the 
kidney has evolved to supply the necessary energy substrates through intrinsic 
synthetic activity. As the static energy reserves within the kidney, such as glycogen, 
are relatively low, the kidney is reliant on the metabolism of circulating substrates. 
These include glucose, lactate, glutamine, free fatty acids, ketone bodies, citrate and 
glycerol (147).  
After filtration of circulating blood across the glomerular membrane in the cortex, 
most of the water and electrolytes are reabsorbed in the proximal convoluted tubule 
(also in the cortex). The cortex, therefore, is the region with the highest energy 
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requirement and resultantly is the site of highest mitochondrial oxidative 
phosphorylation, with only a small proportion occurring in the outer medulla. The 
cells of the proximal convoluted tubules are also unique within the kidney as they 
contain all the enzymes needed for gluconeogenesis (147). 
Cellular response to hypoxia 
Adenosine triphosphate (ATP) is the principal energy source within the cell. Protein 
synthesis and maintenance of the Na+/K+ APT-ase pump are the two principal 
consumers of ATP in mammalian systems during standard metabolic rate (SMR) 
(148). It is thought that 90% of the oxygen consumption of mammalian cells in the 
at SMR is utilised by mitochondria, of which 80% is coupled to ATP synthesis, with 
20% subject to proton leak (148).  
In stress conditions such as hypoxia, human cells are unable to downregulate the 
amount of ATP necessary to maintain cellular functions and therefore an ATP deficit 
is quickly established which is only partially and temporarily abridged by anaerobic 
ATP production such as glycolysis.  In contrast, animals such as the common frog 
(Rana temporaria) can downregulate their energy turnover in hypoxic conditions and 
thus conserve vital sources of ATP. Indeed there is surprisingly little variation in the 
intracellular ATP concentration in certain species despite significant shifts in oxygen 
tension (149). This effective ATP equilibrium in such species is sustained by a 
selective metabolic depression via the down-regulation of energy consuming 
processes and up-regulation of the efficiency of energy-dependent processes (148), 
(150). Protein synthesis, in particular, has been shown to be drastically reduced in 
certain species in hypoxic conditions with prioritisation of more essential energy-
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dependent functions such as membrane ionic stability via the Na+/K+ ATP-ase (151) 
(152). Although ATP-dependent Na+/K+ pumps remain the dominant site of ATP 
consumption, even in species refractory to hypoxia, this is minimised through a 
phenomenon known as 'channel arrest' (146). Suppression of ion channel densities 
effectively results in a reduction in cell membrane permeability with maintenance of 
transmembrane ion gradients and electrochemical potentials (153-155). The concept 
of anoxic ion channel arrest is well established, but the precise mechanism by which 
this occurs is not known. There is some evidence that adenosine may play a role, 
which in itself is an end product of ATP breakdown. 
In contrast, in oxygen-sensitive species such as humans, ion channels often become 
more porous in hypoxic conditions, even further increasing the ATP necessary to fuel 
the ATP-ase dependent ion channels. 
Oxidative phosphorylation occurring in the mitochondria of cells in oxygen-rich 
conditions produces the vast majority of cellular ATP. Of the potential 38 molecules 
of ATP produced from a single glucose molecule, 34 of these are derived through 
mitochondrial oxidative phosphorylation (142). The final step of ATP production 
within the inner mitochondrial matrix relies on the conversion of ADP to ATP via the 
enzyme ATP synthase, in conjunction with the influx of a proton via the F1F0 ATPase 
channel (55). However during periods of anoxia, the reversible enzyme, ATP 
synthase, that normally results in ATP production, works in the contralateral 
direction to pump protons from the mitochondrial matrix and maintain membrane 
stability. Thus during periods of anoxia, the mitochondria become an ATP consuming 
organelle, further exacerbating the hypoxic strain within the cell (156). However, 
only a small concentration of oxygen is necessary to ameliorate this backwards flow 
 
 58 
of ATP synthase, with some evidence that mitochondrial efficiency is actually 
improved in hypoxic conditions due to the reduction of protein leak and uncoupled 
respiration (157). 
Provided there is sufficient oxygen to diffuse into the mitochondria and facilitate 
oxidative phosphorylation, certain tissues exposed to chronic hypoxia in mammalian 
systems display adaptive properties, with both liver and heart cells reducing their 
metabolic rate by up to 50% (158, 159). Some cells, such as cardiac myocytes 
display a reduced functional activity in hypoxic conditions (160). Other adaptive 
mechanisms are less clearly defined but include changes in neurotransmitter release, 
ion channel activation and gene expression (161-163). Examples of hypoxia-induced 
genetic induction include the hormone erythropoietin (EPO), which stimulates red 
blood cell production, and vascular endothelial growth factor (VEGF). Furthermore, 
there is up-regulation of the enzymes involved in anaerobic glycolytic pathways and 
heat-stress proteins which are protective against intracellular stress (55). The 
mechanisms of gene up-regulation are not fully clear but it may be that the hypoxia 
sensor is a haem protein that initiates a cascade that culminates in reactive oxygen 
species (ROS) (55).   
Cellular response to hypothermia 
There is also a profound effect of uncontrolled hypothermia at a cellular level in 
humans and other cold-sensitive mammals. Many transcellular ion-regulatory 
mechanisms are thermosensitive with some evidence that cell membrane 
permeability is also increased at low temperatures and that membrane stabilisers 
such as polyethylene glycol (PEG) or butylated hydroxytoluene may be protective 
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(164, 165).  The term 'cold swelling' has been coined to describe the harmful effect 
of hypothermia on neural tissue and is largely a consequence of the increase in 
intracellular Na+ concentration. Reduction in Na+/K+ ATP-ase activity occurs 
although it is not clear whether this is purely due to a supply / demand discrepancy 
of ATP in hypothermia or a thermodynamic effect of decreased ATP production (146, 
166). Intracellular hypernatraemia is further exacerbated by activation of the Na+/H+  
exchanger and by a relatively greater passive influx of Na+ compared to efflux of K+ 
(167).  
Although the hypothermic effect of the intracellular accumulation of Na+ is perhaps 
best understood, many other active and passive ion transport mechanisms are also 
thermosensitive. Elevated cytosolic concentrations of Ca2+ have been demonstrated 
in animal models during hypothermia (168, 169). Disruption of the cell membrane 
Na+/Ca2+ exchange process and reduced uptake (ATP dependent) and decreased 
efflux of Ca2+ from the sarcoplasmic reticulum are the likely causative factors (146) 
(170).  Further massive calcium influx results if the rise in cytosolic Na+ occurs to 
such an extent so as to trigger membrane depolarisation and the opening of voltage-
dependent Ca2+ channels, which often results in irreversible cellular injury (146, 166, 











Abattoir kidney studies 
Abattoir pig kidneys were used for all animal experiments in this thesis. Organs were 
obtained from a local abattoir. The rationale for using these organs is that they are 
cheap, easily obtainable and do not involve animal slaughter purely for research 
purposes. Porcine kidneys are a widely used large animal model in transplantation 
studies owing to their similar physiological and anatomical properties to human 
organs (171, 172). The use of abattoir kidneys has certain advantages and 
disadvantages compared to the other commonly used porcine model; namely the 
autotransplant model. 
Whilst the use of abattoir kidney makes thorough interrogation of functional 
outcome difficult (in contrast to autotransplant studies), for many studies, the 
purpose was to interrogate the metabolic output. Furthermore, multiple studies have 
reported that when young and otherwise healthy porcine kidneys (e.g. abattoir 
kidneys) are transplanted following periods of up to 24 hours of machine perfusion 
they have good functional outcome (173-177). One of the great advantages of using 
abattoir kidneys is that it permits a paired experiment model (i.e. the two kidneys 
from the same animal can be separately subjected to the control and experimental 
conditions). This is in contrast to the autotransplant setup whereby only one kidney 
from each animal is used for analysis. Abattoir kidneys in these experiments were 
obtained from FA Gill’s abattoir in Wolverhampton and 22–26 week old 'bacon 
weight' pigs, weighing 80–85 kg were used. 
Workstation setup 
Prior to receiving organs, a workstation was created in the abattoir to receive and 
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rapidly flush the organs in order to cool them and remove any remaining blood. All 
equipment used for this purpose was sterile, and the equipment setup is 
demonstrated in Figure 18 and 19. The environment was not truely sterile in the 
same vain as the operating theatre, not least due to the lack of laminar air flow. The 
basic equipment needed included bowls, surgical tools, 14G cannulae with an 
attached giving set and 4°C fluid for flush (either UW or Soltran® in these studies). 
For some studies, a pressure bag was utilised to obtain constant flush pressure and 
in others a drip-stand was utilised for this purpose. Much of the equipment utilised 
was disposable (e.g. cannulae, giving sets, perfusion fluids, etc.). Non-disposable 
items (e.g. drapes, metal bowl sets, etc.) were sterilised using autoclave before 
usage.  
Animal slaughter 
Pigs were killed by electrical stunning, following which they were hung by their hind 
legs and exsanguinated via transection of their jugular veins. Any blood required 
was collected at this stage in a heparinised vessel. The deceased animal then passed 
through several processing stages of hair removal before laparotomy (sternopubic) 
and removal of abdominal viscera. Kidneys were retrieved by abattoir staff with 
maximal lengths of renal vein, artery, and ureter attached. Male pigs were used in 
preference owing to their larger size and therefore vessel calibre. Organ retrieval 
was performed by the abattoir staff with pairs of kidneys used. 
Treatment of kidneys 
Following removal of a pair of kidneys and associated anatomy by the abattoir staff, 
organs were quickly transported to the designated workstation within the abattoir. 
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Organs were rapidly inspected to ensure that no gross 
abnormality/damages/lacerations were present. They were then weighed in order to 
determine the pre-perfusion weight. Kidneys were then placed into a bowl of ice and 
the renal artery cannulated. Perfusion of the organ with prechilled (4°C) 
preservation solution was rapidly commenced through a cannula sited in the renal 
artery (14 G). 5,000 units of heparin were introduced into each bag of perfusion 
fluid prior to receiving the kidneys in order to minimise intra-organ thrombosis. 
Based on the fairly fixed time periods each stage of the abattoir process takes, we 
estimate that the cold flush of pig kidneys was commenced 14 minutes after the 
animal’s death. The perfusion pressure was fixed using an inflatable 'IV pressure 
bag' or dripstand with slight variation in pressure depending on flush fluid and 
experiment. The fluid utilised in these studies was either Soltran® or UW, which are 
both used in clinical practice during the organ retrieval process. Each kidney was 
perfused with 1 L of fluid and the effluent fluid free from blood before perfusion 
ceased.  
Initial period of static cold storage 
Following the rapid cooling and flush-out of any remaining blood from the kidneys 
they were then re-weighed and the excess tissue around each organ resected. 
Kidneys were then placed in a fresh litre of fluid (either UW or Soltran®), placed in a 
sterile bag with air expelled and transported in a cooler box surrounded by ice back 
to the laboratory. 10 ml of Penstrep antibiotics was added to the cold stored kidneys 
to minimise bacterial contamination. The average period that organs were stored in 
these SCS conditions before starting HMP was 2 hours and reflects the period of SCS 
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that human organs undergo between retrieval centre and transplant centre.  
 
 




Figure 19 Abattoir workstation setup (2) 
Hypothermic machine perfusion 
Kidneys were reweighed prior to any perfusion experiments. The LifePort© Kidney 
Transporter 1.0 (Organ Recovery Systems) was utilised for all organ perfusion 
experiments (Figure 2) with two laboratory machines facilitating paired perfusion 
experiments. Where the kidney had an associated aortic patch (normally the left), a 
SealRing® patch connector (Organ Recovery Systems, Chicago, IL) was used to 
connect the kidney to the LifePort© machine (Figure 20). For the contralateral 
kidney, a T-connector was utilised for this purpose with a 5 mm T connector being 
the appropriate size for the majority of experiments (Figure 21). The accompanying 
LifePort© cassettes were used for all studies. Ice was inserted into the ice reservoir 
and the perfusion circuits primed prior to perfusion. The LifePort© ceases to perfuse 
at or above 8°C, and the temperature of most perfusion experiments was 
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consistently below 4°C. The default perfusion pressure of 30 mmHg was utilised for 
experiments in this thesis (Figure 22). For some experiments (e.g. the oxygenation 
experiments), additional equipment was required in the perfusion circuit such as an 
oxygenator (Figure 23 and 24). For this, additional tubing (1/4 inch internal 
diameter) was connected to the existing perfusion circuit and is further discussed in 
Chapter 9. 
 





Figure 21 Kidney connected using a 5 mm T connector 
 
 




Figure 23 Modified LifePort© device with Hilite LT 800 paediatric oxygenator 
 
Figure 24 Hilite 2800 paediatric oxygenator 
 
Perfusion fluid 
The perfusion fluid utilised in this thesis depended on the experiment being 
performed. For some measurements, industry standard KPS-1® fluid was used (e.g. 
for comparing SCS and HMP conditions). In other experiments, particularly where 2D 
NMR studies were used, a home-made variant of KPS-1® was formulated, and the 
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exact composition of this is discussed in the relevant chapter. For all experiments, 1L 
of fluid was used for perfusion. For most porcine perfusion experiments, the flow 
rate after the first hour was approximately 50 ml/minute resulting in the entire litre 
of fluid circulating through the kidney every twenty minutes.  
Perfusate sampling 
Perfusion fluid sampling (perfusate) was performed through the designated sampling 
port on the LifePort© device (Figure 25). Only small volume samples (circa 2 ml) 
were necessary for analytical purposes at each time point which was insignificant 
compared to the total volume of circulating fluid (circa 1 L)  
 
Figure 25 Sampling port for LifePort© device (arrowed) 
Tissue sampling 
Immediately after the designated experiment end time, kidneys were removed from 
the LifePort© and were laterally bisected (Figure 26) to enable the clear identification 




Figure 26 Lateral bisection of kidney 
 
Figure 27 Demonstration of cortex (outer) and medulla of bisected kidney 
This kidney was a control kidney and was not perfused. 
 
Metabolic studies 
From the laterally bisected kidney, chunks (circa 5 g) of renal cortex were dissected 
and snap frozen in liquid nitrogen in order to immediately cease metabolism. From 
the bisected kidney, areas of renal medulla were clearly identifiable, and these were 
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also dissected and snap frozen. All tissue samples were stored in -80°C conditions 
prior to metabolic analysis. Protocols for metabolic studies are discussed below.  
 
Histological studies 
From the bisected kidney, a wedge shape area of kidney encompassing all regions of 
the renal cortex and medulla was dissected (Figure 28) and stored in formalin. 
Sections of renal artery were similarly preserved. Samples were prepared for 
examination by light microscopy using two common stains: haematoxylin and eosin 
and periodic acid shiff’s. These were prepared using published standard techniques.  
 
Figure 28 Specimen of cortex and medulla for histological analysis 
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NMR sample preparation - perfusion fluid 
Non-extracted samples 
Each perfusate sample was stored in a 2 ml cryovial and frozen (-20°C) prior to 
sample preparation. When required this was then thawed at room temperature 
for preparation. A stock NMR buffer solution was prepared for each study. 
The stock solution composed of the following 
 
 60 ml of 0.4 M NaH2PO4 (+2 mM DSS + 8 mM imidazole) 
 90 ml of 0.4 M Na2HPO4 (+2 mM DSS + 8 mM imidazole) 
 60 ml of Deuterated water (D2O) 
(DSS = 4,4-dimethyl-4-silapentane-1-sulfonic acid) 
To do this, 150 ml of ultrapure water was prepared to which the two phosphate 
buffer reagents were added (2.88 g of NaH2PO4 and 5.11 g of Na2HPO4) along with 
0.067 g of DSS and 0.082 g imidazole. Following addition of D2O, the solution was 
mixed thoroughly before use. 
In a microcentrifuge tube, 231 µL of stock solution was added to 429 µL of perfusate 
to make a final volume of 660 µL with a final phosphate buffer concentration of 100 
mM. The lid was closed on the microcentrifuge tube prior to vortex. 5 mm NMR 
tubes were used for perfusion fluid analysis. The lid cap was removed from the NMR 
sample tube, and 600 µL of sample (stock + perfusate mixture) manually pipetted 
into this. Samples were re-capped and centrifuged using a hand centrifuge to 
remove any bubbles. Following this, samples were sonicated for 10 minutes to 
ensure even sample distribution within the NMR tube. The external surface of the 
NMR tube was then dried and re-centrifuged. A lint cloth was used to wipe the NMR 
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sample tubes prior to placing into an NMR sample rack and sealing the tube orifice 
with a polyoxometalate (POM) ball to prevent evaporation. NMR samples were 
stored at 4°C prior to processing or if delays of more than 24 hours anticipated they 
were stored at -80°C. 
 
Extracted samples 
In some studies, extraction of perfusion fluid was performed. Whilst this did 
introduce an additional step to sample preparation, it enabled the removal of large 
protein molecules from the sample, as well as concentrating the samples. Extraction 
was performed using a chloroform/methanol extraction method. 
Either 1.7 mm or 5 mm NMR tubes were used for analysis of extracted perfusion 
fluid depending on the study in question. An example protocol for preparation of 1.7 
mm NMR sample tube is given below. Any variation of this protocol is discussed 
further in the relevant chapter. 
Frozen perfusate samples were thawed and 1.5 ml was mixed with 1.5 ml methanol 
(-80°C) and 1.5 ml of chloroform (-20°C). The resulting 1:1:1 ratio solution was 
vigorously mixed for 10 minutes and then centrifuged at 1300 g at 4°C for 15 
minutes. This resulted in the biphasic separation of the solution, with the top layer 
containing the water, methanol, and polar metabolite fraction of the perfusate 
sample. From the upper fraction (polar), 2 ml was aspirated and dispensed into two 
microcentrifuge tubes (i.e. 1 ml in each). All polar fractions were dried overnight in a 
vacuum dryer set to 30°C. Following this, extracted samples were frozen until 
needed. To prepare samples for analysis, the dried perfusate extracts were retrieved 
from the freezer and resuspended in 480 µL of 0.1 M phosphate buffer (pH 7.0), 
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containing 0.5 mM DSS, 2 mM imidazole and 10% D2O. The dried pellet was 
vortexed until completely dissolved in a microcentrifuge tube and then sonicated to 
dissolve any remaining microparticles. Following this, the perfusate extracts were 
added to champagne vials and 35 µl (<10% of sample volume) of this was 
transferred to 1.7 mm NMR tubes using a Gilson robot. The NMR tubes were 
centrifuged, wiped with methanol and a lint free cloth with inserted POM ball and 
stored at 4 °C. 
 
NMR sample preparation - tissue 
To prepare kidney tissue (cortex or medulla) for NMR analysis, chloroform/methanol 
extraction was also performed. Tissue samples were removed from the -80°C freezer 
and then submerged in liquid nitrogen and pulverised to a fine powder using a 
manual cryogrinder. 0.5 g of the resulting powder was then added to a 7 ml 
Precellys homogenisation tube containing 5.1 ml of methanol at -80°C. 
The prepared 7 ml Precellys tubes were all processed on the Precellys 24 Dual 
homogenisor, and run time was standardised to 8 runs at the lowest RPM/time (i.e. 
5000 RPM for 1 x 10 s) as we have observed this is the minimum required to 
homogenise renal tissue completely. Sample tubes were cooled on dry ice between 
runs to prevent sample overheating. 
The homogenised tissue in 5.1 ml methanol (-80°C) was mixed with 4.65 ml 
deionised water (rather than 5.1 ml, to account for the volume of water already 
present in the tissue, and 5.1 ml chloroform). 
From the upper fraction (polar), 4.5 ml was aspirated and polar fractions were dried 
overnight in a vacuum dryer set to 30°C. Following the drying procedure, samples 
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were prepared analysis as for the extracted perfusate samples above. 
 
NMR data acquisition 
NMR data acquisition was performed at the Henry Wellcome Building NMR facility, 
University of Birmingham. The two most common NMR spectroscopic methods used 
in this thesis were one-dimensional proton NMR spectroscopy (1D-1H NMR) and two-
dimensional proton-carbon heteronuclear single quantum coherence spectroscopy 
(2D 1H,13C-HSQC). The spectrometers used for acquisition were the Bruker AVII 500 
MHz and 600MHz spectrometers, with either a 5 mm or 1.7 mm inverse Cryoprobe. 
1D 1H NMR acquisition protocols 
The sample temperature was set to 300 K. Excitation sculpting was used to suppress 
the water resonance (178). Spectra were acquired with a 6 kHz spectral width 32768 
data points, a 4 s relaxation delay and 128 transients. Manual probe tuning and 
matching was performed before the first sample acquisition. Each sample was 
automatically shimmed (1D-TopShim) to a reference compound (TMSP or DSS) line 
width of less than 1 Hz before acquisition. Samples with a line width of more than 1 
Hz were re-acquired again after manual shimming where the TSP half height line 
width was shimmed below 1 Hz.  The experimental time to acquire 1D spectra was 
approximately 15 minutes per sample. Technical replicates for most experiments 
were performed. All data sets were processed using the MATLAB-based MetaboLab 
software (179). Data sets were zero-filled to 131072 data points. An exponential line 
broadening of 0.3 Hz was applied before Fourier transformation. The chemical shift 
axis was calibrated by referencing the TMSP/DSS signal to 0 ppm. Spectra were 
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manually phase corrected and baseline corrected using a spline before segmental 
alignment of all resonances using Icoshift (180). Spectra were then exported into 
Bruker format. 
 
Samples for NMR analysis were prepared by myself, T.S. or A.G. The data 
acquisition was performed by my supervisor C.L. Phase correction was 
conducted by myself, T.S., or A.G. under the supervision of C.L.  
 
2D 1H,13C-HSQC acquisition protocols 
Spectral widths were set to either 7,812.5 Hz (1H) or 24,155 Hz (13C). 512 complex 
data points were acquired for the 1H dimension of 2D 1H,13C-HSQC NMR spectra. 
30% out of 8192 complex data points (2458) were sampled for the 13C dimension 
using an exponentially weighted non-uniform sampling scheme. 128 transients were 
recorded for the 1D-NMR spectra using a 4 s interscan relaxation delay. 2 transients 
per increment were recorded for the 2D 1H,13C-HSQC NMR spectra. The interscan 
relaxation delay was set to 1.5 s. Each sample was automatically tuned, matched 
and then shimmed (TopShim) to a DSS line width of < 1 Hz prior to acquisition of 
the first spectrum. The chemical shift was calibrated by referencing the DSS signal 
to 0 ppm. 1D-spectra were manually phase corrected before correcting the spectral 
baseline using a spline function (179). 2D 1H,13C-HSQC NMR spectra were 
reconstructed with compressed sensing using the MDDNMR and NMRpipe software 
(181-183). The spectra were zero-filled to 1024 (1H) times 16384 (13C) real data 




Samples for NMR analysis were prepared by myself or T.S. The data 
acquisition was performed by my supervisor C.L. Phase correction was 
performed under the supervision of C.L.  
 
1D 1H NMR metabolite identification 
For 1D 1H NMR analysis, metabolite identification and concentration was determined 
using Chenomx 7.0 or 8.1 (Chenomx INC., Edmonton, AB, Canada). Chenomx 
software quantifies metabolites based upon the area under the peak for known 
spectral peaks for each particular metabolite. The software has a function for 
automated quantification. The quantification of all metabolites in this thesis was 
checked and corrected manually although automated quantification was often used 
as an initial fit process. Where metabolites have multiple peaks within a spectrum, 
there is inevitably some discrepancy in the reported concentration depending on 
which peak from the spectrum is used for this purpose. Therefore, to maintain 
consistency, for a given metabolite the same peaks were used for quantification 
throughout all experiments. The spectral peaks that I have utilised in this thesis for 
quantification purposes are depicted in Appendix p139-145 with examples shown 
below (Figure 29). To further minimize bias during this manual quantification 
process, samples were given unique identification numbers that did not reveal the 
experimental condition, effectively blinding the researcher from the study group. 





All metabolite quantification for 1D 1H spectra was performed or 
supervised by myself.  
  
 




2D 1H,13C-NMR metabolite analysis 
HSQC spectra were analysed using MetaboLab software, which has been designed 
and developed for this purpose by my supervisor C.L. The MetaboLab programme 
uses pyGamma software for multiplet simulations (184). The methyl group of L-
lactate is used to calibrate chemical shift based on the assignment in the human 
metabolome database (185). 
Following chemical shift calibration, potential metabolites are selected from the 
reference library, and the chemical shifts for each constituent 13C nuclei (with 
attached 1H) displayed (Figure 30). Subsequent to manually attributing peaks in the 
spectrum to particular metabolites, a fitting process occurs whereby a best-fit model 
is applied to the observed region based upon known and theoretical 13C-13C spin-
spin J-coupled splitting algorithms (Figure 31). 
Based upon the splitting patterns from adjacent 13C nuclei, the distribution of 
constituent isotopomers can be calculated in MetaboLab, correcting for the natural 
13C  abundance quantity. Thus the relative proportion of a labelled versus unlabelled 
metabolite can be obtained, but not the absolute concentrations using this software 
alone. For example, from a particular sample using MetaboLab software one can 
deduce that of the lactate present, 5% is universally labelled [U-13C] lactate (i.e. 13C 
in all 3 carbon positions). 
Whilst this NMR approach gives unparalleled detail regarding the structural 
isotopologues within a sample, unlike mass spectrometry techniques, the 
determination of this structural composition becomes challenging when there are 
extensive regions of 12C nuclei within molecules. Thus using this HSQC approach, it 
would not be possible to differentiate the presence of molecules of a six 
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hydrocarbon chain with 13C in positions 1, 2, 5 and 6 from equal proportions of 1, 2 - 
only and 5, 6 - only labelled molecules. Such challenges are easily resolved with MS 
and serve to highlight the potential benefits of a combined NMR and MS approach to 
isotopologue analysis.  
 
All fitting and isotopomer analysis using MetaboLab was performed by or 
supervised by myself or my supervisor C.L. 
 
 
Figure 30 MetaboLab software demonstrating chemical shifts for L-Lactic acid 
Only the chemical shift regions correlating to carbon 2 and 3 nuclei are seen as 
carbon 1 has no attached proton and therefore does not produce a signal. In this 





Figure 31 MetaboLab fitting process 
The splitting pattern for carbon 3 of lactic acid is demonstrated (blue line). A 
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Kidney transplantation has been an unprecedented success story of modern 
medicine with well reported patient benefits of survival advantage and improved 
quality of life compared with the alternative of dialysis (9, 186, 187). In addition, 
from a health economics perspective, kidney transplantation is advantageous with a 
cost saving of £250,000 per kidney compared with haemodialysis (assuming median 
graft survival 10 years) (12). 
In the initial five decades since the inception of kidney transplantation, there has 
been a dramatic progressive improvement in outcomes and is well demonstrated in 
Figure 32. The reasons for these improvements are multifactorial, but advances in 
immunosuppression therapy (e.g. introduction of azathioprine and later tacrolimus), 
and improved perioperative management are undoubted contributory factors. 
However whilst kidney transplant recipients in the contemporaneous era enjoy 
excellent outcomes,  with 1-year graft survival (death-censored) rates of  94% for 
deceased donor organs (8) these have not altered over the past decade (188) and is 
perhaps surprising. 
Given that the prognosis for transplant recipients, whilst excellent, appears to be 
static, it would be reasonable to question whether therapies such as hypothermic 
machine perfusion (HMP) can offer any clinical benefit, especially given the financial 
and resource costs of this intervention. 
However, such is the success of transplantation that there is a significant disparity 
between the number of organs available and the demand for such organs. Given the 
need for further organs (discussed in Chapter 1) efforts have focused on increasing 
the number of organs available. Living donor kidney transplantation has partially 
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bridged this gap, with expansion in numbers in the UK over the past decade (Figure 
33). However demand for organs still outstrips supply, and as such, a greater 
reliance on organs from expanded criteria donors, or marginal donors are being 
used. Whilst once organs such as those from deceased after cardiac death (DCD) 
organs were infrequently transplanted, these are now commonplace, even from 
more elderly donors. Indeed whilst the stereotypical donor from several decades ago 
was a previously fit young male involved in a road traffic accident, the equivalent 
donor in the contemporaneous era is several decades older with multiple medical 
comorbidities.  
Not only is there a perception that kidneys utilised for transplant in the modern age 
are from higher risk donors, but that also the recipients of such organs are also 
generally more high risk. Indeed as kidney transplantation has become more 
widespread and recipients of transplants living longer than ever before, it is not 
uncommon for patients to have several previous transplants over their lifetime. Thus 
recipients of kidney transplants performed in this era are often highly sensitised 
(have high levels of preformed circulating antibodies), are often more elderly, with 
resulting cardiovascular comorbidity and many have no easy surgical location in 
which to site the kidney. 
If indeed the organ quality utilised for transplantation has worsened with the 
development of transplantation and that these organs are indeed transplanted into 
more medically complex recipients then even stasis in outcome measures reflects 
significant improvements in clinical practice. Thus the presumption that hypothermic 
machine perfusion has resulted in little improvement in overall transplant outcome is 
oversimplistic as the incorporation of this technology into clinical practice has 
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occurred in an era when both donor and recipients of kidney transplants are more 
complex.  
In this chapter, I aim to determine whether there has been a global worsening of 
deceased donor organ quality for kidney transplants occurring at the Queen 
Elizabeth Hospital, Birmingham over the past decade and whether these organs are 
transplanted into patients with greater medical risks. If indeed this is the case, as 
suspected, then it might provide a good rationale for hypothermic machine perfusion 
and for future technologies in order to optimise the function of these damaged 
grafts.    
Methods 
In this study, all adult patients receiving a kidney transplant from a deceased donor 
at the Queen Elizabeth Hospital, Birmingham between January 2004 and January 
2014 were included. Data was obtained from an in-house database and the NHS 
Blood and Transplant Registry (a national registry to whom transplant centres are 
obligated to submit transplant information to).  
To analyse whether donor and recipient characteristics have altered over the past 
decade, the patients (n=754) were divided into three groups (early, middle and late) 
depending on when the transplant was performed. Donor, recipient, and transplant 
specific factors were compared across the three groups and patient survival, graft 
survival and creatinine values at one year were used as outcome measures.  
Findings 
We found that there was indeed a global worsening of donor organ quality over the 
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three eras. One measure of this was the increase in the kidney donor risk index 
(KDRI), a predictive scoring system used to determine the projected median survival 
of a kidney transplant based on donor, recipient, and transplant specific factors.  
However, despite the increasing complexity of transplantation in the modern era, 
reassuringly there was no corresponding detriment in transplant outcomes with no 
difference in patient or graft survival demonstrated at one year. Indeed graft 
function actually improved between the first and last era, with a decrease in the 
median creatinine values between the early and later era (median: 161 mmol/L vs. 
132 mmol/L, p < .001)  
Conclusion 
In conclusion, in this large single centre analysis, we found outcomes for 
kidney transplants over the past decade have stayed static or for some 
indices actually improved. This has occurred in the context of both 
increasing complexity of kidney donors and recipients and reflects 
considerable improvements in the perioperative treatment. One of the 
major advances to occur during this study period was the advent of 
hypothermic machine perfusion, and as it was our practice to perfuse the 
majority of marginal kidneys used (roughly one third), this is likely to be a 
major contributor to this improvement in outcome.  
We feel that this study provides circumstantial evidence to support the 
usage of hypothermic machine perfusion in the deceased donor setting. 
Furthermore, given the ever increasing demand for kidney transplants, the 
donor pool is likely to be expanded further in the future. Therapies such as 
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HMP are likely to become ever more important in the quest to optimise the 
function of such marginal kidneys.  
The following manuscript was published in the journal Transplantation Proceedings 
in July 2015. I am the first author of this manuscript and was responsible at every 
stage of its production. I have written the manuscript included.   
 
Figure 32 Graft survival by transplantation era. 
Clear demonstration of the progressive improvement in outcomes with successive 







Figure 33 Increase in living donor transplantation 
Demonstrating the increase in living donors in the UK over the past decade (grey 
bars). There has also been an increase in the number of deceased cardiac death 
(DCD) donors over this period (from NHS Blood and Transplant Organ Donation and 
Transplantation Activity Report 2014/15(8).  
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ABSTRACT
Objective. As renal transplantation continues to evolve, there appears to be a change in
both donor and recipient populations. Traditional markers of high-risk donor (e.g.
donation after cardiac death [DCD]/expanded criteria donor [ECD]) and recipient (e.g.
obese, highly sensitized) operations appear to be more common without any noticeable
worsening of patient outcome. The present study aimed to compare outcome and define
the change in donor and recipient populations for cadaveric transplants over a 10-year
period at a large U.K. center.
Methods. Single-center analysis of all adult patients undergoing cadaveric renal trans-
plantation between January 2004 and January 2014 (n ¼ 754). Transplants were divided
into 3 groups (early, middle, and late) depending on the era, with donor, recipient and
outcomes compared.
Results. There were considerable changes in both donor and recipient factors between
the 3 eras, with a greater proportion of high-risk operations performed, as reflected by
significant increases in Donor Risk Index (median: 1.11e1.16, P ¼ .022), and the
proportions of ECD (22.2%e33.9%, P ¼ .003) and DCD kidneys (10.8%e19.4% P ¼
.011). However, 1-year graft survival was comparable between the eras, with a decrease
in the average 1-year serum creatinine between the early and late cohort (median:
161 mmol/L vs 132 mmol/L, P < .001). There was no significant increase in body mass
index (BMI) in either the donor or recipient population across the eras.
Conclusion. Improvement in transplant outcome continues despite a greater proportion
of transplants previously considered as high risk being performed. This is likely to reflect a
considerable improvement in pre- and postoperative management. BMI remains a major
continuing block to transplantation.
THE EVOLUTION of renal transplantation over thepast 60 years is a triumph of modern medicine, with
patients undergoing organ transplant in the modern era
expecting a 90% 1-year graft survival [1]. The decade-upon-
decade improvement in outcome is the consequence of
many factors, including improved immunosuppressive, sur-
gical, and perioperative standards.
Such are the benefits of renal transplantation that greater
numbers of patients are now offered this treatment,
including those with complex medical problems, as there is a
distinct survival advantage compared to dialysis even in
high-risk patients [2e4].
Despite the ever-growing demand, transplantation is
limited by the paucity of available organs, and great efforts
have been made to expand the donor pool, reflected by
increased transplant numbers both in the U.K. and world-
wide [3,5]. Expansion of the living kidney program and
widespread acceptance of both Extended Criteria Donor
(ECD) and Donation after Circulatory Death (DCD) or-
gans as suitable grafts has been central to this.
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Various scoring systems have been derived to predict the
likelihood and duration of post-transplant function. These
have been based on multivariable analysis of donor and
recipient factors on large datasets and have been prompted
by the need for optimal organ allocation. The Kidney Donor
Risk Index (KDRI) and the transplant calculator are the 2
most used in clinical practice, although the latter is only
validated as a predictor of DGF [6,7]. An alternative to the
KDRI was proposed based on a U.K. dataset and was based
solely on donor characteristics [8].
Despite the encouraging outcomes for modern-day
kidney transplants, there is a perception that both the
donors and recipients of cadaveric kidneys have become
more high risk. Some of the contributing factors (e.g.
age, body mass index [BMI]) may simply be reflective of
trends in the general population [9]. However, immu-
nological complexity such as highly sensitized patients,
often from multiple previous failed grafts, are transplant
specific [10].
There is also an opinion that the expansion of the living
donation kidney program has altered the overall group de-
mographics of cadaveric recipients. As a group, recipients of
living donor kidneys are younger, often with less comor-
bidity and often preemptive. Therefore, increased live
donor numbers may have removed a cohort of straightfor-
ward transplants from the list, thus concentrating the more
complex cases in the cadaveric pool.
The aim of this study is to compare chronological co-
horts of patients undergoing cadaveric renal transplant
over the past decade at a single U.K. transplant center to
determine whether perceived changed in donor and
recipient risk are reflected in clinical practice and trans-
plant outcome.
METHODS
Consecutive adult patients who underwent single-organ renal
transplantation at Queen Elizabeth Hospital, Birmingham, between
January 2004 and January 2014 were included. Donor and recipient
details including age, gender, ethnicity, BMI, donor status, comor-
bidity, serum creatinine levels, HLA mismatch, peak PRA value,
and dialysis status were obtained through the National Health
Service Blood and Transplant data registry and a prospectively
maintained in-house database.
Renal transplantation was performed via a retroperitoneal
approach as described elsewhere, with the right iliac fossa used
preferentially [11]. Patients underwent standard transplantation
workup, including chest radiograph, electrocardiogram, echocar-
diogram, myocardial perfusion imaging, coronary angiography, and
pulmonary function tests, where appropriate.
Immunosuppression Regime
All patients received 0.5 g methylprednisolone and 20 mg basilix-
imab (Simulect) at induction of anesthesia. Basiliximab was again
given on day 4 postoperatively. Patients were routinely treated with
a standardized triple immunosuppressive maintenance regime:
mycophenolate mofetil, tacrolimus (Prograf) and prednisolone.
However, for some patients in the early cohort, azathioprine,
cyclosporine and mycophenolate mofetil were used.
Statistical Methods
The data were initially split into 3 “eras,” based on tertiles, to give
approximately equal numbers of transplants in each group. A range
of factors were then compared across these groups. Jonckheere-
Terpstra tests were used for continuous factors, and Kendall’s s
for dichotomous ones, in order to consider the chronological
ordering of the periods being compared. Categorical variables with
more than 2 levels were compared using Fisher’s exact test.
Continuous data were assessed for normality prior to analysis,
and all were found to follow skewed distributions. Hence, the
continuous variables are reported as medians and ranges
throughout. All analyses were performed using IBM SPSS Statistics
22 (IBM Corp., Armonk, N.Y., United States), with P < .05 deemed
to be indicative of statistical significance.
RESULTS
During the 10-year study period, 1276 adult kidney trans-
plants were performed at our center, of which 754 were
cadaveric and met the inclusion criteria. These were divided
into three chronological eras (n ¼ 251 in the first 2 eras, and
n ¼ 252 in the final era) with the comparisons between the 3
eras for donor and recipient factors reported in Tables 1
and 2.
Both donor and recipient age were found to have
increased significantly over the period, from medians of 47
to 51 (P ¼ .035) and 46 to 49 years (P ¼ .018), respectively.
There was no significant increase in either donor (P ¼ .154)
or recipient (P ¼ .964) BMI during the study period. For
cadaveric donors, the rates of hypertension increased from
16.8% to 25.5% (P ¼ .017), but there was no significant
increase in the rate of diabetes (P ¼ .098). The distribution
of causes of death also changed (P < .001), with deaths from
anoxia increasing (4.8%e15.5%), whereas CVA deaths
remained consistent (66.5%, 65.3%, and 67.1% in the 3
eras).
There was a significant increase in the KDRI over the
time period, which increased from a median of 1.11 in the
first era to 1.16 in the last (P ¼ .022). Although modest in
absolute terms, this has prognostic implications, with ex-
pected median graft survival falling from 10.8 to 9.2 years
[6]. Furthermore, the increase in donor KDRI was
tampered by a significant decrease in the median cold
ischemia time (CIT) between groups from 17.5 to 15.8 hours
(P < .001). Indeed the KDRI would have risen further if
such hastening of CIT had not occurred.
Other markers of high-risk grafts also increased during
the study period. The proportion of ECD kidneys increased
from 22.2% to 33.9% (P ¼ .003) with a similar pattern for
DCD kidneys (10.8%e19.4%, P ¼ .011). The proportion of
highly sensitized patients (PRA >80%) increased from
8.4% to 13.5% (P < .001), whereas the proportion of pa-
tients with more than 2 HLA mismatches rose from 43% to
60% (P ¼ .032).
Of the outcomes considered (Table 3), both patient (P ¼
.157) and graft (death censored) (P ¼ .330) survival were
similar across the 3 periods, changing from 96.4% to 98.4%
and 91.3% to 88.7%, respectively. However, renal function
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improved across the study period, with a significant decrease
in 1-year creatinine levels between the early and later era
noted (median: 161 mmol/L vs. 132 mmol/L, P < .001).
DISCUSSION
Our data support the long-held assertion that recipients and
donors are becoming increasingly complex. We have
demonstrated significant increases in age (in both donor and
recipient), donor rates of hypertension, donor deaths to
anoxia, increase in KDRI, increase in the number of ECD
and DCD kidneys transplanted, increases in the sensitisa-
tion level of patients, and increases in the number of HLA
mismatches. Despite such increases in marginality of both
donors and recipients, outcomes have not only been main-
tained but have shown improvement, with superior graft
function noted in the later cohort. This is reassuring against
Table 2. Comparison of Recipient Factors Across the 3 Periods
Jan 1, 2004 to
Jun 10, 2007
Jun 11, 2007 to
Dec 25, 2010




Age (y)† 46 (16e72) 47 (16e77) 49 (17e75) .018*
Sex (male) 148 (59.0%) 148 (59.0%) 153 (60.7%) .699
Ethnicity .457†
Asian 60 (23.9%) 56 (22.3%) 76 (30.2%)
Black 18 (7.2%) 20 (8.0%) 20 (7.9%)
Other 2 (0.8%) 4 (1.6%) 2 (0.8%)








BMI >30 (kg/m2) 49 (24.0%) 54 (26.7%) 62 (24.8%) .902
Graft number 2þ 28 (11.2%) 33 (13.1%) 28 (11.1%) .961
PRA <.001*
0 193 (77.2%) 177 (70.5%) 133 (52.8%)
1e80 36 (14.4%) 48 (19.1%) 85 (33.7%)
>80 21 (8.4%) 26 (10.4%) 34 (13.5%)
Data reported as: “Median (Range)”, with P values from Jonckheere-Terpstra
test, or “N (%)”, with P values from Kendall’s s, as applicable, unless stated
otherwise.
*Significant at P < .05.
†P value from Fisher’s exact test.
Table 3. Transplant Outcome Measures Across the 3 Periods






to Jan 1, 2014 P Value
1-year patient
survival
242 (96.4%) 242 (96.4%) 247 (98.4%) .157
1-year graft
survival†
221 (91.3%) 221 (91.3%) 216 (88.7%) .330
1-year creatinine 161 127 132 < .001*
Data reported as: “Median” with P values from JonckheereeTerpstra test, or
“N (%)”, with P values from Kendall’s Tau, as applicable.
*Significant at P < .05.
†Censored at death.
Table 1. Comparison of Donor Factors Across the Three Periods
Jan 1, 2004 to Jun 10, 2007 Jun 11, 2007 to Dec 25, 2010 Dec 26, 2010 to Jan 1, 2014 P-Value
Age (y) 47 (7e74) 48 (12e72) 51 (13e76) .035*
Sex (male) 142 (56.6%) 126 (50.2%) 131 (52.0%) .303
Ethnicity .004*†
Asian 11 (4.4%) 0 (0.0%) 5 (2.0%)
Black 1 (0.4%) 5 (2.0%) 3 (1.2%)
Other 2 (0.8%) 4 (1.6%) 6 (2.4%)
White 237 (94.4%) 242 (96.4%) 233 (94.3%)
BMI (kg/m2) 24.9 (12.6e47.3) 25.7 (15.6e50.0) 25.5 (16.0e52.1) .154
Obese (BMI >30 kg/m2) 33 (13.1%) 45 (17.9%) 45 (17.9%) .163
Diabetes 6 (2.4%) 11 (4.5%) 13 (5.2%) .098
Hypertension 41 (16.8%) 47 (19.3%) 63 (25.5%) .017*
DCD kidney 27 (10.8%) 52 (20.7%) 49 (19.4%) .011*
Cause of death† <.001*†
CVA 167 (66.5%) 164 (65.3%) 169 (67.1%)
Anoxia 12 (4.8%) 28 (11.2%) 39 (15.5%)
Other 72 (28.7%) 59 (23.5%) 44 (17.5%)
Terminal creatinine (mmol/L) 76 (41e408) 74 (18e198) 73 (25e226) .014*
Total HLA mismatches .032*
0 36 (15.4%) 37 (14.7%) 33 (13.1%)
1 14 (6.0%) 14 (5.6%) 9 (3.6%)
2 83 (35.5%) 63 (25.1%) 58 (23.0%)
3 49 (20.9%) 92 (36.7%) 97 (38.5%)
4 39 (16.7%) 45 (17.9%) 54 (21.4%)
5 7 (3.0%) 0 (0.0%) 1 (0.4%)
6 6 (2.6%) 0 (0.0%) 0 (0.0%)
CIT (h) 17.5 (8.0e38.3) 17.0 (7.5e39.0) 15.8 (5.5e30.0) <.001*
KDRI 1.11 (0.61e2.51) 1.07 (0.51e2.62) 1.16 (0.58e2.19) .022*
Extended criteria donor 55 (22.2%) 53 (21.9%) 82 (33.9%) .003*
Data reported as: “Median (Range)”, with P values from JonckheereeTerpstra test, or “N (%)”, with P values from Kendall’s s, as applicable, unless stated otherwise.
*Significant at P < .05.
†P value from Fisher’s exact test.
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the background of increased complexity and is likely to
reflect improvements in perioperative management.
There have been several changes in practice that have
occurred during the study period that counter the changes
in recipient and donor characteristics. Although no new
major class of drug entered into routine use during the study
period, the evolution of immunosuppression has continued
and may be responsible for some of the improvement in
outcome [12].
Over the study period, the proportion of donor deaths
attributed to anoxia rose significantly from 4.8% to 15.5%.
It is hard to determine exactly the reasons for this. It may be
this rise represents an increase in the number of DCD do-
nors in the latter era.
Kidneys in the latter era were less well matched than in
the earlier era. It may be this reflects the changes to the
allocation system, with greater priority being weighted to-
wards other factors other than the HLA mismatch. It may
be this represents an inherent mismatch in our donor pop-
ulation (predominantly Caucasian) and our recipient pop-
ulation (with a high proportion of non-Caucasians).
During the study period, hypothermic machine perfusion
was adopted into routine clinical practice. Results from the
machine perfusion trial have demonstrated that this can
improve 1- and 3-year graft survival for cadaveric kidneys
overall [13,14]. The benefit of machine perfusion appears
most pronounced for expanded criteria kidneys and may be
partly responsible for limiting the effects of these marginal
organs within our population [15].
Not all donor/recipient factors worsened over the study
period, with an improvement in the donor terminal creati-
nine and CIT noted. The decrease in terminal creatinine is
perhaps surprising, particularly in light of the increasing age
of donors and by association the likelihood of reduced
glomerular filtration rate. A possible explanation for this
finding could be due to improved donor management in the
intensive care setting, with goal-directed therapy often
begun by specialist teams within the U.K. prior to the organ
retrieval process [16].
The reduction in CIT at our center, the only modifiable
transplant risk factor, has been an active development and
the reasons for this observation are likely to be multifacto-
rial. However, routine implementation of the “virtual
crossmatch” for patients with undetectable panel reactive
antibodies has negated the need for a lengthy crossmatch
period in this cohort of patients and has been a major
contributing factor.
Live donor transplants have been excluded from this
analysis to avoid nonmeaningful comparisons between
inherently different groups, especially given the expansion
of the live donor program during the study period. Inter-
estingly, live donors and recipients were found to be
younger than for cadaveric kidneys (median: 46 years and 44
years) with comparable BMIs. However, waiting list times
for live donor recipients are much lower (384 days vs 1344
days) in our population. The notion that the live donor
population has filtered some of the “easier” predialysis
patients from the transplant list therefore appears valid,
perhaps increasing the complexity in the remaining cadav-
eric pool. However, to balance this it must also be consid-
ered that the live donor pool also absorbs some of the most
complex transplants (e.g. ABO-I, HLA-I) and some po-
tential recipients may have technical factors rendering them
only suitable for a planned live donor implant.
This study is limited by only looking at relatively short-
term outcomes from a single, albeit large, center. How-
ever, despite these limitations it does serve to illustrate the
point that the characteristics of donor and recipient groups
have changed and transplants that were once considered
high risk are now performed routinely.
Although overall, donors and recipients have undoubt-
edly become more complex, there has been no change in the
proportion of obese patients transplanted. Reported out-
comes for obese patients receiving kidney transplants are
inconclusive [17e20], with no clear upper guidelines as to
the upper limit of acceptable BMI for transplantation. In
our population, outcomes for this group were worse,
with risks exaggerated in kidneys with multiple arteries [21].
The static BMI of recipients in this study does not reflect
the increase in BMI seen in the general population or the
number of obese patients assessed for transplantation at our
center and, as such, obesity appears to remain a significant
barrier to transplantation.
In the future, both the donor and recipient pool are likely
to show further evolution and present further challenges for
transplantation. Indeed it is estimated that almost a third of
patients commencing dialysis are over 70 [22].
If the changes in the last decade can be maintained,
provision for this evolution should be adequate. BMI re-
mains a major continuing block to transplantation and
careful consideration will be needed in order to best serve
these patients.
CONCLUSION
Although limited to a single center, our results show that
both donors and recipients of cadaveric kidneys are
increasingly more complex. Despite increased risk, out-
comes have improved over the study period, suggesting a
significant improvement in transplant care. It is likely that
both donors and recipients will become increasingly more
complex and that the challenge will be how to improve or
maintain renal transplant outcomes in this era of evolution.
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The benefits of HMP in the deceased donor kidney setting includes improved early 
and late graft function and is discussed in the introduction (p11). Furthermore, given 
the increasing complexity of kidney transplantation and increasing reliance on high-
risk organs, therapies that improve functional outcomes such as HMP are likely to be 
of increasing clinical importance.   
The outcomes for kidney transplants from living donors are superior to those from 
deceased donors (8). The reasons for this are multifactorial, but a major contributor 
is that these organs are from healthy donors and therefore the organs are not 
subjected to the physiological extremis of organs from deceased donors. In addition, 
the cold ischaemia time for living donor organs has traditionally been very short as 
the transplant operations have either occurred immediately after or even 
simultaneous to the organ retrieval (nephrectomy) operation. 
One of the major benefits of HMP for deceased donor kidneys is that it reduces the 
likelihood of delayed graft function (DGF) postoperatively (defined as the need for 
dialysis in the first week after transplant). Given that the rate of DGF in living donor 
kidneys has traditionally been very low (<5%), the benefit of the labour intensive 
and costly intervention of HMP was thought to be limited. Indeed, HMP was not 
utilised on any living donor kidney transplants performed in the UK between 2001 
and 2014 (data obtained following personal communication with NHSBT). 
However, practices within living donor transplantation have evolved over the past 
few years. One of the major developments is that increasing numbers of split site 
living donor transplants are performed, whereby the kidney donation operation and 
the transplant operation occur at two different hospitals. Needless to say, the 
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kidneys utilised in such split-site operations have much longer cold ischaemia time 
(CIT). The reasons for the increase in split-site operations are partly due to the 
increased number of altruistic or non-directed donors whereby members of the 
public donate a kidney to unknown recipients to whom they have no emotional links. 
The increase in numbers of altruistic kidneys has been dramatic over recent years 
and is demonstrated in Figure 34.  
Given that there is an increasing subset of live donor kidneys which have a 
significantly prolonged CIT and that prolonged CIT is associated with inferior 
outcomes for deceased donor kidneys, the following study was performed to 
determine whether living donor kidneys with prolonged CIT have inferior outcomes. 
If this were found to be the case, the beneficial role of HMP for living donor kidneys 
would need to be established, given its benefit in the deceased donor setting.  
Methods 
In this retrospective study of over 9000 transplant recipients using a national 
dataset, outcomes for living donor kidneys in the UK were analysed using 
multivariable modelling based on the duration of CIT (0-2 hours, 2-4 hours and 4-8 
hours). 
Results 
Live donor transplants with modestly prolonged CIT (4-8 hours) were found to have 
excellent outcomes. Although the risk of DGF on multivariable analysis was greater 
in the live donor group with prolonged CIT (p<0.001), the adjusted rates of DGF 
were low in the shortest and longest CIT group 4.3% vs. 8.6%. Whilst the impact of 
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DGF in live donor kidneys is not known, it is unlikely to mirror the prolonged 
deleterious sequelae sometimes seen in deceased donor transplantation. Even 
assuming DGF for live donor kidneys is equivalent to deceased donor organs and 
that HMP would have equal therapeutic benefit, the number of perfused live donor 
kidneys needed to prevent one occurrence of DGF would be 54 and is therefore 
probably not justified. (This is based on the reported reduction of DGF in the 
machine preservation trial for deceased donor kidneys (reduction from 26.5% to 
20.8%)) (28).  
Conclusion 
In conclusion, based on analysis of a large national dataset, there appears 
to be little evidence to support the routine usage of HMP for live donor 
kidneys, even for split-site operations with modestly prolonged CIT (4-8 
hours). In the albeit rare occurrence where there is an unforeseen delay in 
transplant operation (e.g. recipient has an anaphylactic reaction prior to 
anaesthesia) and the projected CIT is likely to be significantly more 
prolonged than this (e.g. 20 hours), then a decision to use HMP for such 
organs would seem reasonable although is not validated by this study.   
 
The following manuscript was published in the British Journal of Surgery in June 
2016. I am the first author of this manuscript. Statistical analysis was performed by 
James Hodson (biostatistician) but I was responsible for every other stage of its 
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Figure 34 Increase in number of unspecified (altruistic) kidney donors in the UK 
Data obtained through NHSBT data request procedures.  
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Background: The aim of the present study was to determine the effects of cold ischaemia time (CIT) on
living donor kidney transplant recipients in a large national data set.
Methods: Data from the National Health Service Blood and Transplant and UK Renal Registry databases
for all patients receiving a living donor kidney transplant in the UK between January 2001 and December
2014 were analysed. Patients were divided into three groups depending on CIT (less than 2 h, 2–4 h,
4–8 h). Risk-adjusted outcomes were assessed by multivariable analysis adjusting for discordance in both
donor and recipient characteristics.
Results: Outcomes of 9156 transplants were analysed (CIT less than 2 h in 2662, 2–4 h in 4652, and
4–8 h in 1842). After adjusting for confounders, there was no significant difference in patient survival
between CIT groups. Recipients of kidneys with a CIT of 4–8 h had excellent graft outcomes, although
these were slightly inferior to outcomes in those with a CIT of less than 2 h, with risk-adjusted rates of
delayed graft function of 8⋅6 versus 4⋅3 per cent, and 1-year graft survival rates of 96⋅2 versus 97⋅1 per cent,
respectively.
Conclusion: The detrimental effect of prolonging CIT for up to 8 h in living donation kidney transplan-
tation is marginal.
Paper accepted 17 February 2016
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10165
Introduction
Living donor (LD) kidney transplantation is associated
with excellent clinical outcomes, and has helped to address
the disparity between supply and demand of available
organs for transplantation. LD transplants now account for
one-third of all kidneys transplanted in the UK1.
Prolonged cold ischaemia time (CIT), the duration for
which the organ is cold stored before implantation, has
been demonstrated repeatedly to correlate with inferior
graft outcome for cadaveric kidney transplants, with higher
rates of delayed graft function (DGF), acute rejection and
inferior long-term outcome2–6.
CIT in the LD setting is usually shorter than for cadav-
eric kidney operations, and CIT times of less than 1 h are
achievable when simultaneous donor and recipient opera-
tions are performed7. However, the effect of a longer inter-
val of cold ischaemia in the LD setting is less clear, and
if associated with inferior outcomes would have important
consequences.
LD transplantation has evolved significantly over the past
decade, with greater numbers of split-site (two hospitals)
donor and recipient operations. This is largely a conse-
quence of the increase in paired exchange programmes
and non-directed or altruistic donors. Split-site procedures
are performed for logistical (to minimize the burden of
travel) and ethical (to avoid emotional coercion) reasons. If
longer CIT resulting from split-site operations were asso-
ciated with inferior outcomes, such decisions would have
to be rationalized against potential harms. Furthermore,
the potential role of hypothermic machine perfusion for
LD kidneys would need to be established. This would
seem attractive, given that it is associated with reduced
rates of DGF8–10 and improved graft survival for cadaveric
organs9,10.
The aim of this study was to determine whether mod-
est prolongation of CIT (up to 8 h) has any effect on
outcome for LD kidney transplants. Excellent outcomes
were reported for kidneys with prolonged CIT in a
previous study11 based on US registry data between 1990
© 2016 BJS Society Ltd BJS
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Table 1 Association between cold ischaemia time and patient demographics
Cold ischaemia time (h)
Valid no. < 2 2–4 4–8 P‡
Recipient
Age (years)* 9156 43 (32–53) 44 (33–54) 46 (36–56) <0⋅001§
Sex (men) 9149 1630 (61⋅3) 2829 (60⋅6) 1049 (56⋅9) 0⋅008¶
Ethnicity 9068 0⋅009
White 2326 (87⋅7) 3949 (86⋅0) 1548 (85⋅0)
Asian 188 (7⋅1) 376 (8⋅2) 174 (9⋅5)
Black 86 (3⋅2) 189 (4⋅1) 78 (4⋅3)
Other 52 (2⋅0) 80 (1⋅7) 22 (1⋅2)
Diabetes 9156 175 (6⋅6) 235 (5⋅1) 124 (6⋅7) 0⋅792¶
Dialysis at transplant 8619 <0⋅001
Haemodialysis 1290 (50⋅5) 2048 (46⋅9) 978 (57⋅4)
Peritoneal dialysis 589 (23⋅1) 1015 (23⋅3) 312 (18⋅3)
Not on dialysis 674 (26⋅4) 1300 (29⋅8) 413 (24⋅3)
Graft no. 9156 0⋅001¶
1 2322 (87⋅2) 4107 (88⋅3) 1528 (83⋅0)
2 292 (11⋅0) 478 (10⋅3) 257 (14⋅0)
≥3 48 (1⋅8) 67 (1⋅4) 57 (3⋅1)
CMV-positive 8570 1114 (44⋅5) 1889 (43⋅8) 865 (49⋅4) 0⋅007¶
Blood group 9150 0⋅822
A 1090 (41⋅0) 1904 (40⋅9) 758 (41⋅2)
AB 87 (3⋅3) 162 (3⋅5) 70 (3⋅8)
B 300 (11⋅3) 558 (12⋅0) 228 (12⋅4)
O 1181 (44⋅4) 2026 (43⋅6) 786 (42⋅7)
Donor
Age (years)* 9151 48 (39–56) 47 (38–56) 49 (40–57) 0⋅055§
Sex (men) 9150 1218 (45⋅8) 2115 (45⋅5) 847 (46⋅0) 0⋅949¶
Body mass index (kg/m2)† 8673 26⋅4(4⋅0) 26⋅7(4⋅0) 26⋅4(3⋅9) 0⋅280§
Ethnicity 9083 0⋅432
White 2299 (87⋅8) 4004 (86⋅5) 1618 (88⋅1)
Asian 184 (7⋅0) 347 (7⋅5) 128 (7⋅0)
Black 83 (3⋅2) 185 (4⋅0) 59 (3⋅2)
Other 51 (1⋅9) 93 (2⋅0) 32 (1⋅7)
Blood group 9146 0⋅018
A 848 (31⋅9) 1486 (32⋅0) 644 (35⋅0)
B 215 (8⋅1) 403 (8⋅7) 178 (9⋅7)
O 1595 (60⋅0) 2758 (59⋅4) 1019 (55⋅4)
Values in parentheses are percentages unless indicated otherwise; values are *median (i.q.r.) and †mean(s.d.). CMV, cytomegalovirus. ‡χ2 test, except
§Jonckheere–Terpstra test and ¶Kendall’s τ for binary/ordinal variables to account for the ordering of cold ischaemia time groups.
and 2005. Validation through a second large data set
is justified, given the potential implications for clinical
practice.
Methods
All adult patients receiving a LD kidney transplant between
January 2001 and December 2014 in the UK with CIT
between 0 and 8 h were included. Kidney transplant cen-
tres within the UK are obliged to submit demographic and
clinical data to both NHS Blood and Transplant (NHSBT)
and Renal Registry professional bodies for each transplant
performed; the data set can be assumed to be complete. The
two bodies collect different patient-specific and outcome
variables, and therefore the two data sets were amalga-
mated to try to include all possible variables.
Outcome measures
Primary outcome measures were 1-, 3- and 5-year graft
survival (death censored). Secondary outcome measures
were rates of DGF, serum creatinine values at 1, 3 and
5 years, patient survival, and rates of acute rejection within
3 months.
Statistical analysis
Initially, univariable analyses were performed to compare
factors across the CIT groups, using a combination of
© 2016 BJS Society Ltd www.bjs.co.uk BJS
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Table 2 Association between cold ischaemia time and matching/transplant factors
Cold ischaemia time (h)
Valid no. < 2 2–4 4–8 P†
Wait time (days)* 6605 287 (122–600) 285 (114–579) 358 (142–925) <0⋅001‡
Sensitization (PRA) 4701 < 0⋅001‡
0 601 (59⋅4) 1565 (63⋅7) 573 (46⋅5)
1–20 78 (7⋅7) 144 (5⋅9) 58 (4⋅7)
21–80 177 (17⋅5) 495 (20⋅2) 336 (27⋅3)
81–100 156 (15⋅4) 252 (10⋅3) 266 (21⋅6)
Year of transplant 9156 <0⋅001
2001–2005 879 (46⋅2) 852 (44⋅7) 173 (9⋅1)
2006–2008 672 (32⋅6) 1149 (55⋅8) 238 (11⋅6)
2009–2011 649 (26⋅1) 1297 (52⋅3) 536 (21⋅6)
2012–2014 462 (17⋅0) 1354 (49⋅9) 895 (33⋅0)
HLA mismatch group 9142 0⋅001
1 283 (10⋅7) 540 (11⋅6) 241 (13⋅1)
2 357 (13⋅5) 619 (13⋅3) 324 (17⋅6)
3 1241 (46⋅8) 2182 (46⋅9) 763 (41⋅5)
4 773 (29⋅1) 1308 (28⋅1) 511 (27⋅8)
Related donor 9150 1746 (65⋅7) 2989 (64⋅3) 926 (50⋅3) < 0⋅001
Antibody incompatibility 9156 <0⋅001§
Not present 2339 (87⋅9) 4178 (89⋅8) 1679 (91⋅2)
HLAi 175 (6⋅6) 178 (3⋅8) 72 (3⋅9)
ABOi 126 (4⋅7) 270 (5⋅8) 79 (4⋅3)
Both HLAi and ABOi 22 (0⋅8) 26 (0⋅6) 12 (0⋅7)
Values in parentheses are percentages unless indicated otherwise; values are *median (i.q.r.). PRA, panel reactive antibody; HLAi, HLA-incompatible;
ABOi, ABO-incompatible. †Kendall’s τ, except ‡Jonckheere–Terpstra test and §χ2 test (factor not ordinal).
Jonckheere–Terpstra, Kendall’s τ and χ2 tests, as appro-
priate. Multivariable analyses were then done, to account
for differences in demographics across the CIT groups.
These were based on binary logistic regression, Cox regres-
sion and general linear models, depending on the out-
come being considered, and used a stepwise approach to
select variables for inclusion. Full details of the statisti-
cal methodology can be found in Appendix S1 (supporting
information).
Categorical variables are reported as numbers and rates
throughout. Continuous variables are presented as geo-
metric means with 95 per cent confidence intervals (c.i.)
or median (i.q.r.), as applicable. For multivariable analy-
sis, odds ratios or hazard ratios are reported, as applicable,
along with 95 per cent c.i.
All analyses were performed using SPSS® version 22
(IBM, Armonk, New York, USA), with P < 0⋅050 deemed
indicative of statistical significance.
Results
Data were available for a total of 10 043 LD transplants
between 2001 and 2014. Of these, 809 had no data recorded
for CIT and 78 had CIT longer than 8 h, so were excluded.
This left a total of 9156 transplants, with a CIT of less than
2 h in 2662 (29⋅1 per cent), 2–4 h in 4652 (50⋅8 per cent)
and 4–8 h in 1842 (20⋅1 per cent).
The data set was generally well populated, with only
two co-variables (sensitization and pretransplant duration
on waiting list) being unavailable for more than 10 per
cent of transplants. Complete patient demographics and
data availability are reported in Tables S1–S3 (supporting
information).
The three CIT groups were markedly different on uni-
variable analysis (Tables 1 and 2). The prolonged CIT group
was associated with many markers of transplant complexity,
and recipients were generally older (P < 0⋅001), more likely
to be non-white (P = 0⋅009), more sensitized (P < 0⋅001),
with more previous transplants (P= 0⋅001), higher rates
of haemodialysis (P < 0⋅001) and cytomegalovirus (CMV)
positivity (P= 0⋅007), longer wait times (P < 0⋅001) and
were less likely to receive organs from related donors
(P < 0⋅001). However, several factors thought to convey
favourable outcome were more prevalent in the longer CIT
group, such as female sex (P= 0⋅008), fewer HLA mis-
matches (P= 0⋅001) and lower rates of antibody incompat-
ibility (P < 0⋅001). More recent transplants were also found
to be associated with longer CIT (P < 0⋅001).
Owing to these differences in patient demographics,
multivariable analyses were used to account for poten-
tially confounding factors. Table 3 summarizes the results
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Table 3 Adjusted associations between cold ischaemia times and outcomes detemined by multivariable analyses
Cold ischaemia time
2–4 h 4–8 h
Valid no. Overall P Statistic* P Statistic* P
Patient survival† 8019 0⋅440 1⋅08 (0⋅88, 1⋅33) 0⋅468 1⋅20 (0⋅91, 1⋅58) 0⋅205
Graft survival† 8056 0⋅049 1⋅06 (0⋅91, 1⋅24) 0⋅471 1⋅31 (1⋅05, 1⋅62) 0⋅016
Rejection within 3 months‡ 8334 0⋅004 0⋅81 (0⋅71, 0⋅94) 0⋅004 1⋅00 (0⋅84, 1⋅20) 0⋅970
Delayed graft function‡ 7168 < 0⋅001 1⋅14 (0⋅88, 1⋅49) 0⋅314 2⋅16 (1⋅60, 2⋅92) < 0⋅001
Creatinine level at 12 months§ 5191 0⋅025 1⋅5 (−0⋅2, 3⋅2) 0⋅094 3⋅1 (0⋅8, 5⋅5) 0⋅007
Values in parentheses are 95 per cent confidence intervals. *Relative to the group with a cold ischaemia time of less than 2 h. †Hazard ratios from
multivariable Cox regression model; ‡odds ratios from multivariable binary logistic regression model; §percentage differences from multivariable general
linear model. The full multivariable models are reproduced in Tables S4–S8 (supporting information).
Table 4 Adjusted outcomes from multivariable analyses
Cold ischaemia time (h)
< 2 2–4 4–8
Patient survival
1 year 99⋅1 99⋅1 99⋅0
3 years 98⋅0 97⋅9 97⋅6
5 years 96⋅5 96⋅2 95⋅8
Graft survival
1 year 97⋅1 96⋅9 96⋅2
3 years 94⋅8 94⋅5 93⋅3
5 years 92⋅4 92⋅0 90⋅3
Rejection within 3 months 17⋅2 14⋅6 17⋅2
Delayed graft function 4⋅3 4⋅9 8⋅6
Mean creatinine at 12 months (μmol/l) 122 124 126
Adjusted rates generated from the multivariable models in Table 3.
of these analyses, indicating the adjusted relationships
between CIT and the outcomes considered. The models
used to generate these adjusted statistics are reproduced in
full in Tables S4–S8 (supporting information).
Graft survival
After adjusting for confounding factors, there was no sig-
nificant difference in graft survival between the shorter
CIT groups (less than 2 versus 2–4 h), with a hazard ratio
of 1⋅06 (95 per cent c.i. 0⋅91 to 1⋅24; P= 0⋅471). How-
ever, the risk of graft failure was significantly higher in the
4–8-h group relative to the group with a CIT of less than
2 h (hazard ratio 1⋅31, 1⋅05 to 1⋅62; P= 0⋅016) (Table 3).
Adjusted rates of death-censored 1-year graft survival from
this model were 97⋅1, 96⋅9 and 96⋅2 per cent for the groups
with a CIT of less than 2, 2–4 and 4–8 h respectively, with
similar discrepancy at 3 and 5 years (Table 4).
Delayed graft function
DGF was defined as the need for dialysis in the first
postoperative week; the overall rate was 5⋅1 per cent. The
association between CIT and DGF was significant on
multivariable analysis (P < 0⋅001). Although there was no
difference between the groups with a CIT of less than 2 h
versus 2–4 h (P= 0⋅314), patients with a CIT of 4–8 h were
significantly more likely to develop DGF, with an odds ratio
of 2⋅16 (95 per cent c.i. 1⋅60 to 2⋅92; P< 0⋅001) relative
to the shortest CIT group (Table 3). The adjusted rates of
DGF were 4⋅3, 4⋅9 and 8⋅6 per cent for the groups with a
CIT of less than 2, 2–4 and 4–8 h respectively (Table 4).
Patient survival
CIT was not associated with survival on multivariable
analysis (P= 0⋅440). The adjusted 1-year patient survival
rates were 99⋅1, 99⋅1 and 99⋅0 per cent for the groups with
a CIT of less than 2, 2–4 and 4–8 h respectively.
Creatinine
After adjustment for confounding factors, a significant rela-
tionship was detected between CIT and creatinine level
at 12 months (P= 0⋅025). There was no significant differ-
ence in 12-month creatinine values for the two shorter CIT
groups (P= 0⋅094), but patients in the 4–8-h group had
significantly higher values than those with a CIT of less
than 2 h, with a mean difference of 3⋅1 (95 per cent c.i.
0⋅8 to 5⋅5) per cent (P= 0⋅007). The adjusted average cre-
atinine levels at 12 months were 122, 124 and 126 μmol/l
in the groups with a CIT of less than 2, 2–4 and 4–8 h
respectively.
Acute rejection
The rates of acute rejection (within 3 months) differed
significantly by CIT group in multivariable analysis
(P= 0⋅004). Interestingly, this difference was not between
the shortest (less than 2 h) and longest (4–8 h) CIT groups
(odds ratio 1⋅00, 95 per cent c.i. 0⋅84 to 1⋅20; P= 0⋅970).
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Instead, rejection was significantly less common in the
middle CIT group (2–4 h), with an odds ratio of 0⋅81
(0⋅71 to 0⋅94; P= 0⋅004) relative to the shortest CIT. The
adjusted rates of acute rejection were 17⋅2, 14⋅6 and 17⋅2
per cent for the groups with a CIT of less than 2, 2–4 and
4–8 h respectively.
Discussion
Based on a large UK national data set with good complete-
ness, this study has demonstrated that LD kidneys with
moderate prolongation of CIT (4–8 h) have excellent out-
comes, although these are marginally inferior to those with
shorter CIT.
This report of outcomes for moderately prolonged
CIT in UK patients corroborates the findings from the
earlier US study11, which is reassuring given the variable
transplant practice and patient outcomes between North
American and European centres. The American study
reported adjusted odds ratios for DGF of 1⋅84 and 2⋅05
in the longest CIT groups (4–6 and 6–8 h), compared
with 2⋅16 in the 4–8-h group in the present study. The US
study also observed a similar pattern of rejection, with odds
ratios of 0⋅72, 0⋅65 and 1⋅07 for the 2–4-, 4–6- and 6–8-h
CIT groups, compared with 0⋅81 and 1⋅00 for the 2–4-
and 4–8-h groups in the present study. The reproducible
finding, that several hours of CIT appears to minimize
rates of post-transplant rejection, is interesting and war-
rants further investigation, as the biological mechanism
for this is unclear.
In contrast to the US study, there was a small but sig-
nificant difference in graft survival between CIT groups,
which was worst in the 4–8-h CIT group (hazard ratio
1⋅31). Omission of era of transplant as a variable, and the
lower statistical power in the US study, are likely to be
the major reasons for this difference. The identification of
CIT as an independent risk factor for graft failure is an
interesting finding. However, adjusted graft survival rates
of 96⋅2 per cent at 1 year and 90⋅3 per cent at 5 years in
the 4–8-h CIT group justify planning LD transplants with
anticipated CITs of 4–8 h. Similarly, although statistically
significant, the minimal rise in serum creatinine concen-
trations in the prolonged CIT group is unlikely to be of
clinical relevance.
The classification of CIT into three groups in this study
(less than 2, 2–4 and 4–8 h) was deliberate, to reflect
typical CITs in different operative conditions. Times
under 2 h are achievable practically only when donor and
recipient operations occur simultaneously. Between 2 and
4 h reflects consecutive donor/recipient operations, and
4–8 h is a realistic target for most split-site procedures7,12.
The outcomes of this study reflect previous reports and
suggest that, with regards to CIT reduction, simultane-
ous procedures offer no clinical benefit compared with
sequential operations7, and that split-site operations con-
fer satisfactory outcomes12,13. It must be noted, however,
that the 4–8-h CIT group in the present study included a
number of sequential same-site procedures.
The donor and recipient differences between the three
CIT groups are surprising, with greater proportions of
highly sensitized, older, haemodialysed, CMV-positive
patients with multiple previous transplants, but with lower
levels of mismatch, in the 4–8-h CIT group. This is
likely to reflect the greater proportion of altruistic and
paired exchange kidneys in this group. Altruistic kidneys
are offered to the best match patient from the transplant
waiting list, and such patients are inherently more com-
plex than those receiving traditional LD transplants14.
Similarly, highly sensitized patients are more likely to find
a compatible donor via the paired exchange programme,
as this effectively increases the size of the donor pool
for this hard-to-match group15,16. Given the inherent
differences in donor and recipient characteristics between
CIT groups, univariable (unadjusted) outcome measures
are of limited value in this type of study; this highlights
the strength of population-based analysis to identify subtle
differences in outcome.
Although this data set included a multitude of donor,
recipient and transplant factors, the list was not exhaustive.
Even though there is no reason to suspect an unequal
distribution across CIT groups, initial warm ischaemia
time, anastomosis time, vessel anatomy and recipient body
mass index have been shown to affect outcome in cadaveric
kidney transplants17–20 and would have been interesting
to include.
As anticipated, this study has demonstrated significantly
higher rates of DGF in LD kidneys with a CIT of 4–8 h
compared with less than 2 h and 2–4 h (adjusted rates 8⋅6,
4⋅3 and 4⋅9 per cent respectively). Although these DGF
rates are low compared with those for cadaveric kidneys,
the almost twofold increase resulting from modest CIT
prolongation is surprising. DGF is defined as the need for
dialysis in the first week post-transplant and it is not clear
whether this was largely a single postoperative session or
more prolonged treatment. As such, the associated patient
and graft morbidity of DGF after cadaveric transplants may
not be applicable to LD kidneys.
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Initial work, performed largely by my predecessor, Ms Alison Guy focused on 
metabolomic analyses of human perfusate samples during hypothermic machine 
perfusion. Ms Guy was awarded an MD at the University of Birmingham (2015), and 
my role in this research was largely data analyses, interpretation and manuscript 
preparation.  
The rationale for this human perfusate analysis was twofold. Firstly a baseline 
understanding of the degree and type of metabolite production occurring in a 
machine perfused kidney would potentially offer a target for metabolic manipulation, 
with the potential to improve the function of ischaemically damaged kidneys.  
Secondly, we were hoping that analyses of perfusate metabolites would identify a 
metabolite, or more likely a panel of metabolites, that could act as a useful 
biomarker that could predict graft function. Such a biomarker would prove extremely 
useful in the clinical setting as greater numbers of high-risk kidneys are being 
considered for transplantation owing to the profound shortage of organs. Whilst 
some clinicians use perfusion parameters during HMP to aid decision making as to 
whether such kidneys are 'transplantable' this is not supported by robust evidence 
and there remains no sensitive, reproducible test to determine functional outcome in 
the pre-transplant period (78-81). A simple biomarker or panel of biomarkers 
detected during the perfusion process which accurately predicted post-transplant 





Ethical approval for this study was obtained from the West of Scotland Research 
Ethics Service (12/WS/0166) in July 2012. The decision to subject a kidney to HMP 
was based upon clinical parameters and kidneys were perfused using the LifePort© 1 
kidney transporter and 1L of KPS-1® fluid at 4°C. Informed consent was taken for 
each potential recipient of machine perfused kidneys with a patient information 
sheet provided. Further hospital Research and Development approval for this project 
was also attained. 
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Study overview 
During the study period, a total of 29 patients were recruited. 3 kidneys were not 
perfused for anatomical reasons resulting in machine perfusion of 26 kidneys that 
were subsequently transplanted. Perfusate samples were taken at 45 minutes and 4 
hours with metabolite identification and quantification performed using 1D 1H NMR 
spectroscopy and Chenomx 7.0 software (Chenomx Inc., Edmonton, AB, Canada). A 
total of 28 metabolites were identified in the perfusate. Not only were the 
concentrations of these demonstrated to vary significantly over time but four of the 
 
 108 
compounds were highly predictive of post-transplant graft function.  
There appears to be a strong correlation between the metabolic phenotype of 
transplant kidneys during the period prior to transplantation and the functional 
outcome for that organ. The implications of this are twofold; firstly that a metabolic 
‘panel’ could be used as a useful biomarker to determine which organs are non-
viable and should not be transplanted. Secondly, the metabolism could potentially be 
optimized during perfusion to improve the function of highly damaged organs. NMR 
spectroscopy is a valid technique for metabolic characterization of organs during 
perfusion and is likely to be used increasingly for this purpose. 
 
The work was summarised and published in the journal Transplantation in 2015, and 
the full paper is included in this thesis for review. As the second author, my 
contribution to this project was largely in data analysis, interpretation, and scientific 
writing. However, the bulk of the work was performed by Ms. Guy 
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Metabolomic Analysis of Perfusate During
Hypothermic Machine Perfusion of
Human Cadaveric Kidneys
Alison J. Guy,1,5 Jay Nath,1 Mark Cobbold,2 Christian Ludwig,3 Daniel A. Tennant,4
Nicholas G. Inston,1 and Andrew R. Ready1
Background. The metabolic processes occurring within the preserved kidney during hypothermic machine perfusion (HMP)
are not well characterized. The aim of this study was to use nuclear magnetic resonance (NMR) spectroscopy to examine the
metabolomic profile of HMP perfusate from human cadaveric kidneys awaiting transplantation and to identify possible
discriminators between the profiles of kidneys with delayed graft function (DGF) and immediate graft function (IGF).
Methods. Perfusates from HMP kidneys were sampled at 45 min and 4 hr of preservation with the LifePort Kidney
Transporter 1.0 (Organ Recovery Systems, Chicago, IL) using KPS-1. Prepared samples underwent 1-D Proton-NMR
spectroscopy, and resultant spectra were analyzed. Clinical parameters were collected prospectively.
Results. Perfusate of 26 transplanted cadaveric kidneys was analyzed; 19(73%) with IGF and 7(27%) with DGF. Glucose
concentrations were significantly lower in DGF kidneys compared to those with IGF at both 45 min (7.772 vs. 9.459 mM,
P = 0.006) and 4 hr (8.202 vs. 10.235 mM, P = 0.003). Concentrations of inosine and leucine were significantly different
between DGF and IGF kidneys at 45 min (0.002 vs. 0.013 mM, P = 0.009 and 0.011 vs. 0.006 mM, P = 0.036), and
gluconate levels were also significantly different between DGF and IGF kidneys at 4 hr (49.099 vs. 59.513 mM, P = 0.009).
Conclusion. Significant metabolic activity may be occurring in kidneys during HMP. The NMR spectroscopy of the
perfusate can identify differences in the metabolomic profiles of DGF and IGF kidneys that might have a predictive
role in viability assessment. Modification of harmful metabolic processes may improve outcomes for HMP kidneys.
Keywords: Cadaveric kidney, Hypothermic machine perfusion, Metabolomics, NMR, Transplantation.
(Transplantation 2014;00: 00Y00)
Hypothermic machine perfusion (HMP) is increasinglyused to preserve cadaveric kidneys in the period before
transplantation (1). Studies have demonstrated reduced
rates of delayed graft function (DGF) and improved graft
survival in machine-perfused kidneys compared to those
preserved in traditional static cold storage (SCS) (2Y5).
Hypothermic machine perfusion also provides a unique
opportunity for assessment of cadaveric kidneys during
storage with easy and safe access to perfusate samples, kid-
ney tissue and information regarding flow dynamics.
Accurate evaluation of allograft quality is essential to
prevent unnecessary kidney discard, allow maximized
donor-recipient matching and to plan appropriate periop-
erative care. Viability assessment is of increasing importance
in an era where marginal kidneys, with a greater risk of poor
graft function, are increasingly being used in an attempt to
address the organ shortage (6Y9). Despite considerable in-
terest in various indicators and markers of graft quality, few
are used routinely in clinical practice, and no single bio-
marker or parameter has proven to be definitive.
Although the clinical benefits of HMP are now well
documented, the exact processes by which this occurs remain
unclear. Although initially the mechanism of action was
thought to be the maintenance of vascular bed patency, there is
increasing evidence that substantial metabolic activity persists,
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and this may also have a role (10). However, the metabolic
activity in the ex vivo, hypoxic, hypothermic environment
provided by HMP is poorly understood.
Proton-nuclear magnetic resonance (1H-NMR) spec-
troscopy, or metabolomics, can be used to analyze fluids or
tissues and can simultaneously detect, identify, and quantify
hundreds of metabolitesVsome of which may have prog-
nostic or therapeutic value (11). Although several publica-
tions have demonstrated the feasibility of NMR for
evaluating different clinical scenarios in transplantation, no
previous studies, to our knowledge, have examined the
perfusate of human cadaveric kidneys during HMP using
NMR (11Y14).
The aim of this study was to use NMR spectroscopy to
examine the metabolic profile of the perfusate of human
cadaveric kidneys for transplantation and to identify possi-
ble discriminators between the profiles of kidneys with de-
layed and immediate graft function (IGF).
RESULTS
Twenty-nine kidneys were included in the study.
Three kidneys were rejected for implantation after HMP.
Reasons included severe atherosclerosis of the renal artery
with an adverse donor history, a hypoplastic cystic kidney,
and inadequate initial flush of the kidney at recovery. No
kidneys were rejected on HMP parameters. Transplantation
proceeded in the remaining 26 kidneys. Donor and recipient
characteristics, along with HMP parameters, are shown in
SDC1, http://links.lww.com/TP/B51. There were no statisti-
cally significant differences in characteristics or parameters
between the IGF and DGF kidneys.
Twenty-eight metabolites were detected in the per-
fusate of these kidneys at both 45 min and 4 hr of HMP. Of
these metabolites, six were recognized constituents of the
KPS-1 fluid (SDC2, http://links.lww.com/TP/B51): adenine,
gluconate, glucose, glutathione (reduced form), mannitol,
and ribose. Median concentrations of these metabolites
measured by 1H-NMR at each timepoint, and the P values
for change over time are shown in Table 1. There was a
significant change in concentration of glucose and gluta-
thione between the two timepoints.
The remaining 22 metabolites are not listed as con-
stituents of KPS-1. Median concentrations of these metab-
olites at each timepoint, and P values for change over time
are shown in Table 2. The majority of these metabolites
changed significantly.
Of the 26 transplanted kidneys after HMP, 19 (73%)
kidneys displayed IGF posttransplant, and seven (27%)
suffered from DGF. There were differences between the
metabolomic profile of these groupsVmetabolites that were
significantly different at one or both timepoints were glu-
cose, inosine, leucine, and gluconate.
Glucose concentrations were significantly lower in
DGF kidneys compared to those with IGF at both 45 min
(7.772 vs. 9.459 mM, P = 0.006) and 4 hr (8.202 vs. 10.235
mM, P = 0.003) (Fig. 1A). Receiver operating characteristic
(ROC) curves assessing the predictive accuracy of glucose
for DGF yielded an area under the ROC (AUROC) curve of
0.842 (standard error [SE], 0.080) at 45 min and 0.895 (SE,
0.069) at 4 hr (Fig. 2).
Concentrations of inosine and leucine were signifi-
cantly different between DGF and IGF kidneys at 45 min
(0.002 vs. 0.013 mM, P = 0.009 and 0.011 vs. 0.006 mM, P =
0.036) (Fig. 1B and C) but not at 4 hr. The AUROC for
inosine at 45 min was 0.833 (SE, 0.082) and for leucine at
45 min was 0.732 (SE, 0.135) (Fig. 2).
Gluconate levels were also significantly different be-
tween DGF and IGF kidneys at 4 hr (49.099 vs. 59.513 mM,
P = 0.009) (Fig. 1D) but not at 45 min. The AUROC for
gluconate at 4 hr was 0.851 (SE, 0.089) (Fig. 2). Cutoff
points for ROC curves are shown in SDC3 (http://
links.lww.com/TP/B51).
DISCUSSION
To our knowledge, this is the first report to detail the
metabolomic profile of perfusate during HMP of human
cadaveric kidneys. Changes in the perfusate composition
during this time may represent substances being removed by
the kidney to supply ongoing cell processes or products of
metabolism or degradation being released from the kidney.
This study demonstrates that after only 45 min of machine
perfusion, the perfusate is markedly different from the
original preservation solution. Furthermore, this study has
identified differences in the metabolomic profile of IGF and
DGF kidney perfusate that may allow prediction of func-
tional graft outcome after transplantation.
Accurate assessment of graft quality is increasingly
important to achieve the highest levels of success in trans-
plantation. Although donor information, such as patient
age, comorbidity, or terminal serum creatinine, along with
kidney biopsy data are important, they still have a limited
capacity for accurate prediction of graft outcomes (15,16).
Machine perfusion parameters, such as resistance, are also
TABLE 1. Metabolite concentrations (mM) for constituents of KPS-1 identified in kidney perfusate
Metabolite
Median Conc at
45 min of HMP Interquartile range
Median Conc at
4 hr of HMP Interquartile range P (change over time)
Adenine 4.82 4.12Y5.51 4.69 3.92Y5.57 0.804
Gluconate 53.05 50.69Y59.02 56.31 51.08Y61.87 0.340
Glucose 9.07 8.32Y10.04 9.75 8.35Y10.79 0.041a
Glutathione 0.89 0.79Y0.94 0.50 0.40Y0.60 G0.001a
Mannitol 32.13 31.13Y34.68 34.84 29.65Y40.50 0.111
Ribose 0.00 0.00Y0.00 0.00 0.00Y0.00 0.129
a Statistically significant at less than 0.05, Wilcoxon signed rank test.
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accepted as good indicators of graft quality, but several
studies have warned of the dangers of using resistance values
to determine kidney discard (17Y19).
Theoretically, biomarkers measured in urine and
perfusate have an advantage over biopsy data of being
noninvasive and can be measured frequently and objec-
tively. A recent review highlighted the biomarkers that have
been assessed in regards to graft outcome (20). Few studies
were recent, and even fewer deemed to be of good quality.
Levels of lactate dehydrogenase, glutathione-S-transferase
and aspartate transaminase were significantly associated
with DGF in the greatest number of studies, but further
validation was recommended.
The NMR-based metabolomics is a novel approach for
rapidly identifying the changes in global metabolite profiles
of biologic samples and is widely used in other disease enti-
ties (21). Several studies have demonstrated possibilities for
the use of NMR-based metabolomics within transplantation;
it has shown promise as a tool to predict long-term graft
outcome based on the energy state of the kidney in vivo, and it
may be able to assess markers of kidney injury ex vivo (22Y24).
More recently, NMR has been used to examine HMP perfus-
ate in a preclinical donation after cardiac death porcine model
(14). This study concluded that analysis of biomarkers during
HMP using NMR could be an interesting tool to assess graft
quality and was compatible with clinical application.
In this study, the main constituents of KPS-1 were
identified by 1H-NMR, except for HEPES and hydroxyethyl
starch which the software cannot recognize. Of the identified
metabolites, median levels of gluconate, mannitol, adenine,
and ribose did not change significantly over HMP time for all
perfused kidneys. However, gluconate levels were significantly
lower in the perfusate of DGF kidneys at 4 hr with a good
AUROC for prediction of DGF. Gluconate (like mannitol) is
present to provide osmotic stability so a significant change in
concentration is unexpected. It is possible that cellular damage
in the DGF kidneys allows influx of gluconate into the cell that
would not normally occur within healthy tissue.
Glutathione is included in many preservation solutions,
including KPS-1, and acts as a free radical scavenger to at-
tenuate ischemia-reperfusion injury. Concentrations of re-
duced glutathione decreased over time during HMP in both
DGF and IGF kidney perfusate. Glutathione in its oxidized
form was not detected.
Glucose levels in the perfusate of DGF kidneys were
significantly lower at both timepoints than those found in the
perfusate of IGF kidneys, with good AUROCs for prediction
of DGF. Although the reason for this is not known, it is pos-
sible that more glucose is used for repair by damaged DGF
kidneys or that DGF kidneys are not effectively suppressed by
hypothermia and require more glucose for metabolism.
Of the metabolites discovered that are not part of the
preservation solution two of these, leucine and inosine, had
significantly different concentrations in the perfusate of DGF
kidneys compared to IGF kidney perfusate at 45 min. Leucine,
a branched chain essential amino acid, was detected in sig-
nificantly higher levels in the perfusate of DGF kidneys at 45
min. It is known that larger proteins are released into the
perfusate during HMP as a sign of cellular damage (25).
Raised concentrations of amino acids could indicate increased
TABLE 2. Metabolite concentrations (mM) measured in kidney perfusate not listed as constituents of KPS-1
Metabolite
Median Conc at
45 min of HMP Interquartile range
Median Conc at
4 hr of HMP Interquartile range P (change over time)
3-Hydroxybutyrate 0.008 0.006Y0.014 0.021 0.014Y0.030 G0.001a
3-Methylxanthine 0.016 0.014Y0.018 0.017 0.013Y0.019 0.363
Acetate 0.100 0.082Y0.113 0.087 0.062Y0.102 0.085
Alanine 0.047 0.034Y0.065 0.121 0.077Y0.147 G0.001a
Citrate 0.477 0.000Y0.830 0.621 0.000Y1.299 G0.001a
Ethanol 0.017 0.014Y0.020 0.015 0.011Y0.019 0.282
Formate 0.051 0.037Y0.071 0.055 0.037Y0.086 0.013a
Fumarate 0.002 0.001Y0.003 0.003 0.001Y0.004 0.005a
Glutamate 0.145 0.065Y0.325 0.646 0.375Y0.807 G0.001a
Glycine 0.469 0.391Y0.541 1.363 0.902Y1.792 G0.001a
Hippurate 0.003 0.000Y0.005 0.002 0.000Y0.006 0.093
Hypoxanthine 0.041 0.020Y0.067 0.086 0.034Y0.157 G0.001a
Inosine 0.006 0.002Y0.015 0.008 0.003Y0.020 0.014a
Isoleucine 0.003 0.002Y0.004 0.004 0.003Y0.006 G0.001a
Isopropranolol 0.015 0.010Y0.021 0.015 0.012Y0.021 0.164
Lactate 0.602 0.481Y0.694 1.158 0.932Y1.322 G0.001a
Leucine 0.008 0.006Y0.010 0.012 0.008Y0.016 G0.001a
Malonate 2.136 1.050Y2.344 1.975 0.000Y2.408 0.568
N-Phenylacetylglycine 0.003 0.000Y0.006 0.004 0.000Y0.012 0.009a
Tyrosine 0.003 0.002Y0.003 0.004 0.003Y0.006 G0.001a
Uracil 0.007 0.003Y0.008 0.009 0.006Y0.013 G0.001a
Valine 0.005 0.004Y0.006 0.003 0.006-0.010 G0.001a
a Statistically significant at less than 0.05, Wilcoxon signed rank test.
* 2014 Lippincott Williams & Wilkins Guy et al. 3
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
cellular breakdown in the more ischemically damaged DGF
kidneys. Other amino acids identified in the perfusate were
alanine, glycine, glutamate, isoleucine, tyrosine, and valine.
The concentrations of all of these increased significantly over
time in the perfusate of all kidneys but were not significantly
different between the DGF and IGF groups.
In contrast, concentrations of inosine were significantly
lower in DGF kidney perfusate at 45 min compared to IGF
perfusate. Inosine is formed from the breakdown of adenosine
nucleotides, such as adenosine monophosphate, adenosine
diphosphate, and adenosine triphosphate. The lower levels of
inosine detected in the more ischemically damaged DGF
kidneys would suggest that this is not being released as a
product of cellular degradation but is a product of cellular
metabolism. Although the pathway involved is not clear, it is
unlikely that the detected inosine was formed from the ade-
nine in the preservation fluid because adenine levels did not
decrease over time to correspond with this. The AUROCs for
leucine and inosine at 45 min were good at 0.833 and 0.732.
Other metabolites of interest identified in HMP per-
fusate include the ketone body 3-hydroxybutyrate, increas-
ing concentrations of which may indicate ongoing fatty acid
metabolism which is the main source of energy in the renal
cortex during hypothermia (26). Levels of lactate increased
in the perfusate of HMP over time, as might be expected,
because of the production of lactate by glycolysis in anaer-
obic conditions. Also detected to be increasing over time
were citrate and glutamate which are both intermediates of
the tricarboxylic acid cycle.
To further elucidate the processes occurring during
HMP, examination of additional timepoints would be
useful. Two early timepoints were chosen for this study to
examine the potential for indicators of graft function
that would be applicable in a clinically useful timeframe
and to ensure that samples at comparable times were
available for all kidneys. Furthermore, HMP parameters
changed most markedly within the first hour of perfusion
which might have been reflected in the metabolic profile
of the perfusate. A combined analysis of HMP parameters
and metabolomic data might be of interest but has not
been performed in this study.
All cadaveric kidneys arrive at our unit in SCS. In this
study, as in normal departmental practice, the decision to transfer
to HMP was based on donor-recipient readiness and theatre
availability. If the predicted time to theatre was within elective
hours (8:00 A.M. to 8:00 P.M.), the kidney was transplanted from
FIGURE 1. Box and Whisker plots representing the significantly different metabolites between the kidney perfusate of
DGF and IGF kidneys. DGF, delayed graft function; IGF, immediate graft function.
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SCS. If the predicted time to theatre was outside of these hours
(8:00 P.M. to 8:00 A.M.), the kidney was transferred to HMP and
then transplanted at the earliest opportunity during elective
hours. This is to ensure that as many renal transplants as possible
are performed in optimal conditions in the dedicated renal
transplant theatre.
At present, HMP is not used as a standard preservation
technique at organ recovery in the United Kingdom. In this
study, kidneys were placed on HMP at the accepting unit and
remained at the center for transplantation. If HMP were used
from recovery, sample collection for studies such as this
would be more complicated. However, some evidence sug-
gests that using HMP from recovery might be more beneficial
than using a combination of SCS and HMP (2,27).
The NMR has revealed many metabolites that may help
to elucidate the underlying metabolic processes occurring
during HMP. However, not surprisingly, there are limitations.
Not every signal produced on the spectra can, as yet, be iden-
tified, and complex molecules can produce spectral patterns
that overlap each other. This can sometimes make identification
and quantification difficult. Furthermore, it is unclear how ac-
curately levels of perfusate metabolites reflect intracellular ac-
tivity. This study has used the technique to screen perfusate and
has identified specific metabolites (glucose, inosine, leucine,
gluconate) that might be predicative of graft function. Studies
have now commenced to determine whether routine bio-
chemical assays of these metabolites would be helpful in pro-
viding real time data to support clinical practice.
In this study, it has been possible to identify differences
in the metabolomic profiles of perfusate from kidneys with
IGF and DGF. These differing metabolites may prove to have a
useful predictive role in viability assessment. With a better
understanding of the underlying metabolic processes occurring
in damaged kidneys, it may be possible to modify harmful
metabolic processes, support cell function, and possibly extend
storage periods before transplantation.
MATERIALS AND METHODS
Adult cadaveric kidneys accepted for transplantation and undergo-
ing HMP at the Queen Elizabeth Hospital, Birmingham between July 2012
and August 2013 were included, subject to consent and resource availability.
Ethical approval was obtained (REC reference number: 12/WS/0166). All
kidneys arrived at the unit in SCS. The decision to transfer a kidney to HMP
was made according to departmental guidelines. Demographic and clinical
data were collected prospectively. Delayed graft function was defined as the
requirement for dialysis within the first postoperative week. Immediate graft
function kidneys were those not requiring dialysis support postoperatively.
Kidneys were cold stored in the period after retrieval and transferred to
the LifePort Kidney Transporter 1.0 (Organ Recovery Systems, Chicago, IL) at
the host center under aseptic conditions. The decision to perfuse kidneys was
FIGURE 2. Receiver-operator Characteristic (ROC) Curves and Areas Under the ROC Curves (AUROCs) for Significant
Metabolites.
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determined by clinical protocol taking into account donor-recipient issues and
theatre availability. Perfusion pressure was set at 30 mm Hg and not altered
during perfusion time. All kidneys were perfused with 1 L of KPS-1 at 4 -C. No
additional oxygen was supplied.
Two milliliters of perfusate was sampled at 45 min and 4 hr for each
HMP kidney. Perfusate was transferred to a cryogenic vial and stored at
j20-C until thawed at room temperature, prepared, and processed.
The NMR samples were prepared by mixing 150 KL of a 400 mM pH
7.0 phosphate buffer solution containing 2 mM (3-trimethylsilyl)propionic-
(2,2,3,3-d4)-acid sodium salt (TSP) with 390 KL of each perfusate sample
and 60 KL of deuterium oxide to reach a final phosphate buffer concentra-
tion of 100 mM and a final TSP concentration of 500 KM. Deuterium oxide
provides a field-frequency lock, whereas TSP is used as a chemical shift as
well as a concentration reference. After mixing, the 600-KL samples were
pipetted into NMR tubes and centrifuged to remove any air bubbles.
The 1H-NMR spectra were acquired using a Bruker AVII 500 MHz
spectrometer equipped with a 5 mm inverse Cryoprobe (Bruker Corpora-
tion, Billerica, MA). The sample temperature was set to 300 K, excitation
sculpting was used to suppress the water resonance (28). One-dimensional
spectra were acquired using a 6-kHz spectral width, 32,768 data points, 4 s
relaxation delay and 128 transients. Matching was manual before acqui-
sition of first sample, and each sample was automatically shimmed (1D-
TopShim) to a TSP line width of less than 1 Hz before acquisition. Samples
with a TSP line width greater than 1 Hz were acquired again after manual
shimming where the TSP half height line width was shimmed below 1 Hz.
Total experimental time was approximately 15 min per sample.
All data sets were processed using the MATLAB based MetaboLab
software (29). Data sets were zero filled to 65,536 data points. An expo-
nential line broadening of 0.3 Hz was applied before Fourier transforma-
tion. The chemical shift axis was calibrated by referencing the TMSP signal
to 0 ppm. Spectra were manually phase corrected and baseline correction
using a spline before segmental alignment of all resonances using Icoshift
(30). Spectra were then exported into Bruker format.
Resultant spectra were examined using Chenomx 7.0 (Chenomx Inc.,
Edmonton, AB, Canada) profiling to identify metabolites and their concentrations.
Chemical shift assignments are shown in SDC4, (http://links.lww.com/TP/B51).
Example spectra are shown in SDC5, http://links.lww.com/TP/B51. Each sig-
nal annotation and quantification was checked manually.
Statistics
Data were analyzed using GraphPad Prism version 6.0c for Mac (GraphPad
Software, La Jolla, CA, www.graphpad.com) and IBM SPSS 19 (IBM Corp.
Armonk, NY). Metabolite averages stated as median values because of non-
parametric data distribution. Change in metabolite concentration over time was
analyzed by Wilcoxon signed rank test. Metabolite concentrations were com-
pared using Mann-Whitney U test. P less than 0.05 was considered to be indic-
ative of statistical significance.
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The finding that the metabolic profiles within the perfusion fluid of human kidneys 
predicted outcome was interesting and supported the theory that pre-transplant 
metabolism correlates with post-transplant graft function. Furthermore, the ability to 
optimise the metabolic function during the pre-transplant organ preservation period 
through manipulation of the parameters of perfusion would be a potential target to 
improve the function of transplanted kidneys.  
In order to determine how different factors influence metabolism during the 
preservation period, an experimental model was needed. Porcine kidneys are now 
the most widely used large animal model for transplantation studies, although both 
canine and primate models are also used in preference in some centres (190). Pig 
kidneys are reported to have similar physiological and anatomical properties to 
human kidneys (171, 191-193) and the metabolism of such organs at least in vivo is 
thought to be comparable (194, 195). However, the porcine model has not been 
validated as a metabolic model for human studies during the highly non-
physiological conditions of hypothermic machine perfusion.  
Aims 
In this chapter of this thesis, I aim to determine through comparison of metabolites 
within the perfusion fluid of perfused pig and human kidneys using 1H NMR 
spectroscopy, whether the pig is a valid model for such transplantation studies. If 
indeed the pig is a valid model, then it will justify the use for future experimental 




The ethical approval necessary for the analysis of human perfusate samples during 
the machine perfusion process was valid from the previous human study 
(12/WS/0166). No specific ethical approval was necessary for experiments on 
porcine abattoir kidneys.  
 
Methods 
The perfusate from 12 standard criteria human kidney during perfusion was 
compared to 10 porcine kidneys. All kidneys were perfused with 1L of KPS-1® 
solution as per clinical practice. Perfusate samples were taken at both 45 minutes 
and 4-hour time points. Metabolite identification and quantification was performed 
using 1D 1H NMR spectroscopy and Chenomx 7.0 software (Chenomx Inc., 
Edmonton, AB, Canada).  
Results 
30 metabolites were identified in both pig and human perfusate. There was no 
difference in concentration levels identified for the majority of these between pig 
and human experiments. For 29 of the 30 metabolites, there was no difference in 
the rate of change with time of the metabolite.  
Conclusions 
Based on this porcine abattoir DCD kidney model, we concluded that from 
a metabolomic perspective the pig was a valid model for human studies 
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Abstract
Introduction: Hypothermic machine perfusion offers great promise in kidney
transplantation and experimental studies are needed to establish the optimal
conditions for this to occur. Pig kidneys are considered to be a good model for this
purpose and share many properties with human organs. However it is not
established whether the metabolism of pig kidneys in such hypothermic hypoxic
conditions is comparable to human organs.
Methods: Standard criteria human (n512) and porcine (n510) kidneys
underwent HMP using the LifePort Kidney Transporter 1.0 (Organ Recovery
Systems) using KPS-1 solution. Perfusate was sampled at 45 minutes and
4 hours of perfusion and metabolomic analysis performed using 1-D 1H-NMR
spectroscopy.
Results: There was no inter-species difference in the number of metabolites
identified. Of the 30 metabolites analysed, 16 (53.3%) were present in comparable
concentrations in the pig and human kidney perfusates. The rate of change of
concentration for 3-Hydroxybutyrate was greater for human kidneys (p,0.001). For
the other 29 metabolites (96.7%), there was no difference in the rate of change of
concentration between pig and human samples.
OPEN ACCESS
Citation: Nath J, Guy A, Smith TB, Cobbold M,
Inston NG, et al. (2014) Metabolomic Perfusate
Analysis during Kidney Machine Perfusion: The Pig
Provides an Appropriate Model for Human
Studies. PLoS ONE 9(12): e114818. doi:10.1371/
journal.pone.0114818
Editor: Helge Bruns, University Hospital
Oldenburg, Germany
Received: June 30, 2014
Accepted: October 21, 2014
Published: December 12, 2014
Copyright: ! 2014 Nath et al. This is an open-
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that, for
approved reasons, some access restrictions apply
to the data underlying the findings. Data are
available at Dryad: doi:10.5061/dryad.9jc16.
Funding: University Hospital Birmingham Charities
£60,000 Grant number Dkaarcde17496. Organ
Recovery Systems, Donation of Lifeport machine
(value circa £25,000).
Competing Interests: Mark Cobbold is a PLOS
ONE Editorial board member. This does not alter
the authors’ adherence to PLOS ONE Editorial
policies and criteria.
PLOS ONE | DOI:10.1371/journal.pone.0114818 December 12, 2014 1 / 12
Conclusions: Whilst there are some differences between pig and human kidneys
during HMP they appear to be metabolically similar and the pig seems to be a valid
model for human studies.
Introduction
The use of Hypothermic Machine Perfusion (HMP) in the period between kidney
retrieval and implantation is supported by robust clinical evidence with improved
early graft outcome [1–9]. Flow dynamics during perfusion is likely to account for
some of the benefits of HMP, with reduced intra-renal resistance (and therefore
increased flow) a marker of good graft function [10–12]. However, the exact
mechanism by which HMP improves outcome remains unclear and there is likely
to be a metabolic component underlying these beneficial effects [13, 14].
Accordingly, improved metabolic support during perfusion becomes a target for
graft optimisation. Experimental studies are needed to clarify these mechanisms
and optimisation of preservation may lead to improved transplant outcomes,
especially in marginal kidneys. However the metabolic activity in this ex vivo,
hypoxic, hypothermic environment is poorly understood.
Metabolomic analysis using 1H NMR spectroscopy permits identification and
quantification of a large number of metabolites within a biological sample and is
the subject of great interest. Easy access to perfusate during HMP and ability to
perform serial measurements render this an attractive technique with which to
establish a reliable biomarker and may even provide the option to improve the
metabolic function of organs with obvious potential benefits. We have shown that
perfusate analysis of human cadaveric kidneys is feasible and can be used to
reliably predict post transplant graft function [15]
Porcine kidneys are a convenient and accessible animal model for experimental
studies. They are readily available and have comparable size and physiological
properties to human organs [16–19]. Within transplantation, porcine models
have been studied extensively and normothermic perfusion is a good example of
how this has translated into clinical practice [20]. On a functional level, analysis
using 1H-NMR spectroscopy of perfusate from autotransplanted pig kidneys has
demonstrated that metabolite concentrations do correspond to graft outcome
indicating that there is a strong correlation between pre-transplant metabolism
and graft function [21].
Under normal physiological conditions, the metabolic profiles of porcine
blood, kidney tissue, urine and serum have been shown to be comparable to
humans [22, 23]. As of yet, this has not been validated in the ex vivo hypothermic
environment as encountered during HMP. The aim of this study is to compare the
metabolic profile of human and porcine kidneys using 1H-NMR spectroscopy of
HMP-derived perfusate to determine whether the porcine model is a valid
surrogate for human studies.
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Methods
Human subject research
Ethical approval was obtained from the West of Scotland Research Ethics Service
for collection of human perfusate samples and subsequent NMR analysis (REC
reference number: 12/WS/0166). Written consent for research purposes was
granted from donor next of kin and from prospective kidney recipients to allow
for collection and publication of postoperative transplant function information.
Animal Research
Abattoir/slaughterhouse pig kidneys were used in this study, acquired through
F.A. Gill, Wolverhampton. No animals were sacrificed solely for the purposes of
this study and therefore no ethical board approval was necessary.
Human studies
Standard criteria (e.g. donor age ,60) adult cadaveric kidneys (n512) accepted
for transplantation and undergoing HMP at the Queen Elizabeth Hospital,
Birmingham between July 2012 and August 2013 were included, subject to
consent and resource availability. Kidneys from DCD (Donation after Cardiac
Death) donors and those fulfilling standard criteria definitions but with predicted
delayed graft function (e.g. Cold ischaemia time .16 hours) were excluded to
enable valid comparison with the pig group.
Organs were cold stored at 4 C̊ in the period following retrieval according to
local retrieval team protocols and transferred to the perfusion machine at the host
centre. Decision to preserve organs with HMP was determined by centre policy.
Pig studies
Experiments were performed on 22–26 week old ‘bacon weight’ pigs, weighing
80–85 kg (n510). All experiments were performed following the principles of
laboratory animal care according to NIH standards. Animal were sacrificed by
electrical stunning and exsanguination. Cold perfusion was performed ex-vivo
following laparotomy and retrieval and occurred within 14 minutes of death.
Kidneys were initially cold flushed (4 C̊) with 1L Soltran solution under aseptic
conditions at pressure of 150 mmHg. Organs were then cold stored in KPS-1
solution for two hours prior to machine perfusion to replicate human organ cold
storage conditions.
Hypothermic Machine Perfusion
Perfusion pressure for both animal and human organs was set at 30 mmHg and
kidneys were perfused with 1 L of KPS-1 at 4 C̊ using LifePort Kidney Transporter
1.0 (Organ Recovery Systems). Separate devices were used for human and animal
studies. 2 mL of perfusate was sampled at 45 minutes and 4 hours for each
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kidney. Perfusate was transferred to a cryogenic vial and stored at 220 C̊ until
thawed at room temperature, prepared and processed.
Sample preparation
NMR samples were prepared by mixing 150 mL of 400 mM (pH 7.0) phosphate
buffer containing 2 mM TMSP [(3-trimethylsilyl)propionic-(2,2,3,3-d4)-acid
sodium salt] with 390 mL of each perfusate sample and 60 mL of deuterium oxide
(D2O) to reach a final phosphate buffer concentration of 100 mM and a final
TMSP concentration of 500 mM. After mixing, the 600 mL samples were pipetted
into NMR tubes and centrifuged to remove any air bubbles.
1H-NMR spectra were acquired using a Bruker AVII 500 MHz spectrometer
equipped with a 5 mm inverse Cryoprobe. The sample temperature was set to
300 K, excitation sculpting was used to suppress the water resonance [24]. One-
dimensional spectra were acquired using a 6 kHz spectral width, 32768 data
points, 4 s relaxation delay and 128 transients. Matching was manual prior to
acquisition of first sample and each sample was automatically shimmed (1D-
TopShim) to a TMSP line width of less than 1 Hz prior to acquisition. Samples
with a TMSP line width .1 Hz were acquired again after manual shimming
where the TMSP half height line width was shimmed below 1 Hz. Total
experimental time was approximately 15 minutes per sample.
All data sets were processed using the MATLAB based MetaboLab software
[25]. Data sets were zero filled to 65536 data points. An exponential line
broadening of 0.3 Hz was applied before Fourier transformation. The chemical
shift axis was calibrated by referencing the TMSP signal to 0 ppm. Spectra were
manually phase corrected and baseline correction using a spline before segmental
alignment of all resonances using Icoshift [26]. Spectra were then exported into
Bruker format.
Resultant spectra were examined using Chenomx 7.0 (ChenomxInc) profiling
to identify metabolites and their concentrations, as illustrated in Fig. 1.
Concentrations were corrected to compensate for the dilutional effect of the
buffer.
Statistical Methodology
Prior to analysis, the distribution of metabolites was examined. Where non-
normality was detected, Log10-transformations were applied, after adding 1 to
remove zero values. Repeated measures ANOVA models were then used to
compare metabolite concentrations, both between pig and human samples, and
between 45 minute and 4 hour timepoints. In addition to the main effect terms in
the models, interactions were also included, in order to compare the rate of
change over time in the metabolite concentrations between pig and human
samples.
Data were reported as arithmetic means and 95% confidence intervals for the
normally-distributed data. Where Log-transformations were used, the resulting
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summary statistics were back transformed, and reported as geometric means and
95% confidence intervals.
All analysis was performed using IBM SPSS 19 (IBM Corp. Armonk, NY), with
p,0.05 deemed to be indicative of statistical significance.
Results
Metabolic support may be an important factor in the observed benefit of HMP
compared with cold storage for preserving kidneys prior to transplantation.
Experimental studies are needed to detail the metabolic activity of kidneys under
various storage conditions, but the usage of healthy human kidneys for such
research purposes is not justified.
This study seeks to ascertain whether the abundant and accessible porcine
kidney can provide a reliable metabolic model for the human kidney during
HMP.
Fig. 1. Example metabolic quantification using Chenomx database. Localised spectral plots for
metabolites of interest with shaded figures illustrating metabolite quantification via best fit analysis using
Chenomx metabolite database.
doi:10.1371/journal.pone.0114818.g001
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Metabolite concentrations as determined from 1H-NMR spectra from 10
porcine kidneys were compared with 12 standard criteria cadaveric human
kidneys, all of which were successfully transplanted with immediate graft function.
A spectral overlay analysis was performed for the mean spectra for pig and
human samples at 45 minutes and 4 hours. There were similar profiles for both
pig and human groups (Fig. 2). There were no metabolites consistently present in
significant quantities that were not detected in the other group.
In total, 30 metabolites were identified in the perfusate of both pig and human
kidneys during hypothermic machine perfusion. Of these, 6 (gluconate, mannitol,
glucose, adenine, ribose and glutathione) were constituents of the original KPS-1
perfusion fluid. There was consumption of glutathione in both pig and human
groups but no other significant interspecies or time effect differences for the other
five metabolites present.
For the 24 metabolites present de novo (therefore likely produced by the
kidney), there was an overall change over time for 12, with production of lactate,
glycine, glutamate, hypoxanthine, alanine, 3-hydroxybutryate, inosine, N-
phenylacetylglycine, leucine, valine, isoleucine and fumarate.
When concentrations were analysed according to species, there was no
difference during HMP between pig and human kidneys for 16 metabolites as
assessed using a repeated measures analysis. The rate of change of concentration
for 3-hydroxybutyrate was greater in human kidneys compared to pig kidneys
(0.017 to 0.040 mM vs 0.012 to 0.013 mM) (p,0.001). The vast majority of
metabolites detected (29/30) demonstrated no difference in the rate of change
between pig and human samples (Table 1, Fig. 3).
Discussion
The aim of this study was to determine whether or not the porcine kidney
provides a reliable metabolic model for the human kidney, as assessed by 1H-
NMR.
Whilst it is recognized that 1H-NMR can be used to detect metabolic changes
present within the perfusates during HMP, this paper demonstrates that in both
human and pig studies a significant amount of metabolic activity occurs. Some
interspecies metabolite differences are evident but nevertheless, the similarity
between the two groups is striking. This appears to validate porcine HMP as a
valid metabolic model for human studies and would suggest that a defined
optimal metabolic support protocol for HMP in a pig model would be
translatable into clinical practice.
The majority of metabolites were present in similar concentrations in both
species. For metabolites where concentration differences were observed, all but 3-
hydroxybutryate had comparable rates of change in concentration for pig and
human samples. This would imply that the active metabolic pathways during
HMP in both human and pig kidneys are broadly comparable. The kidney cannot
synthesise the ketone body 3-hydroxybutyrate to any significant extent but can
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consume it as an energy source and is likely to be more pronounced in stressful
conditions such as hypothermia [27, 28]. Interspecies differences in the levels of
the enzyme responsible for metabolising 3-hydroxybutyrate, 3-hydroxybutyrate
dehydrogenase within the renal cortex and in plasma levels of 3-hydroxybutyrate
have been reported and may account for this finding [29].
The pig kidneys were subjected to a warm ischaemia time of 14 minutes which
is more prolonged than many Donation after Brain Death (DBD) human kidneys.
However the cold ischaemic time for the pig organs (2 hours) was shorter than
the human group in this study (mean 8 hr 40 min). There was also a significant
age discrepancy between the pig and human organs, with the older human
kidneys also likely subject to the global metabolic changes associated with brain
death prior to retrieval including thyroid, catecholamine and glycaemic effects
[30–35]. Such difference in retrieval conditions is likely to account for many of
the interspecies differences found such as the trend towards higher levels of lactate
in the human kidneys.
The authors acknowledge that the good quality standard criteria human
kidneys in this study are not representative of many of the organs used in clinical
practice. Indeed extended criteria organs may have most to gain from metabolic
optimistion during machine perfusion and further studies would be of value.
Fig. 2. 1H-NMR spectral overlay plot demonstrating the similarity of HMP perfused pig (red) and human (blue) kidneys after 4 hours of perfusion.
doi:10.1371/journal.pone.0114818.g002
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Table 1. Concentration of metabolites present after 45 minutes and 4 hours of perfusion in pig and human kidneys.
Time point p-Values
Species 45 Minutes 4 Hours Time Species Int.
Gluconate Human 92.9 (85.3–100.4) 96.6 (84.1–109.2) 0.799 0.342 0.616
Pig 89.6 (78.4–100.7) 88.3 (76.4–100.3)
Mannitol Human 48.8 (45.6–52.1) 52.3 (46.0–58.5) 0.543 0.368 0.667
Pig 53.3 (45.8–60.7) 53.9 (45.0–62.7)
Glucose Human 9.8 (9.0–10.6) 10.7 (9.6–11.7) 0.158 0.088 0.709
Pig 11.4 (9.3–13.5) 12.9 (9.7–16.1)
Adenine Human 7.0 (5.8–8.1) 7.1 (5.7–8.5) 0.924 0.681 0.816
Pig 6.7 (5.7–7.7) 6.7 (5.4–7.9)
Ribose Human 3.0 (2.8–3.3) 3.0 (2.4–3.6) 0.548 0.147 0.718
Pig 3.7 (2.9–4.5) 3.4 (2.6–4.3)
Glutathione Human 1.3 (1.2–1.4) 0.8 (0.6–0.9) ,0.001* 0.731 0.1
Pig 1.4 (1.2–1.7) 0.6 (0.4–0.8)
Malonate Human 2.36 (2.04–2.67) 2.42 (1.90–2.95) 0.778 0.855 0.91
Pig 2.26 (1.26–3.26) 2.41 (1.58–3.23)
Citrate# Human 1.0 (0.6–1.6) 1.1 (0.5–1.8) 0.478 0.005* 0.672
Pig 2.8 (1.7–4.5) 3.1 (1.9–4.8)
Lactate# Human 0.94 (0.80–1.09) 1.88 (1.49–2.33) 0.002* 0.005* 0.057
Pig 0.73 (0.37–1.17) 0.93 (0.69–1.22)
Glycine# Human 0.58 (0.47–0.70) 1.86 (1.40–2.41) ,0.001* 0.086 0.683
Pig 0.87 (0.67–1.09) 2.20 (1.65–2.85)
Glutamate# Human 0.26 (0.22–0.30) 1.05 (0.80–1.34) ,0.001* 0.013* 0.545
Pig 0.63 (0.34–0.99) 1.48 (1.07–1.96)
Hypoxanthine# Human 0.17 (0.12–0.22) 0.29 (0.22–0.36) 0.005* 0.782 0.888
Pig 0.19 (0.10–0.28) 0.30 (0.16–0.45)
Acetate# Human 0.13 (0.11–0.15) 0.13 (0.09–0.17) 0.507 ,0.001* 0.462
Pig 0.31 (0.20–0.43) 0.34 (0.23–0.47)
Formate# Human 0.10 (0.07–0.13) 0.11 (0.08–0.15) 0.594 0.306 0.411
Pig 0.13 (0.09–0.18) 0.13 (0.09–0.18)
Alanine# Human 0.08 (0.07–0.09) 0.20 (0.16–0.24) ,0.001* 0.961 0.133
Pig 0.10 (0.08–0.12) 0.18 (0.13–0.23)
Creatinine# Human 0.031 (0.020–0.043) 0.057 (0.049–0.065) 0.084 0.031* 0.558
Pig 0.080 (0.029–0.133) 0.133 (0.040–0.233)
Ethanol# Human 0.024 (0.021–0.027) 0.036 (0.010–0.063) 0.385 0.018* 0.573
Pig 0.076 (0.040–0.114) 0.079 (0.037–0.123)
Isopropanol# Human 0.023 (0.017–0.030) 0.025 (0.018–0.032) 0.792 0.063 0.167
Pig 0.017 (0.015–0.019) 0.016 (0.014–0.018)
3-Methylxanthine Human 0.020 (0.016–0.025) 0.024 (0.019–0.028) 0.361 0.118 0.44
Pig 0.017 (0.010–0.023) 0.017 (0.010–0.023)
3-Hydroxybutyrate Human 0.017 (0.013–0.021) 0.040 (0.031–0.048) ,0.001* ,0.001* ,0.001*
Pig 0.012 (0.006–0.017) 0.013 (0.005–0.020)
Inosine# Human 0.017 (0.008–0.025) 0.023 (0.011–0.035) 0.038* 0.008* 0.241
Pig 0.003 (0.001–0.004) 0.005 (0.002–0.007)
Uracil Human 0.011 (0.010–0.012) 0.018 (0.013–0.023) 0.05 0.020* 0.258
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Whilst the number and concentration change of the metabolites in pig and human
perfusates are comparable in this study, it lacks the power to detect small
interspecies differences. Furthermore in 1-D spectra, metabolites with small single
peaks can be obscured by more dominant signals from other metabolites with
similar chemical shifts.
Perfusate analysis determines the concentration of metabolites in the
extracellular environment of the kidney. Whilst the intracellular activity of many
metabolites can be inferred from this, metabolomic analysis of kidney tissue
would provide a more detailed account of the intracellular milieu and is a
limitation of this study.
This study demonstrates that 1H-NMR spectroscopy profiles of perfusate
samples for porcine and human kidneys during HMP are similar and implies that
similar metabolic processes occur during preservation in the two species. This




Species 45 Minutes 4 Hours Time Species Int.
Pig 0.007 (0.005–0.008) 0.009 (0.000–0.017)
N-Phenylacetyl glycine# Human 0.011 (0.005–0.016) 0.022 (0.010–0.034) 0.041* 0.18 0.094
Pig 0.009 (0.003–0.014) 0.010 (0.004–0.016)
Pyruvate# Human 0.011 (0.006–0.016) 0.010 (0.005–0.015) 0.371 0.112 0.24
Pig 0.012 (0.005–0.019) 0.020 (0.010–0.030)
Leucine# Human 0.008 (0.006–0.010) 0.017 (0.009–0.025) 0.020* ,0.001* 0.787
Pig 0.027 (0.016–0.037) 0.038 (0.025–0.052)
Valine# Human 0.008 (0.006–0.010) 0.013 (0.010–0.016) 0.002* ,0.001* 0.082
Pig 0.024 (0.018–0.029) 0.041 (0.025–0.057)
Tyrosine# Human 0.007 (0.001–0.012) 0.006 (0.005–0.008) 0.132 0.001* 0.083
Pig 0.014 (0.010–0.017) 0.020 (0.014–0.026)
Hippurate# Human 0.005 (0.002–0.007) 0.027 (0.000–0.067) 0.298 0.198 0.337
Pig 0.001 (0.000–0.002) 0.002 (0.000–0.004)
Isoleucine# Human 0.004 (0.004–0.005) 0.008 (0.006–0.010) 0.001* ,0.001* 0.074
Pig 0.014 (0.010–0.017) 0.024 (0.016–0.032)
Fumarate# Human 0.003 (0.002–0.004) 0.004 (0.002–0.006) 0.012* 0.002* 0.295
Pig 0.007 (0.004–0.009) 0.010 (0.007–0.013)
Data reported as ‘‘Arithmetic Mean (95% Confidence Interval), unless stated otherwise.
#Analyses were log-transformed in the analysis, hence are reported as ‘‘Geometric mean (95% CI).
p-values: Time – Main effect of measurement time; Species – Main effect of species; Int. – Interaction between measurement time and species.
*Significant at p,0.05.
doi:10.1371/journal.pone.0114818.t001
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Although the superior outcomes resulting from hypothermic machine perfusion are 
well accepted (28, 29, 48), the precise mechanism by which these benefits are 
derived is not entirely clear. There is increasing evidence that the promotion of 
metabolism may be a key component of this and our earlier study elegantly 
demonstrated that that metabolite concentrations within the perfusate correlate with 
post-transplant graft function (3). We felt that if we could demonstrate metabolic 
differences between the two main storage conditions (HMP and SCS), this would 
provide complementary evidence that the metabolism of the kidney during these 
perfusion conditions is altered. Surprisingly there are no studies comparing the 
metabolome of kidneys during these two common kidney storage conditions. 
Aims 
The aim of this study was to determine whether the type and time-dependent 
relationship of metabolites in the perfusion fluid of porcine kidneys was similar for 
HMP and paired SCS kidneys, using 1H 1D NMR spectroscopy.  
Ethical approval 
No specific ethical approval was necessary for this study using porcine abattoir 
kidneys.  
Project funding 
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Twenty kidneys were cold flushed and stored for two hours following retrieval. 
Paired kidneys then underwent 24 hours of HMP or SCS or served as time zero 
controls. Metabolite quantification in both storage fluid and kidney tissue was 
performed using one dimensional 1H-NMR spectroscopy. For each metabolite, the 
net gain for each storage modality was determined by comparing the total amount 
in each closed system (i.e. total amount in storage fluid and kidney combined) 
compared with controls. 26 metabolites were included for analysis 
Results 
The total system metabolite quantities following HMP or SCS were greater for 14 
metabolites compared with controls (all p<0.05). In addition to metabolic differences 
with control kidneys, the net gain in metabolite quantity during HMP was greater 
than SCS for 8 metabolites (all p<0.05). These included metabolites related to 
central metabolism (lactate, glutamate, aspartate, fumarate and acetate).  
 
Conclusions 
The metabolic environments of both perfusion fluid and the kidney tissue 
are strikingly different between SCS and HMP systems in this animal 
model. The total amount of central metabolites such as lactate and 
glutamate observed in the HMP kidney system suggests a greater degree 
of de novo metabolic activity than in the SCS system. Maintenance of 
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central metabolic pathways may contribute to the clinical benefits of HMP. 
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a b s t r a c t
Hypothermic machine perfusion (HMP) and static cold storage (SCS) are the two methods used to
preserve deceased donor kidneys prior to transplant. This study seeks to characterise the metabolic
profile of HMP and SCS porcine kidneys in a cardiac death donor model.
Twenty kidneys were cold flushed and stored for two hours following retrieval. Paired kidneys then
underwent 24 h of HMP or SCS or served as time zero controls. Metabolite quantification in both storage
fluid and kidney tissue was performed using one dimensional 1H NMR spectroscopy. For each metabolite,
the net gain for each storage modality was determined by comparing the total amount in each closed
system (i.e. total amount in storage fluid and kidney combined) compared with controls.
26 metabolites were included for analysis. Total system metabolite quantities following HMP or SCS
were greater for 14 compared with controls (all p < 0.05). In addition to metabolic differences with
control kidneys, the net metabolic gain during HMP was greater than SCS for 8 metabolites (all p < 0.05).
These included metabolites related to central metabolism (lactate, glutamate, aspartate, fumarate and
acetate).
The metabolic environments of both perfusion fluid and the kidney tissue are strikingly different
between SCS and HMP systems in this animal model. The total amount of central metabolites such as
lactate and glutamate observed in the HMP kidney system suggests a greater degree of de novometabolic
activity than in the SCS system. Maintenance of central metabolic pathways may contribute to the clinical
benefits of HMP.
© 2016 Elsevier Inc. All rights reserved.
1. Introduction
Hypothermic Machine Perfusion (HMP) and Static Cold Storage
(SCS) are the two methods of kidney preservation that are used
widely in clinical practice during the time period between organ
retrieval and implantation [16]. A key concept for both preservation
modalities is that cellular metabolism, and therefore cellular
metabolic requirements, are minimised in these hypothermic
conditions and the rate of metabolism reported to be about 5e8% at
temperatures below 4 !C [29] with a similar decrease in oxygen
requirement [1].
The superiority of HMP over SCS is well documented
[4,17,22,23,27] but the mechanisms by which this occurs are not
clear. Improvement in flow dynamics, with fall in the intra-renal
resistance is likely to be one factor but the additional metabolic
support derived from the circulation of nutrient-containing
perfusion fluid may also help preserve organ function and have a
beneficial effect [7,30].
Metabolomic analyses of preservation fluid during HMP using
1D-1H NMR (One-dimensional proton nuclear magnetic resonance)
spectroscopy, by groups including our own, have demonstrated this
to be reproducible and highly specific for metabolite identification
and quantification [2,10,24]. However, surprisingly, to our knowl-
edge there are no studies that have sought to compare the
metabolomic profiles, or metabolome, of HMP and SCS kidneys.
Porcine kidneys are widely used in transplantation studies
owing to their similar physiological and anatomical properties to
human organs [9,11]. In addition, the metabolic profiles during
* Corresponding author.Department of Renal Surgery, University Hospitals Bir-
mingham, Birmingham, UK.
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periods of HMP for porcine and human kidneys are comparable
[24], with a correlation between metabolite profiles during storage
and post transplant outcome [2]. For HMP preserved human kid-
neys, the metabolic profile from perfusates of immediate graft
function kidneys differs from those with delayed function [10] and
reinforces the concept that significant metabolism occurs during
HMP and that metabolism reflects functional outcome.
The aims of this study were twofold. Firstly, to determine the
distribution of metabolites between the two different compart-
ments (fluid and tissue) during the organ preservation period.
Secondly, to determine the total amount of each metabolite within
HMP and SCS kidneys systems after 24 h of organ storage and




Abattoir/slaughterhouse pig kidneys (F.A. Gill, Wolverhampton,
UK) were used and no animals were sacrificed solely for the pur-
poses of this study, negating any need for ethical board approval.
Experiments were performed on 22e26 week old male ‘bacon
weight’ pigs, weighing 80e85 kg. All experiments were performed
following the principles of laboratory animal care according to NIH
standards. Animals were sacrificed by electrical stunning and
exsanguination. Initial organ preservationwas performed following
organ retrieval and occurred within 14 min of death, replicating
deceased cardiac death (DCD) donor conditions. Kidneys were cold
flushed (4 !C) with 1 L SPS-1 (UW) solution at a pressure of
100 mm Hg. Organs were then stored at 4 !C in SPS-1 for 2 h to
replicate the clinical period of organ transportation.
2.2. Experimental groups
Paired kidneys were randomly allocated to receive either HMP
or SCS for 24 h. HMP kidneys were perfused with 1 L of KPS-1 using
the LifePort Kidney Transporter 1.0 (Organ Recovery Systems, Chi-
cago, IL). (Perfusion pressure 30 mm Hg). SCS Kidneys were sub-
merged in 1 L of fresh chilled SPS-1 solution with a surrounding ice
bath. Preservation fluid was sampled for each kidney at baseline
and 2, 4, 8,12,18, and 24 h. After 24 h, organs were rapidly dissected
and tissue samples (1 cm3 sections) flash frozen and stored
("80 !C). All experiments were performed in a cold room (4 !C) to
ensure consistency.
2.3. Control kidneys
To ascertain metabolism during SCS or HMP storage conditions,
baseline values prior to storage conditions were needed (time 0).
Large volume tissue sampling precludes effective organ perfusion
and therefore ‘Control kidneys’ were used to establish baseline
metabolite levels. These were (n ¼ 6) flushed and cold transported
in identical fashion to experimental kidneys and tissue samples
obtained as described above (i.e. not subjected to 24 hr of SCS or
HMP).
2.4. Sample processing and metabolite quantification
NMR samples were prepared from storage fluid by mixing
150 mL of 400 mM (pH 7.0) phosphate buffer containing 2 mM DSS
(4,4-dimethyl-4-silapentane-1-sulfonic acid) and 8 mM imidazole
with 390 mL of each fluid sample and 60 mL of deuterium oxide
(D2O) to reach a final phosphate buffer concentration of 100 mM
and a final DSS concentration of 500 mM. After mixing, the 600 mL
samples were pipetted into 5 mm NMR tubes, sonicated and
centrifuged. Technical replicates of samples ($3) were prepared for
each timepoint.
For cell extract studies, 500 mg of renal cortex was manually
cryo-homogenised in liquid nitrogen. 5.1 ml of both methanol
("80 !C) and chloroform was added to the powdered tissue and
samples diluted with 4.65 ml of dH20 at 4 !C. Samples were
centrifuged to separate into polar and non-polar layers and 1.5 ml
of the upper polar layer was dispensed into a cryovial and dried.
Three technical replicates were performed for each tissue sample.
Dried polar residuewas then dissolved in 390 mL of dH20 and 210 mL
of buffer solution as described above.
The protocol used for 1H NMR analysis has been described
previously [10,24]. Briefly, this entailed processing on a Bruker AVII
500 MHz spectrometer, acquisition of one dimensional spectra and
then metabolite identification and quantification using Matlab
based ‘Metabolab’ software [18] and Chenomx 8.1 (ChenomxInc)
software respectively. Metabolites were deemed to be present if
they exhibited non-ambiguous spectral patterns or their presence
deemed biologically plausible and confirmed on ultra performance
liquid chromatography mass spectrometry. Any metabolites that
were present in different concentrations in the SCS and HMP fluid
(e.g. glucose, gluconate, mannitol, adenine, adenosine etc.) were
excluded from comparative analysis. Metabolite quantifications
were corrected to allow for sample dilution with sample buffer.
When determining concentrations of metabolites using Chenomx,
the researchers were blind to the storage group. Quantification of
the total amount of metabolite in the storage fluid, tissue and total
systemwas calculated based upon the weight of the kidney at time
of sample acquisition and final volume of storage fluid.
2.5. Statistical analysis
For each timepoint, three results were obtained (technical rep-
licates) and themedian value used. For comparison of SCS and HMP
conditions, analysis was performed using Wilcoxon paired signed
rank test (two tailed) as one kidney from each pair was subjected to
each condition and normality was not consistent on prior analysis.
When comparing SCS or HMPwith control kidneys, Mann-Whitney
u test (two tailed) was used, as these were non-paired samples.
Datawere reported as median concentrations and interquartile (IQ)
range. All analysis was performed using GraphPad Prism version
6.00 for Mac OS X, GraphPad Software, La Jolla California USA, with
p < 0.05 deemed to be indicative of statistical significance.
3. Results
Metabolic optimisation of cadaveric kidneys is a potential target
to improve the function of kidneys for transplantation. This study
seeks to establish the degree of metabolism, if any, that occurs in
the two widely used methods of kidney organ storage prior to
transplantation (HMP and SCS).
The total quantity of each metabolite after 24 h of either HMP or
SCS was calculated using 1H NMR methods and compared with
control organs to determine the net metabolic change during each
storage method.
We found evidence of metabolite production for both storage
modalities with 14 metabolites present in significantly greater
quantities in the HMP or SCS system compared with controls (all
p < 0.05) (Table 1) (Fig. 1, Fig 1(Suppl)). There were significantly
more metabolites with a net increase in the HMP system (13/14)
compared with the SCS system (7/14) (p ¼ 0.033).
Eight of the metabolites were significantly elevated in the HMP
system compared with both the control and SCS systems (all
p < 0.05), indicating a greater degree of metabolite production.
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These included lactate, glutamate, aspartate, fumarate, acetate,
myo-inisitol, niacinamide and formate (Fig. 1).
Despite the additional 24 h of organ preservation, albeit in static
conditions, the amount of lactate in the SCS systemwas comparable
to controls (1.37 vs 1.11 mmol p ¼ 0.138). However the amount in
the HMP system (2.13 mmol) was almost twice the amount of
either controls or SCS systems (p ¼ 0.002 and p ¼ 0.031). However,
despite greater amounts overall, the amount present in the HMP
tissue (0.76 mmol) was actually lower than SCS tissue (1.14 mmol)
or control tissue (1.11mmol) (p¼ 0.031 and p¼ 0.002 respectively),
reflective of lower intracellular concentrations for HMP kidneys.
The distribution of metabolites between the extracellular stor-
age fluid and tissue samples for both storage conditions are detailed
in Table 2. As expected, there were greater quantities of metabolites
in the circulating HMP fluid compared with the static conditions of
SCS at most time-points. After 24 h, the total amount of metabolite
in the perfusate for the HMP kidneys was significantly greater than
the SCS group for (21/26 ¼ 80.8%) of metabolites. Whilst concen-
trations rose most rapidly in the first 2 h of perfusion and therefore
may be in part due a metabolite washout phenomenon, there was
an increase in most metabolites over sequential timepoints as
would be expected with on-going production (Fig. 2aec).
Reduced glutathione is a constituent of both KPS-1 (used in
HMP) and SPS-1 (used in SCS) fluids at equal concentrations. Whilst
this remained at stable in the SCS environment, the glutathionewas
clearly consumed by the HMP group and after 8 h concentrations
were 17.6 fold higher in the SCS fluid (1.60 mM vs. 0.091 mM,
p ¼ 0.001) (Fig. 2d). Despite apparent organ uptake of reduced
glutathione, there was no evidence of this in the tissue samples
from either group.
4. Discussion
The aim of this study was to determine any metabolic differ-
ences between the two clinically used methods of organ storage in
this animal model.
Whilst the calculation of the total amount of metabolite within
the system does rely on several assumptions (complete metabolite
extraction from tissue and metabolite homogeneity within tissue),
we felt this was imperative to draw meaningful comparison be-
tween groups and enables the calculation of net metabolite pro-
duction/consumption in these two closed systems (HMP and SCS).
Although the storage fluid used in each experimental group
differs (most notably absence of glucose in the SCS fluid) and
therefore caution should be exercised in attributing any differences
merely to the parameters of storage (i.e. HMP or SCS), this study
was designed to assess metabolism during the two clinically used
organ preservation techniques, not merely the storage modality in
isolation.
This study clearly demonstrates the presence of major central
metabolites such as lactate, glutamate, fumarate, aspartate and
acetate at greater levels in the HMP system compared with both
controls and SCS (Fig. 1). This strongly suggests that these metab-
olites are being produced during HMP. Furthermore, the accumu-
lation of these metabolites into the circulating perfusion fluid
demonstrates effective homeostatic mechanisms are active to
prevent over accumulation within the local cellular environment.
The list of metabolites reported in this study is not exhaustive
and is a limitation of this study. Some interesting substrates (eg
glucose) were excluded as this is only present in one of the storage
fluids (KPS-1). For others the 1D 1H NMR spectral pattern is either
ambiguous or can be hidden under more domineering peaks from
other compounds.
The increased total lactate in the HMP system is likely to reflect
increased glycolysis in the HMP model. Although new glycolytic
activity of the glucose within the HMP fluid is one likely contrib-
utor, this is unlikely to the singular cause. This is supported by
evidence that the HMP fluid glucose concentrations did not
decrease during the study period and replicates findings from
previous human studies [10]. However conversion of a proportion
of perfusion fluid glucose into lactate through glycolytic pathways
has been corroborated by work demonstrating activity of these
pathways using 13C labelled glucose tracers [25].
The net gain of glutamate, fumarate, aspartate and acetate
during HMP is also intriguing. Whilst identification of responsible
metabolic pathways is difficult to ascribe solely with 1H NMR
studies, one explanation could be increased oxygen dependent
tricarboxylic acid (TCA) cycle activity. Although uniform upregu-
lation of TCA intermediates would support this theory, as discussed,
many are not easily identifiable using 1H NMR methods [6] and are
rarely found in equipoise even in vivo [14]. Several (13C) NMR
studies have reported glutamate as a valid marker of TCA activity
[3,5,20].
For some metabolites, the total system amounts for HMP and
SCS kidneys were comparable to the controls, suggesting that either
de novo production does not occur during the 24 h preservation or
that consumption mirrors production (Table 1 supplementary).
However, for metabolites with similar total amounts, the
compartment in which they were located varied per metabolite.
Some metabolites were entirely contained within the HMP kidney
Table 1
Total amount of metabolite present in each of the storage modalities at time zero (controls) or after 24 h of preservation (SCS or HMP). Data reported as Median (Interquartile
Range), unless stated otherwise. Statistical test: J Mann-Whitney u test (two tailed) #Wilcoxon paired signed rank test (two tailed). *Significant at p < 0.05.
Storage Modality p-Values
Control System (mmol) SCS System (mmol) HMP System (mmol) Control vs SCS J Control vs HMP J SCS vs HMP #
Glutamate 1.54 (1.12e1.84) 1.38 (1.11e1.66) 3.97 (3.69e4.71) 0.731 0.002* 0.031*
Myoinositol 1.18 (1.16e1.19) 1.29 (1.01e1.52) 2.16 (1.85e2.41) 0.731 0.002* 0.031*
Lactate 1.11 (0.976e1.23) 1.38 (1e1.75) 2.13 (1.67e2.71) 0.138 0.002* 0.031*
Hypoxanthine 0.454 (0.356e0.515) 0.710 (0.641e0.762) 1.05 (0.909e1.17) 0.001* 0.002* 0.156
Formate 0.442 (0.274e0.638) 0.643 (0.589e0.779) 0.842 (0.750e0.943) 0.101 0.004* 0.031*
Acetate 0.210 (0.206e0.212) 0.296 (0.253e0.301) 0.552 (0.494e0.654) 0.234 0.041* 0.031*
Alanine 0.302 (0.243e0.360) 0.486 (0.339e0.499) 0.501 (0.368e0.558) 0.035* 0.015* 0.313
Succinate 0.283 (0.267e0.297) 0.462 (0.312e0.52) 0.434 (0.307e0.541) 0.001* 0.015* 0.844
Inosine 0.588 (0.561e0.628) 1.08 (0.885e1.12) 0.185 (0.146e0.233) 0.001* 0.002* 0.031*
Aspartate 0.114 (0.104e0.118) 0.107 (0.0879e0.11) 0.165 (0.140e0.215) 0.234 0.041* 0.031*
Leucine 0.0476 (0.0441e0.0517) 0.0667 (0.0513e0.0820) 0.0693 (0.0495e0.0773) 0.014* 0.026* 0.688
Niacinamide 0.0196 (0.0181e0.0207) 0.0289 (0.0243e0.0319) 0.0490 (0.0420e0.0557) 0.001* 0.002* 0.031*
Tyrosine 0.0262 (0.0217e0.0302) 0.0434 (0.0339e0.0462) 0.0387 (0.0332e0.0431) 0.001* 0.013* 0.438
Fumarate 0.00412 (0.00339e0.00418) 0.00308 (0.00145e0.00348) 0.0133 (0.0077e0.0212) 0.064 0.002* 0.031*
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tissue (e.g. ADP, AMP, NADþ) and presumably in the intracellular
compartment. Other metabolites were evident in both the tissue
and storage fluid but at higher concentrations in the HMP fluid.
These discrepancies in metabolite location further highlight that
cellular transport processes are active in this environment but that
movement of metabolites into the extracellular fluid is not
Fig. 1. Metabolites significantly elevated in the HMP system compared with both SCS and control kidneys. Metabolite levels represent total amounts (mmol) in the storage fluid,
kidney tissue and entire system for porcine kidneys after 24 hr of HMP or SCS or time zero controls. Highly significant (**p < 0.01) and significant (*p < 0.05) differences between
HMP system versus both controls and SCS kidneys.
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indiscriminate.
Reduced glutathione is a constituent of the preservation fluid
KPS-1 and is thought to play a role in the removal of Reactive Ox-
ygen Species (ROS) generated duringmetabolism [19] In contrast to
the SCS kidney, there is a rapid decrease in the concentration of
glutathione in the preservation fluid of HMP stored kidneys and is
about 5% of the SCS values after 8 h (Fig. 2d.). The rate of glutathione
depletion observed in this study is similar to a previously reported
animal model [28] and is likely to reflect cellular uptake of this
protective antioxidant. Interestingly, glutathione concentration
remained relatively constant in the SCS kidney group. This further
reinforces the concept that HMP exerts its beneficial effects, at least
in part, by providing access to the cellular components of the kid-
ney during perfusion. Absence of reduced glutathione in tissue
demonstrates that not only is this protective antioxidant readily
absorbed by the kidney during perfusion but that even after a few
hours it is not longer available in the reduced state.
Although the number of organs in each experimental group is
small (n ¼ 7), it is comparable to other porcine kidney transplant
reports [8,12,15,21,26,30]. To improve validity, samples were pro-
cessed in triplicate at each timepoint and over 250 NMR spectra
were analysed. One strength of this study is that the kidneys stored
by HMP or SCS were paired, i.e. from the same pig, thus minimising
any metabolic differences arising from polymorphism in cellular
mediators of porcine metabolism. Although this approach does not
provide functional outcome information for the preserved organ,
previous studies have demonstrated good function for otherwise
healthy porcine organs stored by either SCS or HMP for similar time
periods [2,8,13,15,21,26].
This study demonstrates that in a porcine model, the distribu-
tion and amounts of metabolites vary significantly with the storage
method (HMP or SCS). The net gain of many central metabolites
during HMP conditions further supports the notion that significant
metabolism occurs during HMP and this may contribute to the
beneficial role of machine perfusion.
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Table 2
Metabolites present in tissue and storage fluid in HMP or SCS kidney systems at 24 h. Data reported as Median (Interquartile Range), unless stated otherwise. Statistical test:
#Wilcoxon paired signed rank test (two tailed). *Significant at p < 0.05.
Storage Total storage fluid amount (mmol) p-value# Total kidney tissue amount (mmol) p-Value#
Glutamate SCS 0.0812 (0.125e0.155) 0.0312* 0.952 (1.26e1.58) 0.6875
HMP 2.72 (2.75e2.89) 0.94 (1.24e1.68)
Myoinositol SCS 0.316 (0.399e0.879) 0.0625 0.596 (0.676e0.853) 0.5625
HMP 1.05 (1.25e1.38) 0.653 (0.816e1.3)
Lactate SCS 0.153 (0.205e0.245) 0.0312* 0.89 (1.14e1.59) 0.0312*
HMP 1.15 (1.38e1.82) 0.521 (0.755e0.895)
Hypoxanthine SCS 0.294 (0.328e0.404) 0.0312* 0.289 (0.407e0.424) 0.0625
HMP 0.705 (0.781e0.867) 0.189 (0.258e0.31)
Formate SCS 0.132 (0.136e0.186) 0.4375 0.434 (0.486e0.545) 0.0312*
HMP 0.151 (0.16e0.169) 0.688 (0.599e0.774)
Acetate SCS 0.073 (0.0808e0.0912) 0.0312* 0.167 (0.201e0.229) 0.0312*
HMP 0.239 (0.257e0.331) 0.252 (0.289e0.344)
Alanine SCS 0.0465 (0.0643e0.0815) 0.0312* 0.303 (0.415e0.435) 0.0312*
HMP 0.253 (0.306e0.358) 0.116 (0.187e0.207)
Succinate SCS 0.0104 (0.0155e0.0184) 0.0312* 0.298 (0.446e0.498) 0.0312*
HMP 0.104 (0.131e0.208) 0.203 (0.294e0.347)
Inosine SCS 0.703 (0.852e0.961) 0.0312* 0.145 (0.182e0.201) 0.0312*
HMP 0.0877 (0.108e0.128) 0.058 (0.0723e0.109)
Aspartate SCS e 0.0312* 0.0879 (0.107e0.11) 0.3125
HMP 0.039 (0.0452e0.0682) 0.0874 (0.115e0.155)
Leucine SCS 0.00442 (0.00506e0.00761) 0.0312* 0.0486 (0.0591e0.0775) 0.0312*
HMP 0.0285 (0.038e0.0468) 0.0222 (0.0304e0.0318)
Niacinamide SCS e 0.0312* 0.0243 (0.0289e0.0319) 0.0938
HMP 0.0221 (0.028e0.0282) 0.0194 (0.0221e0.0278)
Tyrosine SCS 0.00336 (0.0071e0.00843) 0.0312* 0.0306 (0.0371e0.0391) 0.0312*
HMP 0.0197 (0.0228e0.0276) 0.0112 (0.0143e0.0171)
Fumarate SCS e 0.0312* 0.00145 (0.00308e0.00348) 0.0312*
HMP 0.00456 (0.00737e0.00895) 0.00314 (0.00574e0.0126)
Fig. 2. Concentration of metabolites in the storage fluid of SCS and HMP kidneys over 24 h time period for four example metabolites. Values plotted as median (interquartile range).
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whole organ metabolism during hypothermic machine perfusion of kidneys. 








1D NMR methods (including 1H, 13C, and 31P) have highlighted an array of 
metabolites that can be used both to understand metabolic processes within the 
organ and potentially serve as biomarkers of post-transplant function. Whilst 
metabolic pathway software is available to try and highlight possible pathways 
involves, such tools have inherent limitations, which are probably exaggerated in the 
highly non-physiological conditions of ex vivo organ preservation. 
Although multiple time point analysis can provide further evidence to demonstrate 
active pathways, 1H 1D NMR essentially details a metabolic snapshot at the time of 
sampling. It is often difficult to draw meaningful mechanistic metabolic information 
from this.  
Metabolic tracer analysis is an alternative way to highlight active metabolic pathways 
and can elegantly and unequivocally demonstrate the presence of de novo 
metabolism within these complex systems. NMR spectroscopy is a powerful tool to 
analyse complex 13C isotopomer/isotopologue distributions in metabolites derived 
from labelled tracer molecules. There are various spectroscopic methods available of 
which the simplest is 1D-13C approach. This is not a new concept with initial studies 
using 13C in NMR tracer experiments reported over 40 years ago (143) with 
subsequent validation of this model in ex vivo organ perfusion models (e.g. heart 
and lung) (145, 196-198).  
Whilst the data requirement (and therefore acquisition time) is much greater for 2 
dimensional (2D) 1H,13C NMR tracer studies, they do have significant advantageous 
compared to 1D 13C NMR experiments (discussed in Chapter 1). In addition to the 
greater sensitivity, there is increased spectral dispersion using 2D NMR and the 
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In an effort to determine metabolism in porcine kidneys during HMP, we 
incorporated [U-13C] glucose into the cooled recirculating perfusion fluid. Analysis of 
perfusion fluid and kidney tissue extracts was performed using both 1D 1H and 2D 
1H, 13C heteronuclear single quantum coherence NMR (2D 1H,13C-HSQC). This 
approach enables both metabolite quantification and proportionate distribution of 13C 
isotopomers to be calculated.  
 
Results 
In this small study, we found that there was significant enrichment of 13C in central 
metabolites such as [U-13C] lactate during hypothermic machine perfusion. This 
provides unequivocal evidence of de novo glycolytic pathway activity occurring 
during ex vivo organ perfusion. 
Conclusion 
Both 1D-1H NMR and 2D studies offer metabolic insights into this complex 
system with the high throughput, reproducible quantification of 
metabolites determined by 1D-1H analysis complemented by mechanistic 
information from 2D 1H, 13C studies.  This study demonstrates that the 2D 
NMR techniques described can be successfully applied to the study of 
metabolism during ex vivo whole organ perfusion. Indeed, the 2D NMR 
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approach described provide the platform for further work described in this 
thesis.  
 
The following manuscript was published in the journal Transplantation Research in 
November 2016 I am the first author of this manuscript and was responsible at 




13C glucose labelling studies using 2D NMR
are a useful tool for determining ex vivo
whole organ metabolism during
hypothermic machine perfusion of kidneys
Jay Nath1,2* , Tom Smith2, Alex Hollis2, Sam Ebbs2, Sefa W. Canbilen2, Daniel A. Tennant2, Andrew R. Ready1
and Christian Ludwig2
Abstract
Background: The aim of this study is to determine the feasibility of using nuclear magnetic resonance (NMR) tracer
studies (13C-enriched glucose) to detect ex vivo de novo metabolism in the perfusion fluid and cortical tissue of
porcine kidneys during hypothermic machine perfusion (HMP).
Methods: Porcine kidneys (n = 6) were subjected to 24 h of HMP using the Organ Recovery Systems LifePort
Kidney perfusion device. Glucose, uniformly enriched with the stable isotope 13C ([U-13C] glucose), was incorporated
into KPS-1-like perfusion fluid at a concentration of 10 mM. Analysis of perfusate was performed using both 1D 1H
and 2D 1H,13C heteronuclear single quantum coherence (HSQC) NMR spectroscopy. The metabolic activity was then
studied by quantifying the proportion of key metabolites containing 13C in both perfusate and tissue samples.
Results: There was significant enrichment of 13C in a number of central metabolites present in both the perfusate
and tissue extracts and was most pronounced for lactate and alanine. The total amount of enriched lactate (per
sample) in perfusion fluid increased during HMP (31.1 ± 12.2 nmol at 6 h vs 93.4 ± 25.6 nmol at 24 h p < 0.01). The
total amount of enriched alanine increased in a similar fashion (1.73 ± 0.89 nmol at 6 h vs 6.80 ± 2.56 nmol at 24 h
p < 0.05). In addition, small amounts of enriched acetate and glutamic acid were evident in some samples.
Conclusions: This study conclusively demonstrates that de novo metabolism occurs during HMP and highlights
active metabolic pathways in this hypothermic, hypoxic environment. Whilst the majority of the 13C-enriched
glucose is metabolised into glycolytic endpoint metabolites such as lactate, the presence of non-glycolytic pathway
derivatives suggests that metabolism during HMP is more complex than previously thought. Isotopic labelled ex
vivo organ perfusion studies using 2D NMR are feasible and informative.
Keywords: Hypothermic machine perfusion, Kidney, Transplantation, Metabolism, NMR, Isotopic tracer study, 13C
Background
Although there is good evidence to support the use of
hypothermic machine perfusion (HMP) in clinical practice
[1–3], there are surprisingly few reports detailing renal
metabolism during this process. This is likely to reflect the
widely held belief that metabolism is deleterious during
organ preservation and should be therefore minimised by
both hypothermia and keeping cold ischaemia times (CIT)
as short as possible. The concept that metabolic support
may have beneficial effects during HMP in addition to the
mechanical effects is relatively recent [4, 5].
Using a one-dimensional (1D) 1H nuclear magnetic res-
onance (NMR) metabolomic approach, we have previously
identified a panel of metabolites within the perfusion fluid
during HMP that are predictive of post-transplant graft
function [6]. We have also demonstrated that porcine and
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human metabolic profiles are similar, validating the pig as a
valid metabolic model for kidney transplant studies [7].
However, the metabolic ‘snapshot’ provided by this
conventional NMR metabolomic approach has limitations
for the understanding of cellular metabolism in complex
models such as ex vivo organ perfusion. Merely identifying
and quantifying a metabolite is often insufficient in the
determination of any reliable mechanistic information:
even with serial measurements, such relationships are
often unclear. For example, the detection of lactate within
the perfusate of a machine-perfused kidney could be
secondary to the metabolism or release of pre-existing
intracellular substrate stores as well as de novo metabol-
ism of substrates derived from the perfusion fluid. Thus,
the appearance of a particular metabolite within the perfu-
sion fluid does not confirm de novo metabolism. For this
reason, we propose performing isotopic 13C-labelled
glucose studies.
Incorporation of stable isotopes such as 13C into
common compounds enables metabolic tracer studies
within a biological system. This is not a new concept,
with initial studies reported over 40 years ago [8].
Introduction of labelled metabolic precursors can high-
light specific pathways within the metabolic network.
For example, after addition of [U-13C] glucose to the
fluid of a kidney during HMP, detection of uniformly
labelled 13C lactate provides unequivocal evidence of
glycolytic pathway activity.
NMR spectroscopy is a powerful tool to analyse com-
plex 13C isotopomer/isotopologue distributions in me-
tabolites derived from labelled tracer molecules. There
are various spectroscopic methods available, of which
the simplest is a 1D 13C approach. 1D NMR organ
perfusion studies have been reported in ex vivo heart
and lung animal models using perfusate labelled with
13C glucose and pyruvate [9–12]. This demonstrates the
feasibility of using 13C-labelled metabolic precursors to
determine de novo metabolism in a whole organ perfu-
sion model. 2D 1H,13C HSQC NMR is an alternative to
1D 13C NMR, benefitting from higher sensitivity and in-
creased spectral dispersion. Whilst previous authors
have demonstrated the utility of a human 2D NMR ap-
proach using 13C-labelled glucose [13], to our knowledge
there are no reports of this technique in the field of
transplantation.
The aim of this study is to assess whether metabolic
pathway activity within a machine-perfused porcine kid-
ney can be determined using 13C-labelled glucose tracer
experiments and 2D NMR.
Methods
Pig studies
Experiments were performed on 22–26-week-old ‘bacon
weight’ pigs, weighing 80–85 kg (n = 6) as described
elsewhere [7]. All experiments were performed following
the principles of laboratory animal care according to NIH
standards. To replicate human conditions, kidneys were
initially cold flushed (4 °C) with 1 l Soltran solution under
aseptic conditions at a pressure of 150 mmHg, followed by
2 h of cold storage. Organs were then perfused with 1 l of a
modified version of KPS-1 solution containing 10 mM of
[U-13C]-labelled glucose and 30 g of PEG 35 kDa as an
impermeant in place of hydroxyethyl starch. The LifePort
Kidney Transporter 1.0 (Organ Recovery Systems) was
used for perfusion at a pressure of 30 mmHg (Fig. 1).
Kidneys were perfused for 24 h with perfusate sampled
at times 6, 12, 18 and 24 h from each kidney via the
designated LifePort sampling port and stored at −20 °C.
The samples were thawed at room temperature, pre-
pared and processed as described below. Kidney cortex
tissue samples were also taken at the study endpoint and
flash frozen prior to homogenization.
2D NMR spectroscopy
2D HSQC NMR experiments were performed in this study.
This type of 2D NMR exploits the spin properties of both
protons (1H) and isotopic carbon (13C) such that only 13C
nuclei with an attached 1H produce a signal on the result-
ing spectrum (Fig. 2). Whilst the pulse sequence used here
actively decouples 1H and 13C, inter-proton and inter-
carbon couplings are still active. However, the only coup-
ling resolved in the resulting NMR spectra is the 13C–13C
coupling. Thus the spectral peak of a 13C nuclei is altered if
there is an adjacent 13C nuclei, in that the signal is split
and two peaks exist, splitting into four if flanked by a 13C
either side (Fig. 3). In these experiments, [U-13C] glucose
was used as a tracer (i.e. 13C nuclei in all six carbon posi-
tions of the glucose molecule) therefore forming lactate
Fig. 1 LifePort Kidney Transporter 1.0 (Organ Recovery Systems)
containing a porcine kidney. a Bubble chamber. b Reservoir for ice.
c Aortic patch connector for perfusion. d Peristaltic pump. e
Controls (pressure, prime, wash, infuse). f Sampling port
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with all three carbons in the isotopic 13C version produced
through glycolysis. As the natural abundance of 13C is
known (1.1 %) and the likelihood of adjacent 13C nuclei
occurring naturally very low (1.1 %2 = 0.0121 %), it is pos-
sible to determine the relative concentration of isotopic
carbon molecules compared to the natural abundance
levels by performing quantum-mechanical simulations of
the different components of an experimental HSQC multi-
plet (Fig. 3). Absolute concentrations of metabolites can be
determined using 1D 1H NMR, and therefore, absolute
concentrations of labelled metabolites can be calculated
using a combination of these two NMR approaches.
Sample preparation
Perfusates
Perfusate samples were extracted using a chloroform/
methanol extraction. Briefly, 1.5 ml of perfusate was com-
bined with 1.5 ml of chilled methanol (at −80 °C) and
1.5 ml chloroform (i.e. a 1:1:1 ratio). This was mixed vig-
orously for 10 min and then cooled on wet ice for 10 min.
The polar and non-polar phases were separated by centri-
fugation (1300g for 15 min at 4 °C) as described elsewhere
[14, 15] and 2 ml of the polar fraction aspirated and dried
at 30 °C overnight. The dried samples were resuspended
in 480 μl NMR phosphate buffer containing 0.1 M phos-
phate buffer (pH 7.0), 0.5 μM DSS (4,4-dimethyl-4-sila-
pentane-1-sulfonic acid), 2 mM imidazole, and 48 μl D20
(deuterium oxide), and vortexed until the dried pellet had
completely dissolved. Following this, 35 μl of the sample
was added to a 1.7-mm NMR tube, sonicated for 10 min
to dissolve any remaining micro particles and then centri-
fuged to remove air bubbles. The sample was stored at 4 °
C until processed.
Tissues
Immediately after storage, the kidneys were laterally
bisected and sections of cortex were excised and snap
frozen in liquid nitrogen. Sections of cortex were then
pulverised to a fine powder using a manual cryogrinder.
After this, 0.5 g of the powdered sample was added to a
7-ml Precellys homogenisation tube containing 5.1 ml
of chilled methanol (−80 °C) to quench ongoing metab-
olism. The sample was homogenised using the Precellys
24 Dual homogeniser set at the lowest mode (5000 rpm
for 15 s) until fully homogenised (this was standardised
to eight courses of the lowest setting with cooling in
dry ice between runs to prevent overheating). Once
homogenised, the samples were mixed with 4.65 ml
ultrapure water accounting for the estimated 79 %
water (around 395 μl) present in the tissue already [16]
and 5.1 ml chloroform (i.e. a 1:1:1 ratio as with the
perfusate samples).
Metabolite extraction and resuspension in NMR buffer
was performed as in the perfusate sample preparation,
with the exception that 4.5 ml of the top polar layer was
Fig. 2 A 2D HSQC spectrum of extracted pig kidney cortex is shown in a. A 3D plot of the methyl group (carbon 3) signal of lactate is displayed
in b. c A cross section through the middle of the methyl group signal. The recorded spectrum is plotted in black, whereas a quantum-
mechanical simulation of the same multiplet is shown in red. The plot demonstrates that the simulation allows for a fully quantitative analysis of
the NMR multiplets, which forms the base for a subsequent isotopomer/isotopologue analysis
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aspirated and dried before resuspension in 60 μl of
NMR phosphate buffer and 35μl of this was added to a
1.7mm NMR tube as before.
NMR spectroscopy
Both 1D 1H NMR and 2D 1H,13C HSQC NMR spectra
were acquired on a 600-MHz Bruker Avance III NMR
spectrometer equipped with a TCI 1.7-mm z-PFG cryo-
genic probe at 300 K. NMR acquisition time was circa
5 h per sample (Fig. 4). The spectral widths for all spec-
tra were set to either 7812.5 Hz (1H) or 24,155 Hz (13C).
For the 1D 1H NMR spectra, 16,384 complex data points
were acquired. For the 1H dimension of 2D 1H,13C
HSQC NMR spectra, 512 complex data points were
acquired. Out of 8192 complex data points (2458), 30 %
were sampled for the 13C dimension using an exponen-
tially weighted non-uniform sampling scheme. Using a
4-s interscan relaxation delay, 128 transients were
recorded for the 1D NMR spectra. Two transients per
increment were recorded for the 2D 1H,13C HSQC
NMR spectra. The interscan relaxation delay was set to
1.5 s. Each sample was automatically tuned, matched
and then shimmed (1D TopShim) to a DSS line width of
<1 Hz prior to acquisition of the first spectrum. 1D 1H
NMR spectra were processed using the MATLAB-based
MetaboLab software [17]. All 1D data sets were zero-
filled to 131,072 data points prior to Fourier transform-
ation. The chemical shift was calibrated by referencing
the DSS signal to 0 ppm. 1D spectra were manually
phase corrected before correcting the spectral baseline
using a spline function [17]. 1D 1H NMR spectra were
then exported into Bruker format for metabolite identifi-
cation and concentration determination using Chenomx
8.1 (ChenomxINC). 2D 1H,13C HSQC NMR spectra
were reconstructed with compressed sensing using the
MDDNMR and NMRpipe software [18–20]. The spectra
Fig. 3 Possible multiplet components for the central carbon (carbon 2) of lactate. Clockwise (a–d), the four possible multiplet components are
shown. The spectrum shown in a contains 13C in position 2 only, whereas positions 1 and 3 carry a 12C nucleus. In both b and c, one of the
adjacent carbon nuclei carries an additional 13C nucleus in the same molecule. Therefore, the NMR signal is split into two resonance lines
(doublet). Because of the different chemistry of carbons 1 and 3, the amount of splitting depends on which neighbour carries the 13C nucleus.
This is why splittings can be used to uniquely assign which neighbouring carbon is labelled even though it may be impossible to directly
observe that carbon, such as carbon 1, in a HSQC spectrum. The multiplet for a fully labelled lactate molecule is plotted in d. Because both
neighbouring carbons are 13C, the signal is now split into four peaks (doublet of doublets). Under normal circumstances, multiplets will contain a
mixture of those patterns. Such a mixture is shown in e. Despite the rather complex appearance of this signal, it can be fully quantified by a
quantum-mechanical signal deconvolution
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were zero-filled to 1024 (1H) times 16,384 (13C) real data
points. HSQC spectra were then analysed using Metabo-
Lab, which uses the pyGamma software for multiplet
simulations [21]. The methyl group of lactate was used
to calibrate the chemical shift based on its assignment in
the human metabolome database [22].
Statistical analysis
Data were analysed using GraphPad Prism v6 (GraphPad
Software, San Diego, USA). Data were reported as mean
± SD, unless stated otherwise. Statistical significance was
tested using two-tailed Student’s t test. A p value of
<0.05 was considered significant.
Results
An understanding of the active metabolic pathways dur-
ing HMP could potentially facilitate the development of
a more nutritionally supportive perfusion fluid enabling
the metabolic optimisation of these valuable organs prior
to transplantation.
In this donation after cardiac death (DCD) large ani-
mal model of kidney transplant preservation, enrichment
of 13C in a number of metabolites was observed in both
perfusate solution and kidney cortex tissue. This con-
firms that de novo metabolism occurs during HMP and
that the proposed NMR methodology is useful to dem-
onstrate this. Even after 6 h of perfusion, glycolytic activ-
ity was evident with enriched [U-13C] lactate, enriched
[U-13C] alanine and enriched [U-13C] acetate detected in
the perfusion fluid.
The proportion of [U-13C] enriched lactate (as a frac-
tion of the total lactate present) increased over the
study period (3.25 % ± 1.02 after 6 h and 7.74 % ± 1.57
after 24 h p < 0.001). In addition, the total concentra-
tion of lactate present (enriched and non-enriched) in-
creased (1.51 ± 0.20 mM at 6 h and 2.04 ± 0.57 mM at
24 h p < 0.05). Given that the total amount of enriched
lactate present at a given time point is the product of
the relative proportion (e.g. 3.25 %) and total concen-
tration (e.g. 1.51 mM), it is self-evident that as both of
these are increasing; the amount of enriched lactate
being produced is also increasing (total amount of la-
belled [U-13C] lactate (per sample) 31.1 ± 12.2 nmol at
6 h vs 93.4 ± 25.6 nmol at 24 h p < 0.01).
There is a similar pattern observed with alanine with
the enriched proportion increasing (1.25 % ± 0.44 at 6 h
and 2.83 % ± 1.19 at 24 h p < 0.05) and the total concen-
tration increasing by a similar proportion (0.24 mM ±
0.018 at 6 h and 0.41 mM± 0.13 at 24 h p < 0.01) (total
[U-13C] alanine per sample (1.73 ± 0.89 nmol at 6 h vs
6.80 ± 2.56 nmol at 24 h p < 0.05)) (Fig. 5).
Whilst enriched acetate was present at all time
points in the perfusion fluid (circa 1.25 %), there was
no change in concentration over time. Similarly, the
total concentration of acetate did not change over
time, suggesting that either the production of acetate
was limited or being converted to other enriched
substrates.
The same enriched metabolites (lactate, alanine and
acetate) were also present in the extracted kidney cortex
samples at all time points. In addition, glutamate with
13C enrichment in the 4 and 5 carbon position was
present in several samples in small amounts (<0.5 % of
total present). The presence of this labelling pattern in
glutamate indicates mitochondrial tricarboxylic acid
(TCA) cycle activity (via pyruvate dehydrogenase and
complex 1).
Discussion
This paper provides further evidence that a significant
amount of metabolism occurs during HMP and that
NMR methods are useful for identifying these [6, 7, 23].
However, unlike 1H NMR reports, this paper provides
unequivocal evidence that de novo metabolism occurs in
these organs during HMP with the glucose present in
the perfusate used as a substrate. To our knowledge this
is the first report to demonstrate such de novo metabol-
ism in a whole organ ex vivo kidney model using NMR
tracer methods.
The labelled tracer study techniques described herein
highlight active metabolic pathways during the machine
perfusion period. This could be particularly useful as
clinicians seek to alter perfusion characteristics in order
to optimise kidney graft function prior to transplant.
Fig. 4 Schematic representation of 2D HSQC NMR spectrum.
Chemical shift for 1H depicted on the x-axis and 13C on the y-axis.
Whilst in both the projected 1D 1H and the 1D 13C spectrum display
signal overlap, all signals are well resolved in the 2D spectrum
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The metabolic effects of such perfusion modification
(e.g. temperature, oxygenation, oxygen carriers) can be
elegantly demonstrated using 13C NMR, with analysis of
perfusion fluid permitting non-invasive metabolic
monitoring.
The appearance of uniformly labelled lactate and ala-
nine in the perfusate and tissue samples demonstrate
that de novo glycolysis is occurring in this non-
physiological environment and that alternative meta-
bolic pathways such as the pentose phosphate pathway
do not appear to be active. Although cellular metabol-
ism is reported to only be about 5–8 % at temperatures
below 4 °C [24] with similar oxygen requirements [25],
hypothermia does not cause uniform deceleration of all
metabolic pathways [4] and the metabolic effects of
hypothermia within different organs is not uniform
[26]. There is some evidence that the energy substrate
utilised to support metabolism in a hypothermic canine
ex vivo model is predominantly glucose entering
glycolysis [27], highlighting the importance of this
pathway during machine preservation of organs. Inter-
estingly, other studies demonstrate an increase in per-
fusate metabolites such as glutamate during perfusion.
The suggested mechanism was the reduction (and de-
amination) of glutamine to glutamate by glutaminase.
The authors concluded that the deamination of glutam-
ate occurs to form alpha-ketoglutarate, an important
TCA cycle intermediate [28].
The presence of labelled acetate within the perfusate is
interesting. Whilst acetate can be formed from multiple
pathways, the early appearance of the labelled substrate
in these experiments may indicate acetyl-coA hydrolase
activity [29].
The labelled metabolites in this study were detectable
in the extracellular perfusion fluid within 6 h and dem-
onstrates that cellular uptake of glucose, glycolysis and
transport/efflux of resulting metabolites occurs within
this time period. Although the proportion of de novo
metabolites is modest, it does occur independently of
any glucose uptake stimulators such as insulin.
There has been great interest in the role of oxygen-
ation and oxygen carriers during kidney preservation,
with proponents suggesting that oxygenation replenishes
cellular ATP levels [30] and detractors highlighting the
perils of uncontrolled oxygenation exacerbating the
reactive oxygen species (ROS) generation [31] and the
ischaemia reperfusion phenomenon [32]. This study
demonstrates that even in the absence of supplemental
oxygen, small amounts of glucose-derived glutamic acid
were observed in several tissue samples indicative of aer-
obic TCA cycle activity. Although this is surprising, it
must be remembered that HMP is not an anoxic envir-
onment and oxygen solubility increases at lower temper-
atures and increased salinity and the preservation
solution is further saturated by the physical fluid agita-
tion that occurs during perfusate cycling. Whilst other
Fig. 5 Changes over time for lactate and alanine in the perfusion fluid of HMP kidneys. a, b The % enrichment present and c, d the total
concentration of these metabolites. In all cases, there was a significant increase both in 13C enrichment and in concentrations between
the 6- and 24-h samples
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metabolites indicative of TCA activity were commonly
identified using NMR such as citrate, succinate and
fumarate (by 2D and/or 1D), they were not labelled to
indicate de novo formation.
One of the benefits of the 2D NMR methodology used
in this paper is that the sensitivity (per unit time) is in-
creased compared with 1D 13C NMR. However, 13C
NMR is inherently less sensitive than 1H NMR, and
therefore, it is possible that labelled metabolites present
in very small quantities would not be identified using
this method. Furthermore, our 2D database of splitting
patterns and chemical shift parameters for different
metabolites is evolving and other labelled metabolites
may be identified once these have been further clarified.
Whilst we feel the 2D NMR methods in this paper relay
unparalleled amounts of metabolic information, they are
both time consuming and resource intensive and would
not be suitable for real-time analysis to inform clinical
decisions, as proposed for 1D 1H NMR studies [23].
The experimental conditions in these experiments
were standardised as much as possible to reduce inter-
experimental variability and designed to replicate clinical
conditions. Whilst previous studies have repeatedly
demonstrated the viability of porcine kidneys after simi-
lar periods of HMP [23, 33], this study does not seek to
corroborate this and as such we are unable to correlate
de novo metabolism with functional outcome. Given the
findings from earlier studies [6], we hypothesise that
glycolytic activity during perfusion may correlate with
post-transplant function and propose a human observa-
tional study to clarify this, which is possible due to the
non-radioactive nature of the 13C isotope used in this
study.
Conclusions
We conclude that the described 13C labelling study con-
vincingly demonstrates de novo metabolism during kid-
ney storage by HMP, and this can be used to highlight
active metabolic pathways in this hypothermic, hypoxic
environment.
We postulate that although most of the supplied 13C-
enriched glucose is converted to endpoint metabolites
associated with glycolytic metabolism (i.e. lactate), the
presence of labelled non-glycolytic pathway derivatives
suggests that kidney metabolism during HMP storage is
more complex than previously thought.
Isotopic labelled ex vivo organ perfusion studies using
2D NMR are therefore informative and feasible. Meta-
bolic manipulation is a potential target for therapeutic
intervention during the preservation period, and accur-
ate understanding of active metabolic pathways could
potentially facilitate studies to optimise this, potentially
improving the function of the kidneys post-transplant.
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The benefit, if any, of oxygenation during hypothermic kidney preservation is yet to 
be established. There are no high quality studies comparing the effect of 
oxygenation versus non-oxygenation of perfusate during HMP in human kidneys, 
and evidence is largely derived from small scale animal experiments (83, 199-201). 
Hypothermia results in a deceleration of metabolism, and as we have shown in a 
previous chapter (Chapter 7), the metabolism during standard HMP (non-
oxygenated) differs considerably from SCS conditions, with the promotion of multiple 
central metabolic pathways (6). Thus the oxygen requirement, or at least the 
therapeutic value of oxygenation, is likely to differ between kidneys stored in HMP 
and SCS conditions. Furthermore, the promotion of metabolic pathways during HMP 
could potentially be harmful in the absence of oxygen, or could limit the duration for 
which it is effective. Indeed, greater levels of lipid peroxidation, a marker of 
oxidative stress have been demonstrated in HMP kidneys despite improved function, 
which may reflect these hypoxic conditions (202, 203).  
Seemingly, oxygenation would appear to provide a more physiological storage 
environment for the preserved kidney with the promotion of aerobic metabolism, 
improving cellular ATP stores and facilitating the ATP-dependent Na+/K+ pump (56, 
199, 204, 205). The beneficial effects of oxygenation during machine perfusion on 
ATP levels have been demonstrated in multiple animal organ models including liver 
(murine) (205), heart (porcine) (206, 207) and kidney (199). There is also some 
evidence that ATP generation is dependent on ‘dosage’ of oxygen. In a highly 
oxygenated (100 kPa) porcine kidney perfusion model, greater ATP levels were 
demonstrated compared to lower partial pressures (50 kPa) (199, 208).  
 
 156 
The principal HMP device used in clinical transplantation in the UK (LifePort© Kidney 
Transporter, Organ Recovery Systems, US) provides non-oxygenated pulsatile 
perfusion. However, the KidneyAssist Transport device (Organ Assist, NL) does have 
an integrated membrane oxygenator enabling hypothermic (4°C) oxygenated 
perfusion of kidneys. 
The benefits of oxygenation during HMP in the human setting are currently being 
assessed by two European trials using the KidneyAssist device. The COPE POMP trial 
is comparing the outcomes of extended criteria kidneys undergoing oxygenated HMP 
(2 hours) after a period of static cold storage to investigate the role, if any, of 
oxygenated preconditioning (209). The COPE COMPARE trial is comparing the 
outcomes of oxygenated vs. non-oxygenated HMP in donation after cardiac death 
kidneys (209).  
 
Aims 
The aim of this study was to determine the effects of oxygenation during the HMP 
process by comparing the metabolic profiles of paired porcine kidneys perfused with 
oxygenated and aerated perfusion fluid. A combination of analytical technologies 
were used including using both 1H and 13C NMR, gas chromatography mass 
spectrometry (GCMS), and high performance liquid chromatography (HPLC).  
Participants 
I was responsible for the conceptualisation of this project and was involved in all of 
the perfusion experiments. However a number of other persons were involved in this 
project without whom it would not have been possible. These include Thomas Smith, 
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Kamlesh Patel, Alex Hollis, Samuel Ebbs, Sefa Canbilen (Perfusion experiments, 
sample preparation, NMR analysis), Yugo Tsuchiya (HPLC analysis), Alpesh Thakker 
(GCMS analysis), and Christian Ludwig (NMR analysis).  
Methods 
Eight paired abattoir porcine kidneys were retrieved and cold flushed as per the 
protocol described in Chapter 2. At the laboratory these kidneys were connected to 
the LifePort© perfusion machine as previously described. The perfusion experimental 
setup performed differed from that described in Chapter 6 in two distinct ways. 
Firstly, instead of perfusing the kidneys with 1 L of chilled (4°C) homemade KPS-1®-
like perfusion fluid containing 10 mM of [U-13C] glucose, factory KPS-1® fluid was 
used with 5 mM of [U-13C] glucose added to it. As factory KPS-1® contains glucose 
at a concentration of 10 mM, the final concentration of the glucose in the fluid was 
therefore 15 mM, of which only a third was the [U-13C] isomer. The second 
modification was that the fluid was either oxygenated or aerated. 
Oxygenation/aeration setup 
A paediatric membrane oxygenator was used for this purpose and incorporated into 
the LifePort© circuit as depicted below (Figure 35). The oxygenator used was the 
Hilite® 800 LT series hollow fibre oxygenator (Medos, Medizintechnik AG). This was 
selected as the permissible flow rate for both perfusion fluid and oxygen through the 
device was appropriate for HMP. In these experiments we wanted to compare the 
effects of oxygenation versus aeration. For the oxygen group, Carbogen (BOC 
Medical) was used which is composed of 95% oxygen and 5% carbon dioxide. For 
the aerated group, atmospheric air was used and pumped through a filter into the 
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oxygenator using a peristaltic pump. The flow of air or oxygen into the Hilite® 800 LT 
hollow fibre oxygenator was maintained at 0.1 L/min in order to reduce the formation 
of gas microemboli in the perfusion fluid. Flow meters (Platon™) were used to 






Figure 35 Standard LifePort© device(A) and modified device with oxygenator(B) 
(1) Fluid aspirated from reservoir, (2) peristaltic pump, (3) sampling port, (4) bubble 
chamber, (5) fluid entering renal artery. Additional equipment used in the modified 
















Oxygen levels were measured relative to a control (4°C deionised water) using the 
Microx TX3 oxygen sensor (PreSens- Precision Sensing GmbH, Regensburg, 
Germany). To calibrate, deionised water at 4°C left open to the air overnight was 
used as the calibration positive control (i.e. this was the 100% O2 level). For the 0% 
calibration control, a 1% solution of sodium sulphite vigorously agitated was used, 
as per manufacturer’s instructions. The negative control was validated against 
deionized water at room temperature, deoxygenated by bubbling nitrogen gas 
through it for 1 hour, which returned a value of around 0% relative to the 100% and 
0% oxygen calibrators. The phase values for each calibrator was phase:59.37 at 
21.5°C for the 0% oxygen control and phase: 32.87 at 4°C for the 100% control. 
NMR 
Both 1D 1H and 2D 1H,13C-HSQC NMR spectra were acquired for this study as 
described in Chapter 2 and Chapters 5-8. 
GCMS 
GCMS analysis was carried out by a collaborator (Alpesh Thakker) according to a 
protocol used within his group and is briefly described below. Tissue was extracted 
as per the protocol described in Chapter 2 (chloroform/methanol). 90% of the 
extracted sample was used for NMR analysis with the remainder used for GCMS to 
ensure homogeneity between GCMS and NMR. 40 µl of 2 % methoxyamine HCl in 
pyridine (Sigma-Aldrich, Dorset, UK) was added and incubated at 60°C. 60 µl of N-
tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) with 1% (w/v) 
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tertbutyldimethyl-chlorosilane (TBDMSCI) (Sigma-Aldrich, Dorset, UK) derivatization 
reagent was then added and further incubated for 60 mins prior to centrifugation 
(13000 rpm for 5 mins). The supernatant was then transferred to a chromatography 
vial prior to GC-MS analysis.! 
For analysis of the derivatized samples an Agilent 7890B Series GC/MSD gas 
chromatograph with a polydimethylsiloxane GC column coupled with a mass 
spectrometer (GC-MS) (Agilent Technologies UK Limited, Stockport, UK) was used. 
Prior to sample analysis the GC-MS was tuned to a full width at half maximum 
(FWHM) peak width of 0.60 atomic mass units (amu) in the mass range of 50 to 650 
mass to charge ratio (m/z) using PFTBA tuning solution. 1 µl of sample was injected 
into the GC-MS in split mode 1:10 with helium carrier gas at a rate of 1.0 ml/min. 
The inlet liner containing glass wool was set to a temperature of 270°C. Compound 
detection was carried out in full scan mode in the mass range 50 to 650 m/z, with 2-
4 scans/sec, a source temperature of 250°C, transfer line temperature 280°C and a 
solvent delay time 6.5 minutes. 
Raw GC-MS data was converted to common data format (CDF) using acquisition 
software (Masshunter, Agilent) and further processing of the isotope data including 
isotope correction and mass isotopomer analysis was performed on 
Metabolitedetector software (210). 
Combined NMR/GCMS methodology  
As described previously in this thesis (Chapter 8), the MetaboLab software package 
was used to determine the proportion of differing 13C isotopologues based upon the 
2D 1H,13C-HSQC spectra acquired. However, in this chapter, for metabolites readily 
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detectable by both 2D NMR and GCMS (e.g. lactate, alanine and glutamate) we have 
used a combined approach that incorporates data from both of these techniques, 
which is also part of the MetaboLab program. This combination of MS/NMR 
enhances the utility compared to either technique in isolation. Analysis of the same 
sample using two different techniques serves as an internal validation for the 
experiment. In addition to the highly detailed information regarding the local 
environment surrounding 13C nuclei within a molecule as determined using NMR, the 
combination of MS removes structural ambiguity where one 13C nuclei is outside the 
range of magnetic influence of the next 13C nuclei. This combined GCMS/2D NMR 
approach using MetaboLab software has been recently published by supervisors 
(C.L. & D.T.)(211).   
 
HPLC 
AMP/ADP/ATP analysis was performed by a collaborator (Yugo Tsuchiya) at 
University College London. Adenine nucleotides were extracted from frozen 
powdered tissue with ice-cold 0.35 M perchloric acid and analysed by ion-pair 
reverse phase HPLC as described by Sellevold et al (212). 
Results 
Oxygenation in standard HMP 
Prior to commencing experiments looking at the oxygen concentrations in aerated or 
oxygen enriched conditions, we initially wished to established the amount of oxygen 
present during HMP under standard (non-oxygenated) conditions. Therefore, we 
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perfused several porcine abattoir kidneys with KPS-1® solution as described in 
multiple chapters of this thesis and measured the oxygen levels relative to chilled 
deionised water. The oxygen levels were measured at two sites: in the arterial limb 
(i.e. in the perfusion fluid prior to entering the renal artery and perfusing the kidney) 
and in the venous effluent of fluid exiting the kidney.  
Having performed this simple experiment during 10 hours of HMP we made several 
important observations that are clearly demonstrated in the figure below (Figure 
36). Firstly that at the start of perfusion (time zero) the oxygen levels in the KPS-1® 
are the same as that of the control (deionised water) and hence KPS-1® and water 
appear to have the same amount of dissolved oxygen at 4°C. Secondly, the amount 
of oxygen in the venous effluent is substantially lower (circa 10%) than the amount 
of oxygen in the arterial fluid. This clearly demonstrates that oxygen is consumed by 
the kidney during HMP under standard conditions (213) and would seemingly 
corroborate findings in previous chapters that oxygen-dependent metabolism does 
occur during HMP. Thirdly the amount of oxygen in the arterial limb perfusion fluid 
falls rapidly during HMP and after only two hours is less than 20% of that at the 
start. Given that HMP in clinical practice is commonly employed for much greater 
durations than two hours, the effects of supplemental oxygen after this time point 





Figure 36 Diminishing oxygen levels under standard HMP conditions 
 
 
Oxygen levels in experimental groups 
Using the same oxygen measurement system, we sought to determine the oxygen 
levels in the perfusion fluid of our two experimental groups (oxygenated and 
aerated) during HMP. Paired porcine kidneys (n=8) underwent HMP with either 
supplemental oxygen or air provided via a membrane oxygenator. Oxygen levels in 
the perfusion fluid were measured in both the arterial (fluid entering the kidney) and 
venous limbs (fluid exiting the kidney). Chilled deionised water was again used as 
the 100% standard. The results are shown in Figure 37 below. As expected, the 
oxygen levels were highest in the fluid supplemented with oxygen with readings 4 
fold higher than the aerated group. In both groups, the oxygen present in the 
venous fluid is lower than the arterial. This demonstrates that even after prolonged 
periods of HMP (18 hours), oxygen consumption still occurs within the kidney. 







































process. Consumption appeared to be slightly greater in the group where 
supplemental oxygen was provided (410% to 305% vs. 102% to 31%). The fluid 
oxygen level in the aerated group after 18 hours mirrored the readings found under 
standard HMP non-oxygenated conditions at the start of perfusion i.e. 100% in 
arterial limb and 31% in venous (see Figure 36). Thus, it would appear that aerating 
perfusion fluid replenishes the oxygen consumption occurring in the kidney even for 






















































Metabolic profiles using 1D 1H NMR 
Metabolite quantification was performed on neat perfusion fluid and extracted kidney 
cortex tissue as described in Chapter 2 and Chapters 5-7 using Chenomx software 
8.1 (Chenomx Inc., Edmonton, AB, Canada). The metabolite concentrations between 
the two groups (aerated and oxygenated) were compared using a Wilcoxon matched 
pairs signed rank test. All analysis was performed using GraphPad Prism version 6.00 
for Mac OS X (GraphPad Software, La Jolla California USA), with p < 0.05 deemed to 
be indicative of statistical significance. 
In total, 46 metabolites were reliably detected in the perfusion fluid or tissue using 
1H NMR. Of these, there were five metabolites (formate, glutamate, hypoxanthine, 
lactate, succinate) in the perfusion fluid at different concentrations between the 
oxygenated and aerated groups (Figure 38) and three metabolites in the kidney 
cortex samples present in different concentrations (choline, glutamate, succinate). 
For all the metabolites that differed in concentrations between the two perfusion 
conditions (oxygenated or aerated), the concentrations were greater in the aerated 
perfusion group, with no metabolite present in greater concentration in the 




Figure 38 Concentrations of major metaboilites perfusate and cortex T=18 hrs 
Data presented as mean + standard deviation and comparison using Wilcoxon 




Adenine nucleotide (AMP, ADP and ATP) concentrations were determined using 
HLPC analysis of extracted kidney cortex and medulla samples from the oxygenated 
and aerated experiments. The two groups (aerated and oxygenated) were compared 
using a Mann-Witney test (unpaired, non parametric). All analysis was performed 
using GraphPad Prism version 6.00 for Mac OS X (GraphPad Software, La Jolla 
California USA), with p < 0.05 deemed to be indicative of statistical significance. 
This analysis demonstrated strikingly different concentrations of adenine nucleotides 
present. Although the amount of AMP was not significantly different between the 
oxygenated and aerated kidneys, the amount of ADP (both cortex and medulla) and 
ATP (cortex) was significantly higher in the kidneys perfused with oxygenated 
solution.  Indeed the ATP present after 18 hours of perfusion in the cortex samples 
of oxygenated kidneys was over seven-fold greater than for aerated (mean 20.0 vs. 




Figure 39 Adenine nucleotide levels for oxygenated and aerated tissue samples. 
HPLC analysis of adenine nucleotides in oxygenated and aerated porcine kidneys. 




Combined 2D 1H,13C-HSQC NMR and GCMS analysis 
Using both 2D [1H, 13C]-NMR and GCMS, splitting patterns for the metabolites 
alanine, glutamate and lactate were consistently seen in the perfusion fluid, 
extracted kidney cortex and medulla samples for kidneys undergoing both aerated 
and oxygenated perfusion. As mentioned previously the samples were analysed by 
both analytical techniques and a combined presentation of the results for these 
metabolites is demonstrated in the figure below (Figure 40-Figure 42). The two 
groups (aerated and oxygenated) were compared using a Mann-Witney test 
(unpaired, non parametric). All analysis was performed using GraphPad Prism 
version 6.00 for Mac OS X (GraphPad Software, La Jolla California USA), with p < 
0.05 deemed to be indicative of statistical significance. 
Data are presented as mean (standard deviation) for the percentage 13C enrichment 
for the isotopomers of each metabolite. As only a third (5 mM/L) of the glucose in 
the perfusion fluid was [U-13C] glucose, the proportion of labelled metabolites 
demonstrated underestimates the absolute amount of de novo metabolism from 
perfusate glucose (by two-thirds).  
 
Figure 40 displays the different (13C) isotopomers for alanine. This clearly 
demonstrates (as expected) that the most abundant was [U-13C] alanine although 
small amounts of [2,3-13C], [2-13C] and [3-13C] alanine were also present. The 
predominant [U-13C] alanine is derived through glycolysis of [U-13C] glucose in the 
perfusion fluid and conversion from pyruvate into alanine via the enzyme alanine 
transaminase. Interestingly, the proportion of [U-13C] alanine was greater in aerated 
kidneys (perfusate, cortex and medulla) and this was significant for both perfusate 
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and cortex (p<0.001). The biochemical mechanisms responsible for the production 
of the additional 13C isotopomers (e.g. [2,3-13C] alanine) is not clear but indicate 





Figure 40 13C enrichment for different alanine isotopomers 
 
Similar to alanine, a range of (13C) isotopomers was also detected for lactate (Figure 
41), with [U-13C] lactate predominating as, similar to [U-13C] alanine, this is 
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produced from [U-13C] pyruvate following glycolysis of the perfusion fluid [U-13C] 
glucose. The conversion of pyruvate to lactate via lactate dehydrogenase, occurs in 
more anaerobic conditions and therefore, as expected, the proportion of [U-13C] 
lactate was significantly greater in the perfusion fluid, kidney cortex and kidney 




Figure 41 13C enrichment for different lactate isotopomers 
There were also striking differences in the proportions of labelled glutamate between 
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the oxygenated and aerated kidneys on combined MS/NMR analysis (Figure 42). The 
13C tracer studies clearly demonstrate a significantly greater proportion of labelled 
glutamate (both [4,5-13C] and [4-13C] glutamate) in the oxygenated experiments 
compared with aerated. The proposed aetiology of the [4,5-13C] glutamate in this 
study is via glycolysis of the [U-13C] glucose in the perfusion fluid and subsequent 
formation of 2 x [U-13C] pyruvate molecules which is then converted to acetyl-CoA 
within the cell mitochondria via pyruvate dehydrogenase. Propagation of the TCA 
cycle results in the formation of α-ketoglutarate and glutamate formed by the 
reductive amination of α-ketoglutarate by glutamate dehydrogenase. Indeed the 
metabolite [4,5-13C] glutamate is seen due to early cycles of TCA activity with more 
complex labelling patterns formed with subsequent revolutions. The greater 
proportion of labelled glutamate observed in the oxygenated experiments is 
biologically anticipated given the requirement of oxygen to potentiate the TCA cycle. 
However, clearly the amount of oxygen present in the aerated perfusion fluid is 
sufficient do support some (albeit lesser) oxygen-dependent TCA activity which was 
greater than that seen when kidneys were perfused without air or oxygen (Chapter 
8). The absence of [2,3-13C] and [1,2,3-13C] glutamate is also interesting and 
suggests that there is no significant conversion of pyruvate into TCA intermediates 
via pyruvate carboxylase activity. The discrepancy between the proportion of [4,5-
13C] glutamate present in the aerated and oxygenated samples was greatest in the 
medulla samples compared with cortex (mean 3.7% vs 0.45% and 1.5% vs 0.56%, 
respectively). Indeed the difference in proportion of [4,5-13C] glutamate between 
oxygenated cortex and medulla samples is highly significant (p<0.001) and may 
reflect the predilection for TCA metabolism within the mitochondria of the porcine 
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medulla compared with the cortex (214). Interestingly, overall the total (13C labelled 
and unlabelled) amount of glutamate was significantly lower for oxygenated kidneys, 
both in the perfusion fluid and tissue extracts on 1D 1H analysis mentioned above 
(Figure 38). Thus, whilst the highly ATP efficient processes of glutamate production 
via TCA activity is more active in the oxygenated pig kidney, alternative pathways of 
glutamate production are greater in an non-oxygenated environment.  
 
 
Figure 42 13C enrichment for different glutamate isotopomers 
 
Discussion 
The therapeutic value of active oxygenation during hypothermic machine perfusion 
of kidneys has yet to be established in the human setting. In an earlier chapter of 
this thesis (Chapter 7), we demonstrated that the kidney is metabolically active 
during HMP, and even during the presumably hypoxic conditions of HMP there is 
some evidence of aerobic metabolic activity (Chapter 8). The aim of this study was 
to determine whether aeration of perfusion fluid would be sufficient to propagate 
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maximal aerobic metabolic processes within the HMP environment or whether 
oxygenation was needed for this purpose. Given that evidence from other disease 
settings as to the harmful effects of high dose oxygen, it would seem prudent that if 
oxygen provision is beneficial during HMP, it should be provided at the minimum 
level necessary in order to achieve the desired results. 
A modified perfusion device (LifePort© Kidney Transporter 1.0 Organ Recovery 
Systems) was used for these experiments, with a paediatric membrane oxygenator 
incorporated into the circuit. Using a simple oxygen probe to measure oxygen levels 
compared to a control, we demonstrated through comparison of the oxygen levels in 
the ‘arterial’ and ‘venous’ limb of the LifePort© circuit that the kidney is an oxygen 
consuming organ during HMP conditions. Furthermore, the amount of oxygen 
present in the perfusion fluid under standard HMP conditions falls rapidly within the 
first two hours and that the organ is rendered severely hypoxic after this time 
period. However, the amount of oxygen present in the fluid can be maintained at 
constant levels, comparable to those at the start of perfusion through aeration of the 
perfusion fluid using a paediatric membrane oxygenator. Indeed if low flow oxygen 
(0.1 L/min) is used instead of air, the oxygen levels in the fluid increase roughly 
four-fold. Thus this chilled preservation fluid can be rendered hyperoxic by the 
provision of supplemental oxygen. Whether this active oxygenation is sufficient to 
derive maximal benefit for the perfused kidney in comparison to oxygen carriers is 
not explored in this study but would be interesting to determine. 
This study demonstrates that the metabolic profiles for aerated and oxygenated 
kidneys are different. This has been shown using multiple different laboratory 
techniques including 1D 1H NMR, 2D 1H-13C NMR, GCMS and most strikingly HPLC 
 
 175 
analysis of adenine nucleotides. 
Glutamate is a useful molecule for determining TCA cycle activity using 2D NMR 
methods. Indeed when [U-13C] glucose is incorporated into the perfusion fluid and 
[4,5-13C] labelled glutamate is demonstrated, this indicates initial TCA activity. 
However with further revolutions of the TCA cycle, alternative labelling patterns 
occur. In this study, we report a significantly increased proportion of [4,5-13C] 
labelled glutamate present in the kidney cortex and medulla in the oxygenated 
samples (compared with aerated), which clearly demonstrates a greater degree of 
TCA activity. Conversely, the proportion of [U-13C] lactate and alanine was greater 
for the aerated kidneys. The promotion of aerobic TCA metabolism within the 
mitochondria of oxygenated kidneys at the expense of lactate forming anaerobic 
pathways would seem the likely explanation for this. 
Interestingly, upon 1D 1H NMR analysis, the metabolic profiles of oxygenated and 
aerated kidneys appeared very similar. However for a number of metabolites 
(including glutamate and succinate) the total concentrations (i.e. 13C labelled and 
non labelled) present in both perfusion fluid and tissue were actually lower for the 
oxygenated group. The reasons for this are not fully clear but it may be that in the 
absence of additional oxygen, only minimal TCA cycle and electron transport chain 
activity occurs with a reliance on glycolytic pathways to generate the necessary ATP 
required for cell survival. It may be, that in oxygen abundant states, the pathways 
central to cellular maintenance or ATP generation predominate and that whilst some 
pathways are upregulated, there is a global metabolic quiescence under such oxygen 
enriched conditions. 
Regardless whether individual metabolic pathways are upregulated or not, this study 
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does clearly demonstrate that, using the experimental setup we describe, 
oxygenation of perfusate ultimately results in a significantly greater levels of cellular 
ATP (over seven-fold) following prolonged periods of perfusion. This corroborates 
findings from other ex vivo animal perfusion experiments (199, 205-208) and 
supports the hypothesis that a greater degree of aerobic metabolism occurs under 
these conditions. 
Conclusions 
The kidney consumes oxygen during hypothermic machine perfusion. 
Membrane oxygenators can be incorporated into the LifePort© circuit to 
provide additional oxygen and that the metabolic profiles of oxygenated 
kidneys differs from those that are aerated with a greater amount of ATP 














Future work – experimental  
Human cell line model 
The experimental animal work within this thesis has used a whole organ (abattoir 
pig) kidney as the model for transplantation. This model represents a DCD kidney 
with an associated WIT of around 14 minutes. We have demonstrated that from a 
metabolic standpoint, the porcine kidney is a valid model for human studies (4), in 
addition to being of comparable size with similar physiology. Whilst the porcine 
abattoir model is a paired system (i.e. one kidney from each animal can be perfused 
under control and experimental conditions), which is an inherent strength, it does 
have some limitations. The most notable limitation is that logistical factors (i.e. 
number of LifePort© machines) dictate that only one pair of kidneys can undergo 
perfusion experiments at any time. Whilst the effects of major differences in 
perfusion conditions (e.g. oxygen vs. no oxygen) can be determined using this 
model through repetition of experiments, more subtle differences are not possible to 
establish (e.g. optimal concentration of glucose in the perfusion fluid). For this type 
of study, we propose that a cell line would be a more appropriate investigative 
modality. We are therefore in the process of establishing a cell line model of HMP. 
We have cultured a human proximal tubular cell line and are attempting to replicate 
the conditions of HMP through a custom-built motile perfusion device. Furthermore, 
the feasibility of creating a 3D cell line structure to enhance the similarly with the 
whole organ model is under investigation. This work will contribute to the Ph.D. 
thesis of Thomas Smith. The high degree of homogeneity of cell lines should enable 
reproducible experimental conditions. Clearly, any promising avenues of HMP 
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optimization will be verified on a whole organ model. 
Ex-vivo normothermic perfusion model 
During my Ph.D. tenure, we developed a primitive ex vivo normothermic autologous 
blood reperfusion device, based largely on the setup reported by Nicholson et al (18, 
215, 216). We aim to develop this in future laboratory experiments in order to 
provide functional outcome results for future experimental work.  
Further labelling studies 
In this thesis, we successfully describe how information regarding active central 
metabolic pathways can be determined using [U-13C] glucose in the perfusion fluid. 
[U-13C] glucose was the logical initial tracer to introduce into the HMP system and is 
present in high concentrations in the HMP fluid (10 mM in KPS-1®). Furthermore, as 
was confirmed by these studies (5), metabolism of glucose through glycolytic 
pathways was biologically probable. Having confirmed that the kidney is 
metabolically active despite the ex vivo hypothermic conditions, the downstream 
metabolism of alternative substrates would be fascinating. Additional labelling 
studies could include 15N-glutamine.  
13C human perfusion study 
Work contained within this thesis has successfully demonstrated several important 
concepts regarding 13C studies. Firstly that when [U-13C] glucose is introduced into 
the perfusion fluid of HMP preserved kidneys that de novo metabolic activity occurs 
(5). Secondly, that NMR studies (principally 2D 1H,13C-HSQC and 1D 1H spectra) can 
be used to reliably identify these metabolites and calculate both relative proportions 
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of isotopologues and infer absolute concentrations (5). Finally that when the 
parameters of perfusion are changed (supplemental oxygen in this case), so does 
the type and isotopologue distribution of labelled products indicating differences in 
metabolic activity. Kidneys studied in this thesis are largely porcine abattoir kidneys 
(DCD model) with smaller numbers of discarded (non-transplantable) human 
kidneys. We have also demonstrated in the human setting, using 1H NMR of 
perfusion fluid, that the metabolomic profile of kidneys with immediate graft function 
differs from those with delayed graft function highlighting that pre-transplant 
metabolism dictates post-transplant function (3). However, as mechanistic 
information regarding metabolism is difficult to deduce from such 1D studies reliably, 
the next logical step for this project would be to perform 13C labelling studies on 
human kidneys for transplantation. The degree of de novo metabolic activity could 
then be correlated with the functional outcome of that kidney. 
Ethical approval 
In September 2015, ethical approved was granted to perform a single centre study 
at the Queen Elizabeth Hospital Birmingham using KPS-1® perfusion fluid, whereby 
the fluid glucose has been substituted with a [U-13C] glucose version (Appendix p93-
97). Ethical approval has been granted to analyse perfusion fluid, urine, and 
transplant kidney biopsy tissue. The study has been called the 13CHAMPION study 






We aim to perfuse 30 kidneys with the [U-13C] KPS-1® fluid over an 18 month 
period. The 2D labelling studies will be correlated with the kidney outcome (DGF, 
GFR, etc.). The study commenced in October 2016 and is due to complete in April 
2018. Sample collection and data analysis is being performed largely by my 
successor, Mr. Kamlesh Patel. This study should provide clarification of active 
metabolic pathways for transplanted kidneys and is a world first study of its type. A 
copy of the study protocol, consent form and patient information sheet is in 
Appendix p98-128 
Industry collaboration 
This study is reliant on a collaboration between ourselves and an industry 
collaborator (namely Organ Recovery Systems). As the producers of KPS-1® 
perfusion fluid, following discussions with ORS, they have kindly agreed to produce 
(and pay for) 30 litres of clinical grade [U-13C] KPS-1®. This fluid was manufactured 
in August 2016. A Material Transfer Agreement for this study was signed by 




During this three year Ph.D. degree, I have attempted to further understand the 
mechanisms and role of hypothermic machine perfusion for kidney preservation. 
Through a retrospective large (albeit single centre) clinical dataset analysis, I have 
demonstrated that transplantation from deceased donors is increasingly more 
complex with an increase in a multitude of high-risk markers. Although this study 
does not directly demonstrate that HMP is beneficial in this population cohort, 
evidence that HMP improves the short and longer term function of deceased donor 
kidneys is well established. As such, the demonstration of increasing deceased donor 
kidney complexity would suggest that therapies that maximise the potential function 
of such complex organs such as HMP will be of increasing importance. 
The potential role of HMP in living donor kidney transplantation was also explored 
through a retrospective analysis of a national dataset. We found that no live donor 
kidney in the UK had undergone HMP. Furthermore, we found that even in kidneys 
that had a comparatively prolonged cold ischaemia time (4-8 hours), excellent 
outcomes were observed (without HMP). As such, under normal clinical conditions, 
we concluded that there is little evidence to support the use of HMP in the live donor 
setting. 
Having explored the potential role of HMP in the deceased and live donor setting, 
experimental studies were performed to detail the metabolism during HMP further. 
NMR spectroscopy was largely used for this purpose. When the perfusion fluid of 
human kidneys was analysed using 1D 1H NMR, we found that the metabolome (or 
metabolic profile) of kidneys that proceeded to have immediate graft function 
differed from those that had delayed function. This highlights a fundamental 
 
 183 
principle, namely that the metabolic phenotype during HMP denotes the functional 
outcome for that organ. Whilst this study was limited by a relatively small sample 
size (n = 26) and therefore robust analyses of kidney subgroups (e.g. DCD vs. DBD) 
difficult, it does suggests that a metabolic profile (or biomarker panel) could be 
clinically useful to predict the function of kidneys pre-transplantation. 
Given the need for experimental studies to complement the human observational 
studies, a porcine abattoir kidney model was used extensively throughout this thesis. 
Although porcine kidneys are known to resemble human organs both anatomically 
and physiologically, it was important to ensure the validity of this model from a 
metabolic standpoint during the highly non-physiological conditions of HMP. The 
metabolic profile of human and porcine kidneys was therefore compared at 
equivalent time points during HMP using 1D 1H NMR. We demonstrated that the 
metabolome of human and porcine organs are strikingly similar and even where 
absolute concentrations of metabolites differed, the rate of change during perfusion 
was equivalent, suggesting that similar metabolic pathways are active. 
Having demonstrated that the metabolome during HMP reflects functional outcome 
and that porcine organs are a valid model of human metabolism, further studies 
were performed to gain further insight into HMP metabolism. The metabolic profile 
of porcine organs stored using either HMP or static cold storage conditions were 
compared. A paired model was utilised for this purpose and based on the weight of 
organ, tissue and perfusate concentrations, the net metabolic gain for each 
metabolite of interest was calculated. We found evidence of significantly greater 
metabolic activity in the HMP kidney compared with SCS counterparts. These 
included metabolites related to central metabolism: lactate, glutamate, aspartate, 
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fumarate and acetate. This study highlights significant metabolic differences 
between HMP and SCS preserved kidneys. Although this does not provide direct 
evidence that the benefits of HMP over SCS are solely attributable to metabolic 
improvements, these results do support the hypothesis that HMP improves the 
metabolism of preserved kidneys. 
Whilst 1D 1H NMR analysis enables the quantification of a vast number of 
metabolites, it does not provide definitive evidence of active metabolic pathways 
within a system. Even with repeated measures over successive time points, pathway 
activity is inferred but not proven. In order to provide unequivocal evidence of de 
novo metabolic activity during HMP, metabolic tracer studies were undertaken. 
Porcine kidneys were perfused under clinical conditions with a perfusate containing 
isotopic glucose [U-13C] glucose. Metabolites were analysed using a combined 2D 
1H,13C-HSQC and 1D 1H NMR approach. In this unpaired proof of concept study, we 
demonstrated that a significant amount of de novo metabolic activity occurs during 
HMP, with a progressive increase in the amount of labelled lactate and alanine 
present at sequential time points. 
Having demonstrated that HMP induces metabolism and that 13C studies can be used 
to demonstrate de novo activity, we sought to determine the metabolic effects of 
active oxygenation during HMP. The LifePort© perfusion circuit was altered to 
incorporate a paediatric membrane oxygenator, with an aerated group serving as 
the control. [U13C] glucose was added to KPS-1® fluid for isotopic labelling. We 
found several findings from this study involving both porcine and human organs 
(deemed unfit for transplantation): firstly that, the amount of oxygen present in the 
perfusate of oxygenated kidneys was several-fold higher than in the aerated group, 
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highlighting the increase in oxygen carriage of KPS-1® following active oxygenation, 
even in the absence of any oxygen carrier; secondly that the metabolism of 
oxygenated kidneys differed from the paired aerated counterparts; and thirdly that 
oxygenation significantly improves the amount of ATP in kidney tissue (both cortex 
and medulla). Whilst this study does not seek to determine the clinical effects of 
oxygenation during HMP, it does serve to highlight mechanistic differences between 
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Nuclear Magnetic Resonance Strategies 
for Metabolic Analysis
Clement Heude, Jay Nath, John Bosco Carrigan, and Christian Ludwig
Abstract NMR spectroscopy is a powerful tool for metabolomic studies, offering 
highly reproducible and quantitative analyses. This burgeoning field of NMR 
metabolomics has been greatly aided by the development of modern spectrometers 
and software, allowing high-throughput analysis with near real-time feedback. 
Whilst one-dimensional proton (1D-1H) NMR analysis is best described and remains 
most widely used, a plethora of alternative NMR techniques are now available that 
offer additional chemical and structural information and resolve many of the limita-
tions of conventional 1D-1H NMR such as spectral overlay. In this book chapter, we 
review the principal concepts of practical NMR spectroscopy, from common sam-
ple preparation protocols to the benefits and theoretical concepts underpinning the 
commonly used pulse sequences. Finally, as a case study to highlight the utility of 
NMR as a method for metabolomic investigation, we have detailed how NMR has 
been used to gain valuable insight into the metabolism occurring in kidneys prior to 
transplantation and the potential implications of this.
Keywords NMR • Metabolism • Metabolomics • Tracer • Kidney • Transplantation 
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Hypothermic machine perfusion during extended cold ischaemic times – an opportunity 
to improve pathways of care in cadaveric renal transplantation 
Alison Guy, Damian McGrogan, Jay Nath, Clare Pattenden, Ahmed Hamsho, Steve Mellor, Nick 
Inston, Andrew Ready 
Department of Renal Surgery, University Hospitals Birmingham, Birmingham, UK 
Introduction: The logistics of cadaveric renal transplantation are largely driven by Cold 
Ischaemic Time (CIT). However, to achieve successful outcomes in complex donor-recipient 
combinations, recipient and operative issues demand equal consideration. Extending CIT 
without detriment to graft function would therefore be of value. We have investigated the role of 
Hypothermic Machine Perfusion (HMP) as a tool by which such an extension of CIT might be 
obtained. 
Methods: Cadaveric kidneys were allocated to a storage method depending on predicted time 
to theatre. Kidneys to be transplanted between 8am – 8pm in the dedicated transplant theatre 
remained in Static Cold Storage. If predicted operating time was out-of-hours, the kidney was 
transferred to HMP and transplanted at the earliest opportunity on the elective transplant list. 
Results: 75 kidneys were transplanted from SCS; 68 from HMP. Median CIT was 24 hours in 
the HMP group compared to 13 hours in the SCS group (p=<.0001). 18 HMP kidneys suffered 
from DGF (26%) compared to 36 (48%) in the SCS group (p=0.01). There were no other 
significant differences in graft or post-operative complications. 
Discussion: This study demonstrates that comparable outcomes can be achieved following 
longer CITs by utilising HMP storage rather than traditional SCS. This effect is likely to be multi-
factorial; including improved recipient preparation, better peri-operative conditions and the 
inherent effects of HMP itself. 
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“Effect of cold ischaemia time on outcome after living donor renal 
transplantation”  
Authors Sefa W. Canbilen (4), Jay Nath(1), James Hodson (3), 
Nicholas G. Inston (1),Adnan Sharif (2) Andrew R. Ready 
(1) Departments of Renal 1Surgery, 2Medicine & 3Biostatistics, 
University Hospital Birmingham NHS Trust, Birmingham, UK. 4 
Third year medical student, School of Medical & Dental Science, 
University of Birmingham, UK  
Background  
The aim of this study was to determine whether modest prolongation of 
Cold ischaemia time CIT (up to 8 hours) impacts negatively on 
transplant outcome. This is clinically important, owing to the increasing 
number of cross centre kidney transplants performed.  
Methods  
Retrospective cohort study of 9,156 adult primary kidney transplants 
(January 2001-December 2014). Data was obtained from national 
(NHSBT and UK Renal Registry) databases. Patients were divided into 
3 groups depending on CIT (0-2 hours, 2-4 hours and 4-8 hours) and 
outcomes compared.  
Results  
There was a higher rate of delayed graft function in the group with the 
longest CIT (5.0%, 4.4% and 7.2% p=0.008) However, there was no 
difference in five year graft survival (death censored) between groups 
(91.0%, 90.8% and 89.9% p=0.250). There was also no difference in 
five year patient survival (p=0.263) or 12 months creatinine (0.061) 
between groups.  
Conclusion  
Patients receiving kidneys transplants with modest prolongation of cold 
ischaemia time have excellent functional outcomes. The small increase 
in delayed graft function in this group is unlikely to alter clinical practice 
such as cross centre living donor kidney transplantation. 
  
Effect of cold ischaemia time on outcome after living donor renal transplantation 
J. Nath, J. Hodson, S. W. Canbilen, J. Al Shakarchi, N. G. Inston, A. Sharif and A. R. Ready 
 
Appendix S1  Statistical methodology 
Initially, univariable analyses were performed to compare across the three cold ischaemia time (CIT) groups. To 
account for the ordering of the CIT groups, continuous variables were analysed using Jonckheere–Terpstra tests, and 
binary or ordinal variables using Kendall’s τ. Discrete variables that were non-ordinal (such as ethnicity) were 
assessed using χ2 tests.  
Multivariable analyses were then performed, in order to account for differences in demographics across the 
CIT groups. The binary and time-to-event outcomes were analysed using binary logistic and Cox proportional hazards 
regression respectively. In each case, CIT was entered into the model, with all potentially confounding factors 
considered for inclusion using a forwards stepwise approach. To maximize the amount of data available for analysis, a 
three-step process was used. First, this analysis was performed considering all factors. As there were a large number of 
patients with no available data for sensitization or wait time, these factors were excluded if they were not present in 
the final model, and the analysis rerun. The factors found to be significant in this model were then entered into a final 
analysis, in order to prevent the loss of patients owing to unavailable data in the non-significant factors.  Continuous 
variables were tested with Hosmer–Lemeshow tests before the binary logistic regression analyses  to assess the 
goodness of fit. Where poor fit was detected, the variables were either converted into categories, or log10-transformed, 
as applicable. For the Cox regression models, continuous variables were divided into categories, and all factors were 
tested graphically to ensure that the proportional hazards assumption was met. 
Multivariable analysis of creatinine was performed using a general linear model. Owing to the level of skew 
in the distribution of creatinine, values were log10-transformed before analysis, in order to normalize the distribution to 
meet the assumptions of the test. All potentially confounding factors were then entered into the analysis, and a 
backwards stepwise approach was used to produce a parsimonious model. As mentioned previously, the factors in the 
parsimonious model were then entered into a model that did not consider the non-significant factors, in order to 
maximize the available sample size. The resulting coefficients were then antilogged, and converted to represent the 
percentage differences across the levels of the factors.   
Adjusted rates for each outcome were then produced for each of the CIT groups. For the continuous factors in 
the model, the mean value was assumed. For categorical factors, the ‘average’ coefficients were generated by 
multiplying the proportions of patients within each category by the coefficients in the model. The models were then 
evaluated to give the estimated outcome for patients in the three CIT groups for the average patient; that is, with 
average values of all of the factors included in the model. For the Cox regression models, the survival rates were read 
off from the adjusted survival plots produced by SPSS® version 22 (IBM, Armonk, New York, USA). 
 
 
Table S1 Patient demographics 
 No. of people* (n = 9156) Missing data 
Recipient   
   Age (years)† 44 (33–54) 0 (0) 
   Sex (men) 5508 (60.2) 7 (0.1) 
   Ethnicity  88 (1.0) 
White 7823 (86.3)  
Asian 738 (8.1)  
Black 353 (3.9)  
Other 154 (1.7)  
   Diabetes 533 (5.8) 0 (0) 
   Dialysis at transplant  537 (5.9) 
Haemodialysis 4316 (50.1)  
Peritoneal dialysis 1916 (22.2)  
Not on dialysis 2387 (27.7)  
   Graft no.  0 (0) 
1 7957 (86.9)  
2 1027 (11.2)  
≥ 3 172 (1.9)  
   CMV-positive 3868 (45.1) 586 (6.4) 
   Blood group  6 (0.1) 
A 3752 (41.0)  
AB 319 (3.5)  
B 1086 (11.9)  
O 3993 (43.6)  
Donor   
   Age (years)† 48 (39–56) 5 (0.1) 
   Sex (men) 4180 (45.7) 6 (0.1) 
   Body mass index (kg/m2)‡ 26.5(4.0) 483 (5.3) 
   Ethnicity  73 (0.8) 
White 7921 (87.2)  
Asian 659 (7.3)  
Black 327 (3.6)  
Other 176 (1.9)  
   Blood group  10 (0.1) 
A 2978 (32.6)  
B 796 (8.7)  
O 5372 (58.7)  




Table S2 Matching/transplant factors 
 No. of people* (n = 9156) Missing data 
Wait time (days)†  299 (122–643) 2551 (27.9) 
Cold ischaemia time (h)  0 (0) 
< 2  2662 (29.1)  
2–4  4652 (50.8)  
4–8  1842 (20.1)  
Sensitization (% PRA)  4455 (48.7) 
0 2739 (58.3)  
1–20 280 (6.0)  
21–80 1008 (21.4)  
81–100 674 (14.3)  
Year of transplant  0 (0) 
2001–2005 1904 (20.8)  
2006–2008 2059 (22.5)  
2009–2011 2482 (27.1)  
2012–2014 2711 (29.6)  
HLA mismatch group  14 (0.2) 
1 1064 (11.6)  
2 1300 (14.2)  
3 4186 (45.8)  
4 2592 (28.4)  
Related donor 5661 (61.9) 6 (0.1) 
Antibody incompatibility   0 (0) 
Not present 8196 (89.5)  
HLAi 425 (4.6)  
ABOi 475 (5.2)  
Both HLAi and ABOi 60 (0.7)  
 
*With percentages in parentheses unless indicated otherwise; values are †median (i.q.r.). PRA, panel reactive 
antibody; HLAi, HLA-incompatible; ABOi, ABO-incompatible. 
Table S3 Outcomes 
 No. of recipients* (n = 9156) Missing data 
Death 526 (5.8) 45 (0.5) 
Graft failure 899 (9.9) 46 (0.5) 
Rejection within 3 months 1330 (15.8) 722 (7.9) 
Delayed graft function 419 (5.1) 1020 (11.1) 
Creatinine at 12 months (µmol/l)†  124 (69–225) 1926 (21.0)‡ 
*With percentages in parentheses unless indicated otherwise; †values are geometric means and 95 per cent prediction 
intervals (the antilog of the logged mean ± 1.96 s.d., that is, the range in which 95 per cent of cases fall). ‡Comprising 
152 patients with graft failure, 1650 with insufficient follow-up and 124 with no measurements recorded. 
Table S4 Multivariable analysis of factors predictive of death-censored graft survival 
  Hazard ratio P 
Cold ischaemia time (h)  0.049 < 2  1.00 (reference) – 
2–4  1.06 (0.91, 1.24) 0.471 
4–8  1.31 (1.05, 1.62) 0.016 
Dialysis at transplant  0.009 
Haemodialysis 1.00 (reference) – 
Peritoneal dialysis 0.96 (0.81, 1.14) 0.647 
Not on dialysis 0.75 (0.63, 0.91) 0.003 
Donor ethnicity  < 0.001 
White 1.00 (reference) – 
Asian 1.01 (0.75, 1.36) 0.947 
Black 2.34 (1.75, 3.14) < 0.001 
Other 1.12 (0.64, 1.95) 0.688 
Year of transplant  0.058 
2001–2005 1.00 (reference) – 
2006–2008 0.89 (0.74, 1.07) 0.211 
2009–2011 0.76 (0.61, 0.94) 0.014 
2012–2014 0.74 (0.55, 0.98) 0.036 
Antibody incompatibility  < 0.001 
Not present 1.00 (reference) – 
HLAi 1.93 (1.45, 2.57) < 0.001 
ABOi 1.57 (1.11, 2.21) 0.011 
Both HLAi and ABOi 2.57 (1.35, 4.89) 0.004 
Recipient age (years)  < 0.001 
< 30 1.00 (reference) – 
30–39 0.74 (0.61, 0.90) 0.002 
40–49 0.53 (0.43, 0.65) < 0.001 
50–59 0.43 (0.34, 0.55) < 0.001 
≥ 60 0.55 (0.42, 0.72) < 0.001 
Graft no.  0.013 
1 1.00 (reference) – 
2 1.24 (0.99, 1.55) 0.067 
≥ 3 1.73 (1.14, 2.62) 0.009 
HLA mismatch group  0.008 
1 1.00 (reference) – 
2 1.34 (0.99, 1.81) 0.058 
3 1.55 (1.20, 2.02) 0.001 
4 1.39 (1.05, 1.85) 0.023 
Donor age (years)  0.001 
< 30 1.00 (reference) – 
30–39 0.99 (0.72, 1.34) 0.930 
40–49 1.33 (1.00, 1.75) 0.047 
50–59 1.22 (0.92, 1.63) 0.163 
≥ 60 1.65 (1.21, 2.24) 0.002 
Donor body mass index (kg/m2)  0.006 
≤ 25 1.00 (reference) – 
25–30 1.11 (0.95, 1.30) 0.201 
> 30 1.36 (1.13, 1.65) 0.002 
Values in parentheses are 95 per cent confidence intervals. Parsimonious model from a forwards stepwise Cox 
regression analysis. All factors in Tables S1 and S2 (supporting information) were considered for inclusion. n = 8056 
after exclusions owing to missing data. HLAi, HLA-incompatible; ABOi, ABO-incompatible.
Table S5 Multivariable analysis of factors predictive of delayed graft function  
 Odds ratio P 
Cold ischaemia time (h)  
< 0.001 
< 2  1.00 (reference) – 
2–4  1.14 (0.88, 1.49) 0.314 
4–8  2.16 (1.60, 2.92) < 0.001 
Year of transplant  
< 0.001 
2001–2005 1.00 (reference) – 
2006–2008 0.61 (0.44, 0.83) 0.002 
2009–2011 0.44 (0.32, 0.60) < 0.001 
2012–2014 0.31 (0.22, 0.44) < 0.001 
Donor age (per decade) 1.21 (1.11, 1.33) < 0.001 
Recipient sex  
0.007 
F 1.00 (reference) – 
M 1.36 (1.09, 1.70) 0.007 
Dialysis at transplant  
< 0.001 
Haemodialysis 1.00 (reference) – 
Peritoneal dialysis 0.43 (0.32, 0.58) < 0.001 
Not on dialysis 0.25 (0.18, 0.35) < 0.001 
Recipient CMV  
0.008 
Negative 1.00 (reference) – 
Positive 1.33 (1.08, 1.65) 0.008 
Antibody incompatibility   
< 0.001 
Not present 1.00 (reference) – 
HLAi 4.66 (3.35, 6.50) < 0.001 
ABOi 4.90 (3.52, 6.83) < 0.001 
Both HLAi and ABOi 6.04 (2.99, 12.20) < 0.001 
Values in parentheses are 95 per cent confidence intervals. Parsimonious model from a forwards stepwise logistic 
regression analysis. All factors in Tables S1 and S2 (supporting information) were considered for inclusion. n = 7168 
after exclusions owing to missing data. CMV, cytomegalovirus; HLAi, HLA-incompatible; ABOi, ABO-
incompatible.  
Table S6 Multivariable analysis of factors predictive of patient survival 
  Hazard ratio P 
Cold ischaemia time (h)  
0.440 
< 2  1.00 (reference) – 
2–4  1.08 (0.88, 1.33) 0.468 
4–8  1.20 (0.91, 1.58) 0.205 
Recipient age (years)  
< 0.001 
< 30 1.00 (reference) – 
30–39 1.28 (0.81, 2.03) 0.290 
40–49 2.25 (1.48, 3.41) < 0.001 
50–59 4.15 (2.77, 6.21) < 0.001 
≥ 60 7.61 (5.02, 11.53) < 0.001 
Diabetes  < 0.001 
No 1.00 (reference) – 
Yes 2.37 (1.82, 3.09) < 0.001 
Dialysis at transplant  < 0.001 
Haemodialysis 1.00 (reference) – 
Peritoneal dialysis 0.70 (0.56, 0.88) 0.003 
Not on dialysis 0.54 (0.42, 0.69) < 0.001 
Recipient CMV  0.014 
Negative 1.00 (reference) – 
Positive 1.26 (1.05, 1.52) 0.014 
Donor age (years)  0.004 
< 30 1.00 (reference) – 
30–39 1.41 (0.86, 2.31) 0.167 
40–49 1.69 (1.06, 2.69) 0.026 
50–59 1.44 (0.90, 2.30) 0.124 
≥ 60 2.14 (1.33, 3.45) 0.002 
Antibody incompatibility  0.002 
Not present 1.00 (reference) – 
HLAi 1.89 (1.28, 2.80) 0.001 
ABOi 1.34 (0.86, 2.06) 0.192 
Both HLAi and ABOi 2.58 (1.06, 6.28) 0.036 
Values in parentheses are 95 per cent confidence intervals. Parsimonious model from a forwards stepwise Cox 
regression analysis. All factors in Tables S1 and S2 (supporting information) were considered for inclusion. n = 8019 
after exclusions owing to missing data. CMV, cytomegalovirus; HLAi, HLA-incompatible; ABOi, ABO-
incompatible. 
Table S7 Multivariable analysis of factors predictive of 12-month creatinine level 
 Coefficient  P 
Cold ischaemia time (h)  0.025 
< 2  Reference – 
2–4  1.5 (–0.2, 3.2) 0.094 
4–8  3.1 (0.8, 5.5) 0.007 
Recipient age (per decades) –3.0 (–3.6, –2.5) < 0.001 
Recipient sex  < 0.001 
F Reference – 
M 23.0 (21.2, 24.9) < 0.001 
Recipient ethnicity  < 0.001 
White Reference – 
Asian –4.3 (–6.8, –1.7) 0.001 
Black 14.0 (9.7, 18.4) < 0.001 
Other –1.7 (–7.9, 4.9) 0.607 
Diabetes  0.054 
No Reference – 
Yes –3.2 (–6.3, 0.1) 0.054 
Graft no.  0.065 
1 Reference – 
2 –0.8 (–2.9, 1.3) 0.441 
≥ 3 5.2 (0.4, 10.3) 0.035 
Year of transplant  < 0.001 
2001–2005 Reference – 
2006–2008 –8.2 (–10.2, –6.3) < 0.001 
2009–2011 –12.5 (–14.3, –10.6) < 0.001 
2012–2014 –12.7 (–14.8, –10.5) < 0.001 
Antibody incompatibility  < 0.001 
Not present Reference – 
HLAi 9.1 (5.6, 12.8) < 0.001 
ABOi 6.5 (3.1, 10.1) < 0.001 
Both HLAi and ABOi 13.2 (4.8, 22.3) 0.002 
Donor sex  < 0.001 
F Reference – 
M –4.7 (–6.1, –3.3) < 0.001 
Donor age (per decade) 7.6 (6.9, 8.3) < 0.001 
Log10 wait time (days)* 1.2 (0.1, 2.2) 0.034 
Values in parentheses are 95 per cent confidence intervals. Parsimonious model from a backwards stepwise general 
linear model. All factors in Tables S1 and S2 (supporting information) were considered for inclusion. n = 5191 after 
exclusions owing to missing data. The coefficients represent the percentage difference in creatinine between the stated 
category and the reference category, or for a 1-unit increase in continuous variables. *Wait time was log10 
transformed, before analysis, to improve model fit. Hence, the coefficient represents the increase in creatinine for a 
tenfold increase in wait time. HLAi, HLA-incompatible; ABOi, ABO-incompatible. 
 
 
Table S8  Multivariable analysis of rejection within 3 months 
 
Odds ratio P 
Cold ischaemia time (h) 
 
0.004 
< 2  1.00 (reference) – 
2–4  0.81 (0.71, 0.94) 0.004 
4–8  1.00 (0.84, 1.20) 0.970 




F 1.00 (reference) – 




White 1.00 (reference) – 
Asian 0.73 (0.57, 0.94) 0.014 
Black 1.43 (1.06, 1.92) 0.019 
Other 0.91 (0.54, 1.53) 0.730 
Donor age (per decade) 1.10 (1.04, 1.16) 0.001 
Year of transplant 
 
< 0.001 
2001–2005 1.00 (reference) – 
2006–2008 0.52 (0.44, 0.62) < 0.001 
2009–2011 0.43 (0.36, 0.51) < 0.001 
2012–2014 0.39 (0.32, 0.47) < 0.001 
HLA mismatch group 
 
< 0.001 
1 1.00 (reference) – 
2 1.83 (1.30, 2.57) < 0.001 
3 3.82 (2.86, 5.12) < 0.001 




Not present 1.00 (reference) – 
HLAi 1.43 (1.09, 1.86) 0.009 
ABOi 1.44 (1.11, 1.87) 0.006 
Both HLAi  and ABOi 2.29 (1.25, 4.20) 0.007 
Values in parentheses are 95 per cent confidence intervals. Parsimonious model from a forwards stepwise logistic 
regression analysis. All factors in Tables S1 and S2 (supporting information) were considered for inclusion. n = 8334 
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Donor     
Male gender 16 (62%) 11 (58%) 5 (71%) 0.67 
Median age (IQ range) 47 (40-60) 47 (42-59) 51 (31-61) 1.00 
CMV +ve 12 (46%) 8 (42%) 4 (57%) 0.67 
DBD(Maastricht 
Category III) 
23 (88%) 18 (95%) 5 (71%) 0.17 
DCD(Maastricht 
Category IV) 
3 (12%) 1 (5%) 2 (29%) 0.23 
SCD 16 (62%) 13 (68%) 3 (18%) 0.37 
ECD 10 (38%) 6 (32%) 4 (57%) 0.37 
Recipient     
Male gender 18 (69%) 12 (63%) 6 (86%) 0.37 
Median age (IQ range) 50 (44-54) 50 (44-55) 50 (44-53) 0.94 
Ethnicity: British 
                    Asian 













Virology:  CMV+ 
                    HAV+ 
                    HBV cAb+ 
                    HBV sAb+ 
                    HCV + 

























Dialysis:    HD 
                    PD 













Previous transplant ≥1 3 (12%) 3 (16%) 0 (0%) 0.54 
PRA level >5% 13 (50%) 9 (47%) 4 (57%) 1.00 
0.0.0 mismatches 4 (15%) 4 (21%) 0 (0%) 0.55 
Immunosuppression 
standard 
24 (92%) 19 (100%) 5 (71%) 0.06 
Storage Times (hours)     
Cold Storage time 7 (6-11) 8 (6-11) 7 (5-10) 0.33 
HMP time 15 (7-17) 15 (10-17) 15 (5-22) 1.00 
Total CIT 23 (16-27) 24 (17-27) 22 (15-29) 0.92 
HMP Parameters     
Initial Flow ml/min 64 (43-88) 67 (49-92) 47 (39-65) 0.20 
 2 
End Flow ml/min 108 (86-138) 111 (92-135) 95 (74-170) 0.72 





























CMV: cytomegalovirus, DBD: donation after brain-death, DCD: donation after cardiac-death, Maastricht Category: as defined in Kootstra G, Daemen JH, 
Oomen AP. Categories of non-heart-beating donors. Transplantation proceedings 1995; 27: 2893. SCD: standard criteria donor, ECD: extended criteria 
donor: defined as age >60 or 50-59 with 2 or more of hypertension, intracranial cause of death, creatinine >132 uM/L. HAV: hepatitis A virus, HBV: 
hepatitis B virus, HCV: hepatitis C virus, HIV; human immune-defiecieny virus, cAb: core antibody, sAb: surface antibody. HD: haemodialysis, PD: 
peritoneal dialysis. PRA: panel reactive antibodies. HMP: Hypothermic machine perfusion, CIT: cold ischaemic time. Standard immunosuppression: 
Basiliximab, Tacrolimus, Mycophenolate mofetil, Prednisolone. Data reported as: “Median (Quartiles)” or “N (%)”, with p-values from Fisher’s exact 

















SDC2:  Composition of KPS-1® 
Constituents Amount/1000mL Concentration mM 
Calcium chloride (dehydrate) 0.068g 0.5 
Sodium hydroxide 0.70g  
HEPES (free acid) 2.38g 10 
Potassium phosphate (monobasic) 3.4g 25 
Mannitol (USP) 5.4g 30 
Glucose, beta D (+) 1.80g 10 
Sodium Gluconate 17.45g 80 
Magnesium Gluconate (D (-) 
gluconic acid, hemimagnesium salt) 
1.13g 5 
 Ribose, D (-) 0.75g 5 
Hydroxyethyl starch (HES) 50.0g n/a 
Glutathione (reduced form) 0.92g 3 
Adenine (free base) 0.68g 5 













SDC3: Cut-off Values for ROC Curves 
 
 
Predictor Cutoff Sensitivity Specificity Youden’s J 
Glucose (45 Mins) 9.0 100% 74% 0.737 
Glucose (4 Hours) 9.7 100% 68% 0.684 
Inosine (45 Mins) 0.0056 100% 68% 0.684 
Leucine (45 Mins) 0.0087 67% 84% 0.509 
Gluconate (4 Hours) 52.0 83% 84% 0.675 
Based on Youden’s J statistic 














































Hydroxybutyrate 1.204 Hippurate 7.82 
3-
Methylxanthine 8.02 Hypoxanthine 8.20 
Acetate 1.91 Inosine 6.055 
Adenine 8.11 Isoleucine 0.997 
Alanine 1.46 Isopropranolol 1.162 
Citrate 2.67 Lactate 1.40 
Ethanol 1.17 Leucine 0.948 
Formate 8.44 Malonate 3.11 
Fumarate 6.51 Mannitol 3.840 
Gluconate 4.12 N-Phenylacetylglycine 7.412 
Glucose 3.524 Ribose 2.21 
Glutamate 2.341 Tyrosine 6.877 
Glutathione 2.97 Uracil 7.52 
































































SCS, ", 0.031*, 0.094,(0.063"0.112), 0.031*,
HMP, 0.048,(0.037"0.062), , 0.055,(0.050"0.059), ,
Choline, SCS, 0.039,(0.035"0.045), 0.031*, 0.404,(0.329"0.423), 0.063,
HMP, 0.102,(0.099"0.115), , 0.267,(0.205"0.299), ,
Creatinine, SCS, 0.032,(0.008"0.067), 0.031*, 0.564,(0.127"0.699), 0.156,
HMP, 0.196,(0.038"0.386), , 0.228,(0.130"0.328), ,
Hippurate, SCS, 0.002,(0.001"0.002), 0.031*, 0.005,(0.003"0.007), 0.094,
HMP, 0.006,(0.005"0.010), , 0.001,(0.000"0.005), ,
Isoleucine, SCS, 0.004,(0.003"0.005), 0.031*, 0.036,(0.032"0.041), 0.031*,
HMP, 0.026,(0.023"0.027), , 0.019,(0.014"0.020), ,
TMNO, SCS, 0.037,(0.031"0.047), 0.031*, 0.152,(0.096"0.272), 0.219,
HMP, 0.254,(0.165"0.266), , 0.143,(0.099"0.218), ,
Valine, SCS, 0.006,(0.006"0.010), 0.031*, 0.068,(0.057"0.083), 0.031*,
HMP, 0.041,(0.038"0.053), , 0.035,(0.025"0.036), ,
β"Alanine, SCS, 0.013,(0.010"0.021), 0.031*, 0.101,(0.078"0.112), 0.031*,
HMP, 0.085,(0.078"0.099), , 0.038,(0.031"0.048), ,
Taurine, SCS, 0.196,(0.136"0.227), 0.031*, 0.981,(0.929"1.056), 0.063,
HMP, 0.693,(0.640"0.821), , 0.505,(0.437"0.554), ,
ADP, SCS, 0.014,(0.013"0.015), 0.031*, 0.013,(0.011"0.026), 0.438,
HMP, ", , 0.024,(0.019"0.031), ,
AMP, SCS, 0.003,(0.002"0.003), 0.031*, 0.128,(0.105"0.169), 0.563,
HMP, ", , 0.140,(0.131"0.166),
NAD+, SCS, ", ", 0.025,(0.022"0.031), 0.094,
HMP, ", , 0.037,(0.033"0.049), ,
S1 Table.  Distribution of metabolite quantity between extracellular storage 
fluid and entire kidney tissue for 12 metabolites detected in comparable total 
amounts to controls.  
 
Data reported as median (interquartile range), unless stated otherwise. 
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PROTOCOL SIGNATURE SHEET 
This protocol has been approved by: 
 
Name & Address: 
 











Name & Address 
 











Principal Investigator Declaration: 
 
I have read and understood the requirements and conditions of the study protocol. I am aware of my 
responsibilities as an Investigator under the guidelines of the Internal Conference on Harmonisation Good 
Clinical Practice (ICH GCP) standards, the Declaration of Helsinki, local regulations (as applicable) and the 
study protocol. I agree to conduct the study according to these guidelines and to appropriately direct and 
assist the study team assigned to me who will be involved in the study. 
 
I agree to use the study material, including medication, only as specified in the protocol.  
I understand that changes to the protocol must be made in the form of an amendment that must be approved 
by the Ethics Committee and Regulatory Authorities prior to its implementation.  
 
I understand that non-compliance with the study protocol may lead to early termination of the study. 
 
Local Investigator’s Name & Address: 
 








Return the original wet signature* page to the sponsor and retain a copy* with the study protocol within the 
Investigator’s Site file. 
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The" aim" of" this" research" project" is" to" investigate" the" use" of" Machine" Perfusion" (MP)" on" human"
kidneys"that"are"not"suitable"for"transplantation.""
"
Kidney" transplantation" is" the" gold" standard" treatment" for" patients" with" endcstage" renal" failure,"









most" recent" changes" to" emerge" is" the" acceptance" of" kidneys" that" might" previously" have" been"
rejected."These"kidneys"are"termed"marginal,"or"Expanded"Criteria"donor"(ECD)"kidneys."Compared"













The" alternative" to" static" cold" storage" is" Machine" Perfusion" (MP),," Which" is" normally" performed"
under"hypothermic"condition."Such"devices"contain"a"pump"that"provides"a"pulsatile"recirculation"of"
preservation" fluid." Large" international" studies" in" recent" years," have"demonstrated" the"benefits" of"
MP,"including"reduced"rates"of"DGF"and"Primary"NoncFunction"(PNF),"as"well"as"long"term"survival"
benefit" in" selected" kidneys" compared" to" static" sold" storage" (see" below)." In" addition" to" the" direct"





Both" animal" experiments" and" historical" clinical" studies" have" demonstrated" that" Hypothermic"
Machine" Perfusion" of" cadaveric" kidneys" provides" improved" early" graft" function" when" compared"
with" Static" Cold" Storage.4,5,6,7,8,9." Studies" from" the" 1990’s" reported" reduced" rates" of" DGF" and"
increased" rates"of" immediate" function"of" renal" grafts10,11,12,13."MP"was" shown" to"be"preferable" for"
prolonged" preservation" times," both" for" kidneys" donated" after" cardiac" death" and" for" ECD"
kidneys14,15,16."Daemen"et!al!(1997)!demonstrated"reduced"DGF"for"DCD"kidneys"when"preserved"by"


















demonstrated" that" the" metabolites" present" within" the" perfusate" of" human" kidneys" prior" to"
transplantation"correlates"with"post"transplant"graft"function"(Appendix"2)."This"work,"utilising"1D"
NMR"(Nuclear"Magnetic"Resonance)"Spectroscopy"has"provided"us"with"a"metabolic"‘fingerprint’"of"
the" perfusion" fluid" at" various" time" points" of" perfusion." Characterisation" of" metabolic" processes"
occurring" during" machine" perfusion" is" at" an" early" stage," but" such" metabolism" appears" to" be"
fundamental"to"the"success"of"the"transplant"graft."
"
Although" we" have" gained" significant" understanding" of" the" active" metabolic" processes" during"
perfusion" from" this" perfusate" analysis" study," and"will" continue" to" add" to" the" number" of" samples"
obtained," experimental" studies" are" needed" in" addition" to" this" to" gain" a" more" complete"
understanding."
"
Perfusate" 1D" NMR" Spectroscopy," as" we" have" performed," provides" a" metabolic" snapshot" during"
perfusion"in"these"hypoxic,"hypothermic"conditions,"utilising"the"gold"standard"perfusion"fluid"(KPSc
1)." However" these" conditions," including" the" chemical" composition" of" the" perfusion" fluid" were"
developed" on" the" understanding" that" little," if" any"metabolism" occurs" during" organ" preservation."
However,"as"we"have"shown,"metabolic"support"appears"to"be"a"key"beneficial"component"of"organ"











We" have" performed" metabolic" studies" using" the" porcine" model" with" alteration" of" the" perfusion"









In" order" to" develop" a" greater" understanding" of" the"metabolic" benefits" of"machine" perfusion," we"
would" like" to"utilise"human"organs"not"suitable" for" transplantation"and"modify" the"parameters"of"
perfusion.""
The"evidence"suggests"that"MP"has"a"beneficial"effect"on"the"kidney."Metabolic"support"appears"to"be"
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the" suitability" of" the" organ" (e.g." mechanical" damage," suspicious" mass," evidence" of" infection,"
anatomical" abnormality)" then" this" is" relayed" to" the" surgical" team" that"had"provisionally"accepted"
the" organ." If" the" surgical" team" then" decline" the" kidney" based" upon" this" information" for" their"
particular"patient,"the"organ"is"offered"to"all"other"UK"transplant"centres"with"a"suitable"recipient"on"
their" transplant"waiting" list." If" the"organ" is"rejected" for" transplantation"by"all"UK"centres,"and"the"
donor"has"given"consent" for"organ"utilisation" for"research"purposes," the"organ" is" then"offered"via"
the" specialist" nurse" for" organ" donation" at" the" donor" centre" to" suitable" centres" for" research." It" is"
important"to"stress"that"organs"are"always"retrieved"with"the"intention"of"transplantation"and"are"





throughout" the" kidney" during" its" time" on" the" machine" as" occurs" in" standard" clinical" practice."
However"the"parameters"of"perfusion"(temperature,"perfusion"pressures,"and"perfusion"fluid)"will"











and"medulla"of" the"perfused"kidney."This"will"be"primarily" for"cell"extraction" in"order" to"perform"
tissue" NMR" (Nuclear" Magnetic" Resonance)" analysis" and" will" provide" important" information"
regarding" the" intracellular"metabolism"during"perfusion,"which"will" complement" the"extracellular"
indicators"derived"from"the"perfusion"fluid."In"addition"to"this,"tissue"samples"will"also"be"utilised"to"
gain" information" regarding" cellular" and" structural" function," both" immunological" and" endothelial."
Primary" cell" lines"may" also" be" cultured" from" kidney" tissue." At" the" experiment" endpoint" we"will"











































At" the" endpoint" of" each" study," a" tissue" biopsy" will" be" performed." Human" discarded" organs" are"









We" will" take" samples" of" the" perfusion" fluid" for" analysis" at" multiple" timepoints" during" machine"
perfusion,"(commonly"T0,"at"45minutes,"and"at"4,"18,"24"and"48"hours)."Five"milliliters"of"perfusion"
fluid"will"be"taken"at"each"time"interval,"except"for"the"final"sample"which"will"include"all"remaining"




not"contain"any"patient" identifiable"data."Sample"preparation" for"NMR"analysis"currently" involves"
mixing" the" perfusate" samples" with" phosphate" buffer" solution" containing" 2" mM" TSP" [(3c























for" research" purposes," of" which" assuming" a" 50%" acceptance" rate" due" to" organ" suitability" and"



















































































































































































































































Please! include! all! support! your! study! requires! from! NHSBT! i.e.! SNDOD! involvement:!
consent/authorisation! referral! to! researche;! retrieval! by! the! NORS! teams;! packing! of! the!
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Principal Investigator Declaration: 
 
I have read and understood the requirements and conditions of the study protocol. I am aware of my 
responsibilities as an Investigator under the guidelines of the Internal Conference on Harmonisation Good 
Clinical Practice (ICH GCP) standards, the Declaration of Helsinki, local regulations (as applicable) and the 
study protocol. I agree to conduct the study according to these guidelines and to appropriately direct and 
assist the study team assigned to me who will be involved in the study. 
 
I agree to use the study material, including medication, only as specified in the protocol.  
I understand that changes to the protocol must be made in the form of an amendment that must be approved 
by the Ethics Committee and Regulatory Authorities prior to its implementation.  
 
I understand that non-compliance with the study protocol may lead to early termination of the study. 
 
Local Investigator’s Name & Address: 
 








Return the original wet signature* page to the sponsor and retain a copy* with the study protocol within the 
Investigator’s Site file. 
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Kidney( transplantation( is( the( gold( standard( treatment( for( patients( with( endf
stage( renal( failure(providing(both( survival( benefit( and( improved(quality( of( life(
when( compared(with( dialysis.1( In( addition( there( are( economic( benefits.( Renal(




live( donation,( with( cadaveric( donation( remaining( static( over( the( last( decade.(
Strategies( to( increase(donor(numbers(have( recently( been( introduced( including(
the(use(of(more(donations(after(cardiac(death((DCD)(and(identification(of(more(
possible( donors( that( previously( were( considered( unsuitable.( These( strategies(
whilst( increasing( numbers( have( not( concentrated( on( the( quality( of( kidneys(
offered(and(one(of(the(changes(to(emerge(is(the(acceptance(of(kidneys(that(might(
previously(have(been(rejected.(These(kidneys(are(termed(marginal(or(expanded(
criteria( donor( (ECD)( kidneys.( Compared( to( standard( criteria( donor( (SCD)(
kidneys(these(ECD(kidneys(are(associated(with(higher(risks(of(graft(failure.(This(
is(also(the(case(for(DCD(kidneys(that(have(higher(rates(of(delayed(graft(function(
(DGF).3( The( greater( availability( of( marginal( kidneys( has( led( to( an( increased(











Traditionally( the( standard( storage(method( for( kidneys( in( the( UK( is( static( cold(
storage((CS).(After(procurement,(the(organ(is(flushed(with(cold(preservation(fluid(





hypothermic( (HMP).( The( kidney( is( stored( in( a( box( that( provides( a( cold(
environment( and( pulsatile( recirculation( of( preservation( fluid.( From( large(
international(studies(in(recent(years(evidence(has(been(generated(to(support(the(
benefits(of(MP(in(particular(reduced(DGF(and(primary(nonffunction((PNF),(and(a(
longfterm( survival( benefit( for( MP( compared( to( CS( kidneys( (see( below).( In(
addition( to( the(direct( benefits( to( the( organ( the( ability( to( prevent( injury( to( the(






Hypothermic(Machine( Perfusion( of( cadaveric( kidneys( provides( improved( early(
graft( function(when(compared(with(Static(Cold(Storage.4,5,6,7,8,9(Studies(from(the(
1990’s(reported(reduced(rates(of(DGF(and(increased(rates(of(immediate(function(









preservation( times,( for( kidneys( donated( after( cardiac( death( and( for( ECD(
kidneys.14,15,16(Daemen(et!al!demonstrated( reduced(DGF( for(DCD(kidneys(when(
preserved( by(MP( instead( of( CS17(However,( controversy( still( remained( due( to( a(
lack(of(prospective(studies(and(perceived(costs(associated(with(MP.(
(
A( recent( European( multicenter( randomized( controlled( trial( has( provided(
important(evidence18.(The(study(involved(336(consecutive(deceased(donors(from(
whom(one(kidney(was(randomized(to(CS(and(the(other(to(MP.(HMP(reduced(the(




In( addition( to( improved( outcomes,(MP( provides( the( ability( to( evaluate( organs(
from(ECDs(and(DCDs(prior(to(transplantation.(This(may(significantly(increase(the(





perfusate( of( MP( kidneys.16,22,23,24,25( Based( on( results( gained( following( initial(
ethical( approval( (RRK4459),( we( have( shown( that( the( metabolites( that( are(
present(in(the(perfusion(fluid(of(the(kidneys(can(be(used(to(predict(the(outcome(
for(that(kidney,(demonstrating(that(metabolism(during(perfusion(plays(a(key(role(









study( is( to( derive( information( regarding( metabolic( pathways( during( the(
perfusion( process.( This( will( be( achieved( through( perfusing( kidneys( with(
clinically( used( perfusion( fluid( enriched( with( a( safe,( non( radioactive,( naturally(









occurring( safe( isotope( and( needless( to( say( is( not( radioactive.( Increasing( the(
proportion( of( 13C( compared( to( 12C( form( of( glucose( will( allow( informative(
metabolic( studies( through(NMR(analysis.(However( the( total( amount( of( glucose(




occurring( heavy( isotope.( All( fluid( will( be( produced( to( clinical( grade(
pharmaceutical(standards(by(Organ(Recovery(Systems.(
(
There( are( no( risks( from( taking( perfusion( fluid( samples( during( the( perfusion(









performed( in( an( aseptic(manor.( The( total( amount( of( fluid( removed( during( the(
study(will(be(less(than(5%(of(the(circulating(volume.((
Urine( samples(will( be( obtained( from( urine( collected( postoperatively( for( other(
purposes( and( no( additional( samples( needed.( This( poses( no( additional( risk( to(
patients.((
The(risk(of(tissue(biopsy(is(minimal.(The(biopsy(procedure(and(technique(is(the(
same( as( kidney( biopsies( that( are( performed( for( diagnostic( purposes( and( are(
performed( routinely( preftransplantation( by( many( centres.( The( risk( of( any(
adverse(event(as(a(direct(result(of(biopsy(is(minimal(and(this(is(further(reduced(
by( performing( the( biopsy( under( direct( vision( prefoperatively,( whereby( any(
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The(evidence( suggests( that(MP(has( a(beneficial(metabolic( effect( on( the(kidney.(
The(mechanism(of(this(is(poorly(understood.(We(aim(to(improve(understanding(








Various( parameters( have( been( suggested( as( prognostic( indicators( of( how( a(

















This( is( a( prospective( observational( trial( involving( laboratory( investigations.(
Kidneys( available( for( transplantation( are( offered( through( a( national( matching(










are( suitable,( when( kidneys( arrive( at( our( unit,( they(will( be( placed( on(machine(
perfusion(using(13C(enriched(perfusion(fluid.(For(patients(that(do(not(consent(to(
inclusion,( potential( kidneys( will( be( machine( perfused( using( standard( non(
enriched(perfusion(fluid(if(suitable.(Kidneys(will(be(perfused(on(clinical(grounds(
based(on(an(evidencefbased(algorithm(agreed(upon(by(the(renal(unit.(There(will(
be( no( randomization( or( blinding.( There( is( no( evidence( to( date( to( suggest( any(
harmful( effect( of( perfusing( all( kidneys( but( benefits( appear( limited( if( perfusion(
time(is(short((<12(hours).(
(
Fluid( will( circulate( throughout( the( kidney( during( its( time( on( the( machine( as(
standard( clinical( practice.( The( fluid( is( designed( specifically( for( use( in( the(
machine( and( to( preserve( organs( (KPSf1®,( Kidney( Preservation( solution,(Organ(
Recovery( Systems).( The( proportion( of( naturally( occurring( heavy( carbon( (13C)(
incorporated(into(the(glucose(within(the(KPSf1®(fluid(may(be(increased(in(some(
studies(from(the(naturally(abundant(level(of(1.1%(to(over(50%.(As(discussed(in(
background( information( (p12),( this( is( non( radioactive( and( non( harmful( and( is(
naturally( occurring.(There( are(no(health( and( safety( concerns( involved( in(using(
this((Appendix(4).(Increasing(the(proportion(of(13C(compared(to(the(12C(form(of(
glucose(will(allow(informative(metabolic(studies(through(NMR(analysis.(However(
the( total( amount(of( glucose(within( the( fluid( (10mM/L)(will( not( be( altered( and(
this( increased( proportion( of( 13C( glucose( does( not( change( the( biological(
properties( of( the( fluid(with( regards( to( organ(perfusion.(Therefore( this( is( not( a(










be( produced( to( clinical( grade( pharmaceutical( standards( by( Organ( Recovery(
Systems.(We(will( take(small(samples((<5ml)(of( the( fluid( for(analysis(during(the(
perfusion((at(30(mins,(between(6f12(hours,(12f18(hours,(18(to(24(hours(and(at(
the( end( point).( This( does( not( affect( the( perfusion( in( any( way.( At( the( end( of(
perfusion( and( prior( to( transplantation,( we( will( take( a( tissue( biopsy( (14f18F(
biopsy( gun)( to( be( used( for( research( analysis.( This( type( of( biopsy( is( standard(
practice(to(provide(a(baseline(tissue(histology(in(many(centres.((
A( small( amount( of( urine( (about( 10ml)( of( the( urine( that( is( collected( routinely(
postoperatively(will(be(used(for(research(analysis.((
Laboratory( analysis( of( the( samples( will( be( performed( following( storage( and(
processing.( The( basis( of( studies( will( be( metabolite( analysis( using( Nuclear(
Magnetic(Resonance((NMR)(spectroscopy(and(Mass(Spectroscopy((MS).(Cellular(
studies( likewise(will( be(based(on( characterizing( the(number( and(nature(of( the(
cells.(The(analysis(is(simple(and(currently(standard(practice(in(most(laboratories.(
Donor( and( recipient( data( to( correlate( with( this( is( routinely( collected( by( the(
transplant( unit( and( includes( donor( details( (age,( mode( of( death,( creatinine,(
history(of(hypertension)(and(recipient(outcome((creatinine(levels,(graft(function,(
graft(loss(and(other(complications).(Donor(details(need(to(be(collected(to(identify(
whether( the( donor( is( a( SCD( or( ECD( as( this( may( influence( outcome.( Recipient(
























Primary:( ( Identification( of( markers( in( the( perfusate,( urine( and( tissue( of( MP(
kidneys(representative(of(metabolic(activity(during(MP.(





All( deceased( donor( kidneys( accepted( by( the( unit( for( potential( transplantation(
that( also( have( valid( consent( for( research( purposes.( The( procedure( for( donor(









consented( for( inclusion( in( the( study( and( therefore( data( collection(will( only( be(



















(at( 30(mins,( between( 6f12( hours,( 12f18( hours,( 18( to( 24( hours( and( at( the( end(
point).(5(milliliters(of(perfusion(fluid(will(be(taken(at(each(time(interval.(The(fluid(
















minutes.( This( will( separate( cells( and( fluid( from(within( the( sample.( For( tissue(
samples,( cell( extraction(may(be(performed( involving(methanol( and( cholorform(
separation(techniques.(The(fluid(will(be(decanted(from(the(sample,(labeled(with(
the(donor(number,(date(and(time,(and(placed(in(a(f80°C(freezer.(The(cells,(in(the(
form( of( a( pellet,( will( be( mixed( with( 1ml( of( freezing( solution( (mix( of( 5ml(
DMSO/45ml( FCS)( in( an( aliquot,( labeled( as( previously,( and( placed( in( a( f80°C(
freezer.(
Samples(will(be(prepared(for(NMR(analysis(by(mixing(150(μL(of(400(mM((pH(7.0)(
phosphate( buffer( containing( 2( mM( DSS( (4,4fdimethylf4fsilapentanef1fsulfonic(
acid)( and( 8mM( imidazole(with( 390( μL( of( each( perfusate( sample( and( 60( μL( of(















magnetic( resonance( and( mass( spectroscopy.( Cellular( studies( likewise( will( be(






study( for( biomarkers( in( urine( of( renal( transplant( donors.( This( included( both(
multivariate( and( univariate( analysis.( The(markers( used( have( been( assessed( in(
other(models.( It( is( not( assumed( that( distribution(will( be(normal( and( therefore(
mannfwhitney( and( kruskalfwallis( analysis( will( be( used.( In( addition( the( levels(









Over( the( study( period( it( is( estimated( that( 50f75( kidneys(will( be( perfused( per(
year(of(which(assuming(a(50%(consent(rate(will(allow(sample(collection(for(25f
37.( The( assay( used( is( highly( sensitive( and( assumptions( of( results( from( similar(









simple( power( calculation( assuming( levels( of( ~700pg/L( with( SD( 300pg/L( for(
injury(and(300pg/L(SD(100pg/L(with(an(80%(power(and(p(of(0.05(would(require(




Access( to( source( data/documents( by( appropriate( regulatory( bodies( will( be(
permitted.( Data( will( be( stored( on( an( excel( spreadsheet( on( the( departmental(
laptop(which( is(password(protected(with( full(McAfee(security(accessed(only(by(




Whilst( the( biobank( cannot( yet( accept( cadaveric( tissue( the( ownership( of( the(
samples( collected( is( open( to( interpretation.( There( has( been( debate( about(
ownership( and( whether( tissue( and( fluid( taken( from( a( donor( and( not( yet(
implanted( in( the( recipient( is( either( donor( or( recipient( property.( Although(
possibly( an(over( cautious( approach,(we(will( only( include(kidneys( in( this( study(
whereby(the(donor(has(consented(for(research(purposes(and(the(recipient(agrees(
















It( is( predicted( that( data( derived( from( this( study( will( be( disseminated( via(
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We(are(undertaking(this(research(to(help(us(understand(how(the(flushing(process(
benefits(the(kidney(at(a(metabolic(level.(
To( better( understand( this,( one( of( the( components( of( the( fluid( used( to( flush( the(















to! this! during! perfusion.! This! is! a! safe,! naturally! occurring! compound! and! is! biologically!






may!encounter! following! your! transplant.!We!hope! this!will! help!us! to! improve!outcomes!
for! kidney! transplant!patients! and! increase! the!number!of! kidney! transplants! that!we! can!
do.!
'
We( hope( that( by( better( understanding( what( happens( in( the( kidney( during( this(
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have.!There5 are5 no5 extra5 tests,5 needles5 or5 extra5 appointments.! The! results! we! normally!







working( and( any( problems( you( might( have.( Medical( records( and( data( may( be(







Whether!you! take!part! in! the! study!or!not!will!not! influence!the! treatment!you! receive! in!














There(are(no(harmful(effects(of(using( labelled( fluids(during( this( flushing(process.(
The( risk( associated( with( kidney( biopsy( is( very( small( and( is( a( test( performed(
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2-a i te Acetate
ADP lanine
A P Apartate
β-Alanine Choline
Spectral	peak	allocation	for	26	metabolites	detected	in	a	porcine
model	of	HMP	and	SCS	kidney	 storage
0.970.980.991.001.011.021.03
Isoleucine
8.168.178.188.198.208.218.22
Hypoxanthine
7.807.827.847.86
Hippurate
1H [ ]
2.302.322.342.362.38
Glutamate
6.496.506.516.526.53
Fumarate
8.428.438.448.458.468.47
Formate
3.003.013.023.033.043.05
creatinine
6.066.086.106.12
Inosine
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
Creatinine Formate
Fumarate Glutamate
Hippurate Hypoxanthine
Inosine Isoleucine
3.2353.2403.2453.2503.2553.2603.265
TMNO
3.223.243.263.28
2.372.382.392.402.412.42
Succinate
8.908.918.928.938.948.95
Niacinamide
9.309.319.329.339.349.359.36
NAD+
3.243.263.283.30
y
0.920.940.960.98
Leucine
1.291.301.311.321.331.341.35
Lactate
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
1H	[PPM] 1H	[PPM]
Lactate Leucine
Myo-Inisitol NAD+
Niacinamide Succinate
Taurine TMNO
0.981.001.021.04
Valine
6.866.886.906.92
y
1H	[PPM] 1H	[PPM]
Tyrosine Valine
	
	
Spectral	Peak	allocation	for	18	metabolites	found	in	porcine	kidney	cortex	tissue	
after	storage	by	HMP		
	
	
3-Methylxanthine	 Adenine	
	 	
1H[PPM]	 1H[PPM]	
	 	
Adenosine	 Alanine	
	 	
1H[PPM]	 1H[PPM]	
	 	
DSS-d6	 Ethanol	
	 	
1H[PPM]	 1H[PPM]	
	 	
	
	
	
	
	
	
Ethanolamine	 Gluconate	
	 	
1H[PPM]	 1H[PPM]	
	 	
	
	
Glucose	 Glutamine	
	 	
1H[PPM]	 1H[PPM]	
	 	
Glutathione	(reduced)	 Glycine	
	 	
1H[PPM]	 1H[PPM]	
	 	
Imidazole	 Isopropanol	
	 	
1H[PPM]	 1H[PPM]	
	 	
	
	
Mannitol	 Phenylalanine	
	 	
1H[PPM]	 1H[PPM]	
	 	
	
	
	
Pyroglutamate	 Ribose	
	 	
1H[PPM]	 1H[PPM]	
